Studies on Heterocyclic Compounds of Medicinal Interest by Dodiya, Dipti K.
          Saurashtra University 
     Re – Accredited Grade ‘B’ by NAAC 
     (CGPA 2.93) 
 
 
 
 
Dodiya, Dipti K., 2010, “Studies on Heterocyclic Compounds of Medicinal 
Interest”,  thesis PhD, Saurashtra University 
  
http://etheses.saurashtrauniversity.edu/id/eprint/491 
  
Copyright and moral rights for this thesis are retained by the author 
 
A copy can be downloaded for personal non-commercial research or study, 
without prior permission or charge. 
 
This thesis cannot be reproduced or quoted extensively from without first 
obtaining permission in writing from the Author. 
 
The content must not be changed in any way or sold commercially in any 
format or medium without the formal permission of the Author 
 
When referring to this work, full bibliographic details including the author, title, 
awarding institution and date of the thesis must be given.  
 
 
 
 
 
 
 
 
 
Saurashtra University Theses Service 
http://etheses.saurashtrauniversity.edu 
repository@sauuni.ernet.in 
 
© The Author 
 
Studies on Heterocyclic Compounds 
of Medicinal Interest 
 
 
A Thesis Submitted in the Fulfillment of the 
Requirements of the Award of the Degree 
 
 
Doctor of Philosophy 
 
 
From 
 
Saurashtra University 
  
 
By 
 
Dipti K. Dodiya 
 
Under the Guidance of 
Prof. V. H. Shah 
 
Department of Chemistry 
(DST-FIST Funded & UGC-SAP Sponsored) 
Saurashtra University 
Rajkot, Gujarat 
India 
 
 
September 2010 
 
Statement under O.Ph.D.7 of Saurashtra University 
 
 
 
The work included in the thesis is done by me under the supervision of  
Dr. V. H. Shah and the contribution made thereof is my own work.  
 
 
 
Date:  
Place: Rajkot        (Dipti K. Dodiya) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
          Department of Chemistry 
                        (FIST-DST Funded & UGC-SAP Sponsored) 
               Saurashtra University, Rajkot - 360 005. Gujarat (INDIA) 
 
Fax : +91 281-2576802        
Phone : +91 281-2571989       Dr. V. H. Shah 
e-mail : drvireshshah@gmail.com      M. Sc., Ph. D., F.I.C.S. 
  shah_v_h@yahoo.com      Professor     
      
No.:          Date: 
 
 
Resi. : “Vighnahar parasnath”, 26-A/1, Saurashtra University Karmchari Society, University 
Road, Rajkot- 360 005.  Gujarat (India) Tel.: 0281- 2581817 
 
 
Certificate 
 
This is to certify that the present work submitted for the Ph. D. degree of Saurashtra University, 
Rajkot, Gujarat (India) by Ms. Dipti K. Dodiya has been the result of work carried out under my 
supervision and is a significant contribution in the field of synthetic organic chemistry. 
 
 
 
Date:         Dr. Viresh H. Shah 
Place: Rajkot        Professor, 
Department of Chemistry, 
Saurashtra University, 
Rajkot-360005 
Gujarat (India). 
“It takes a day to make a dream, 
But it takes many nights for a seed to become a tree. 
 
Life is a ladder that must be climbed. 
But in every stage, 
 
There are many rivers and battles to fight 
And our hopes determines our future. 
 
Life is a trip through the wilderness 
And everyone must survive for success. 
 
But without a determination 
We can never reach our destination. 
 
There are many roads in life, 
But choice 
 
Stands between the broad and the narrow. 
The world is not only what we see 
 
But what we hear 
Life is time and time is tide. 
 
We are making an endless journey 
But no ladder is without an end 
 
Problems may fall like rain 
But every seed has its season.” 
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General remarks 
 
 
1. 1H NMR spectra were recorded on Bruker Avance II 400 MHz or Bruker DRX 300 MHz  
      or Varian 400 MHz spectrometer using TMS as an internal reference. 
  
2. Mass spectra were recorded on GC-MS QP-2010 spectrometer. 
 
3. IR spectra were recorded on Schimadzu FT-IR-8400 spectrometer. 
 
4. Elemental analysis was carried out on Vario EL III Carlo Erba 1108. 
 
5. Thin layer chromatography was performed on Silica Gel (Merck 60 F254). 
 
6. The chemicals used for the synthesis of compounds were purchased from Spectrochem, 
Merck, Thomas-baker and SD fine chemical. 
 
7. Melting Points were taken in open capillary and are uncorrected. 
 
8. Microwave assisted reaction were carried out in QPro-M microwave synthesizer. 
 
9. All the structures are drawn according to ACS Document 1996 style. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Synopsis 
 
A brief summary of the research work to be incorporated in the thesis entitled “Studies on 
Heterocyclic Compounds of Medicinal Interest” can be divided into five chapters which can 
be summarized as under. 
 
 
Chapter 1  Introduction 
 
Chapter 2  Studies on Cyanopyridines 
 
Chapter 3  Microwave Assisted Synthesis of Heterocycles - An Overview 
 
Chapter 4  Studies on Microwave Assisted Synthesis of Acridines 
 
Chapter 5  Studies on Microwave Assisted Synthesis of Polyhydroquinolines 
 
 
 
 
Chapter 1  Introduction 
 
Nowadays, the entire pharmaceutical industry is faced with the challenge of increasing 
productivity and innovation. The major hurdles are the increasing costs of research and 
development and a simultaneous stagnating number of New Chemical Entities (NCEs). 
 
Chapter 1 gives a brief introduction for the pressing need of New Chemical Entity (NCE) 
for pharmaceutical industry. It also describes importance of bicyclic and tricyclic aromatic 
heterocycles in drug discovery. Concept of “privileged structures” is also explained in brief. 
Chapter 1 also describes aims and objectives of the proposed research work. 
 
 
 
 
Chapter 2  Studies on Cyanopyridines 
 
 
Section-I:  Synthesis and Biological Evaluation of 6-(substituted-2-chloro quinolin-3-yl)-2-
alkoxy-4-aryl-pyridine-3-carbonitriles 
 
  
Many naturally occurring and synthetic compounds bearing pyridine scaffold possess interesting 
biological properties. In association with those, pyridine-3-carbonitrile derivatives have been 
reported to posses a wide spectrum of biological activities such as antitumor, antihypertensive, 
antimicrobial, antiinflammatory, analgesic and antiviral etc.  
 
N
C
O
N
X
R1
R2
Where, R1 = substituted 2-chloroquinolin-3-yl, R2 = Substituted phenyl
             X = Alkyl
DDK-  A-01 to A-20
 
 
 
In the view of these reports, Section-I of Chapter 2 covers synthesis of new 2-alkoxy-
pyridine-3-carbonitrile derivatives in search of better therapeutic agents. The synthesis was 
accomplished by the condensation of chalcones with malononitrile in presence of corresponding 
alkoxide anion. 
 
Section-II:  Synthesis and Biological Evaluation of 6-alkoxy-3-methyl-4-aryl-1H-
pyrazolo[3,4-b]pyridine-5-carbonitriles 
 
Pyrazolopyridines and its hydroderivatives are very interesting pyrazole derivatives with wide-
ranging biological activities. A number of pyrazolo[3,4-b]pyridines exhibit a wide range of 
biological activities, including interesting anxiolytic activity, dopamine D3 receptor antagonist, 
antiherpetic and antiallergic properties.  
 
 
 
 N
C
O
N
X
DDK-  A-21 to A-40
N
N
H
R
Where R = -H, 3-Cl, 4-Cl, 4-Br, 4-CH3, 4-OCH3 etc.; X = Alkyl
 
Keeping in mind the various biomedical applications of cyanopyridines and pyrazolo[3,4-
b]pyridines, it was thought worthwhile to incorporate both these scaffolds in a single molecular 
framework to further assess the biological profile. To achieve this, new pyrazolo[3,4-b]pyridine-
5-carbonitriles were synthesized by reaction of 3-methyl-1H-pyrazol-5(4H)-one with arylidene 
malononitriles in the presence of corresponding alkoxide anion, which is incorporated in the 
Section-II. 
 
All the compounds were characterized by FT-IR, mass, 1H NMR spectral analysis and 
elemental analyses. The newly synthesized compounds are subjected to antimicrobial activity. 
 
Chapter 3  Microwave Assisted Synthesis of  Heterocycles - An 
Overview 
 
 
Microwave assisted organic synthesis has become an important tool to medicinal chemists for 
rapid organic synthesis. A huge number of research papers have appeared over the last decades 
on the application of microwave technology in organic synthesis. Some of the major advantages 
of microwave assisted organic synthesis include spectacular decrease in reaction time, improved 
conversions, clean product formation and wide scope for the development of new reaction 
conditions. 
 
Chapter-3 briefly discusses the history of microwave assisted organic synthesis and their 
application in the synthesis of different heterocycles with different heteroatoms. 
 
Chapter 4  Studies on Microwave Assisted Synthesis of 
Acridines 
 
 
Acridine derivatives have been found to possess a wide spectrum of biological activities such as 
antibacterial, antimalarial, anticancer and mutagenic properties, principally connected with their 
ability to inhibit the enzymes acting on nucleic acids. Acridine derivatives have also been used to 
synthesize labeled conjugates with medicinals, peptides, proteins, and nucleic acids that exhibit 
antitumor and DNA-binding properties.  
 
1,8-Dioxo-9-aryl-polyhydroacridines and their derivatives are polyfunctionalized 1,4-
dihydropyridine derivatives. In recent years, 1,4-dihydropyridines and their derivatives have 
attracted strong interest due to a variety of biological activities such as vasodilator, 
bronchodilator, antiatherosclerotic, antitumor and antidiabetic activity etc. 
 
N
H
H3C
H3C
CH3
CH3
RO O
Where R = Heteroaryl substituent
DDK-  B-01 to B-20
 
 
    
In the view of these observations, synthesis of two new series of 1,8-Dioxo-9-heteroaryl-
polyhydroacridines has been undertaken in Chapter 4. The synthesis was effected by one pot, 
solvent-free condensation of 5,5-dimethyl-1,3-cyclohexane-dione, different heterocyclic 
aldehydes and ammonium acetate. The structures of all the newly synthesized compounds were 
elucidated by FT-IR, mass, 1H NMR spectral analysis and elemental analyses. The newly 
synthesized compounds are subjected to antimicrobial activity. 
 
 
 
Chapter 5  Studies on Microwave Assisted Synthesis of 
Polyhydroquinolines 
 
 
It is common knowledge that quinolines and their derivatives are very useful compounds because 
a large number of natural products and drugs contain this heterocyclic unit. They have attracted 
strong interest due to their useful biological and pharmacological properties, such as antitumor, 
antiviral, antitubercular, antidiabetic and antibacterial activities.  
 
Section-I:  Synthesis and Biological Evaluation of 2-amino-5,6,7,8-tetrahydro-4-heteroaryl-
quinoline-3-carbonitriles 
 
In search of better therapeutic agents, two new series of polyhydroquinolines have been 
synthesized by the microwave-assisted reaction of cyclohexanone with arylidene malononitriles 
in presence of excess of ammonium acetate, which is included in Section-I.  
 
N
C
NH2
N
R
DDK-C-01 to C-20
Where R = Heteroaryl substituent
 
 
 
Section-II:  Synthesis and Biological Evaluation of 7,8-dihydro-7,7-dimethyl-2,4- 
         disubstituted-quinolin-5(1H,4H,6H)-ones 
 
 In Section-II, synthesis of another two series of substituted 5-oxo-polyhydroquinolines is 
included. The synthesis was accomplished by the microwave assisted solid state condensation of 
5,5-dimethyl-1,3-cyclohexane-dione with different chalcones in presence of excess of 
ammonium acetate. 
 
 
 
 
Where R1 and R2 = Aryl or heteroaryl substituents
N
H
R2
H3C
H3C
R1O
DDK-C-21 to C-50
 
 
 
All the compounds were characterized by FT-IR, mass, 1H NMR spectral analysis and 
elemental analyses. The newly synthesized compounds are subjected to antimicrobial activity. 
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 Chapter 1 
 General Introduction 
 
 
 
 
1.1 Heterocycles in drug discovery 
Nowadays, the entire pharmaceutical industry is faced with the challenge of 
increasing productivity and innovation. The major hurdles are the increasing costs of 
research and development and a simultaneous stagnating number of new chemical 
entities (NCEs).  
The cause of this innovation deficit is definitively not the biology. Decoding of 
the human genome has led to a wealth of drug targets. With more than 20,000 human 
genes, the assumption is that at least 1,000 are significantly involved in the emergence 
and course of disease. Furthermore, because each of these genes is linked to the 
function of between five and ten proteins, the conclusion is that there might be 5,000-
10,000 targets for new drugs [1]. Despite the successful introduction of protein 
therapeutics and the promise of gene therapy, major pharmaceutical companies are 
still focused on the discovery and development of low-molecular weight compounds. 
Hence, the challenge is to select the most drugable targets and to find the 
corresponding drug-like molecules, substances that not only interact with the target, 
but also have specific pharmacokinetic and toxicological properties, that allow them 
to be developed as a drug.  
 Medicinal chemistry as a scientific discipline has introduced several new 
techniques over the last few years in order to speed up the drug discovery process, 
such as combinatorial chemistry, microwave-assisted organic synthesis, and high-
throughput purification [2]. Despite this steady increase in R & D, the number of new 
chemical entities (NCEs) reaching the market has actually decreased dramatically. 
It seems clear that selecting the appropriate molecules to synthesize is one of the most 
troublesome questions. It has been estimated that the number of possible molecules 
with a molecular weight of less than 500 atomic mass unit (Da) is 10200, of which only 
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1060 may possess drug-like properties. The proportion of these drug-like molecules 
synthesized to date has been estimated as one part in 1057, or roughly the ratio of the 
mass of one proton to the mass of the sun! The issue is therefore the selection of new 
molecules from this vast universe that have the potential to be biologically active [3]. 
In order to start a new drug discovery project and to find biologically active 
compounds, different options are available. Hits can be obtained via a virtual 
screening approach or can be copied from scientific or patent literature. Very often, 
drug discovery projects start with a high-throughput screening campaign of 
commercially available compound libraries against the target of interest. It became 
clear in recent years that combinatorial libraries are not diverse enough. In this 
context, the concept of privileged structure has drawn remarkable attention. Privileged 
structures, as firstly formulated by Evans et al. [4], are structural motifs common to 
several drug and lead compounds, and endowed with versatile binding properties. 
Therefore, in principle, libraries derived from such scaffolds may provide promising 
compounds in diverse therapeutic areas [5, 6]. Notably, the likely drug-like properties 
of privileged structures and substructures might produce more drug-like compound 
libraries and leads [7]. 
 
N
N N
H NH
N
(1) Quinazoline (2) Indole (3) Benzimidazole
N
H
N
O
(4) 1,4-Benzodiazepine-2-one
O O
(5) Coumarine
N
N
(6) Quinoxaline
O
(7) Benzofuran
S
(8) Benzothiophene
Examples of privileged structures  
 
Well-known examples of privileged substructures include benzodiazepines (4), 
coumarins (5), quinoxalines (6), benzofurans (7) and benzothiophenes (8) [6]. In order 
to improve the hit rate in HTS campaigns, privileged structures provide an ideal 
source of lead compounds. A single library based upon privileged substructures can 
lead to active compounds in variety of biological assays. Several research groups have 
utilized these structures in such a manner. For example, Nicolau K. C. et al. 
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constructed a library based on the benzopyran (9) privileged scaffold [8], whereas 
Schultz P. G. et al. made use of the purine (10) scaffold [9]. 
 
O
(9) Benzopyran
N
N NH
N
(10) Purine
The benzopyran and purine privileged scaffold  
 
1.2 Nomenclature of the fused ring system 
 As the following chapters deal with the synthesis of bicyclic fused ring 
systems, its nomenclature is herewith shortly reviewed. The nomenclature follows the 
following rules: 
(1) The individual components are named without any application of fused ring 
system. 
(2) The parent component is represented in the fusion name by citing it last in the 
name. The parent component is the one with highest priority according to the 
following criteria: 
(a) a heterocyclic component containing the heteroatom occurring earliest in 
the order: N, F, Cl, Br, I, O, S, Se, Te, P, As, Sb, Bi, Si, Ge, Sn, Pb, B, Hg.    
(b) a component containing the larger ring. 
(c) a component containing the greater number of heteroatoms. 
(d) a component containing the greater variety of heteroatoms. 
(3) The attached component is then added as a prefix to the parent component. In 
the name of the prefix, the terminal 'e' is changed to 'o'.    
(4) The bonds of the parent component are indicated by a, b, c…starting with the 
bond normally occupying the 1,2 positions. The atoms of the attached 
component are numbered as usual, following the order of numbers in the 
original heterocycle. 
(5) The numbering of the final condensed heterocycle is carried out 
independently, starting at an atom adjacent to a bridged-head atom, whereby 
heteroatoms receive the smallest possible number. 
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1.3 Objectives 
Our interest in the synthesis and biological evaluation of heterocyclic bi/tricycles and 
the fact that some of these compounds viz. pyridine-3-carbonitriles (11), 
pyrazolo[3,4-b]pyridine-5-carbonitriles (12), acridines (13) and polyhydroquinolines 
(14 & 15) are not frequently used in the synthesis of compound libraries, prompted us 
to elaborate this type of chemistry and to synthesize four different heterocyclic 
scaffolds, which are privileged scaffolds or their derivatives with wide spectrum of 
biological activity. 
 
N
N
(11) Pyridine-3-carbonitrile
N NH
N
(12) Pyrazolo[3,4-b]pyridine
N
H
N NH
(13) Acridine
(14) (15)
Polyhydroquinolines  
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 Chapter 2 
 Studies on cyanopyridines 
 
 
 
 
2.0 Introduction 
The pyridine skeleton is of great importance to chemists as well as to biologists as it is 
found in a large variety of naturally occurring compounds and also in clinically useful 
molecules having diverse biological activities. Cyanopyridines comprise a very 
interesting class of compounds because of their significant and versatile biological 
and pharmacological activities. Cyanopyridines are important intermediates in the 
pharmaceutical industry for the synthesis of nicotinamide, nicotinic acid and 
isonicotinic acid etc [1]. The importance of cyanopyridines in organic synthesis has 
increased over the past few decades because they are among the most versatile 
organic synthetic intermediates [2]. Many fused cyanopyridines have drawn attention 
due to their wide spectrum biological activities [3]. 
In view of these observations and with a view to further explore the 
pharmacological profile of this class of compounds, the present study includes 
synthesis of novel 3-cyanopyridines (pyridine-3-carbonitriles) and fused 
cyanopyridines viz. pyrazolo[3,4-b]pyridine-5-carbonitriles. The study is divided in 
two sections: 
 
2.1: Synthesis and biological evaluation of 6-aryl-4-(substituted-2-chloro-quinolin-3- 
        yl)-2-alkoxy-pyridine-3-carbonitriles 
 
2.2: Synthesis and biological evaluation of 6-alkoxy-3-methyl-4-aryl-1H- 
        pyrazolo[3,4-b]pyridine-5-carbonitriles 
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2.1: Synthesis and biological evaluation  
       of 6-aryl-4-(substituted-2-chloro 
       quinolin-3-yl)-2-alkoxy-pyridine- 
  3-carbonitriles 
        
2.1.1 Introduction 
The pyridine motif is among the most common N-heteroaromatics incorporated into 
the structure of various therapeutic agents. Many naturally occurring and synthetic 
compounds bearing pyridine scaffold possess interesting biological properties. In 
association with those, 3-cyanopyridine or pyridine-3-carbonitrile derivatives draw a 
special attention for their wide spectrum biological activities along with their 
importance and utility as intermediates in preparing variety of heterocyclic 
compounds [1]. 
 
N
N
Pyridine-3-carbonitrile  
 
It has been demonstrated that molecules containing 3-cyanopyridine moiety 
may be able to work as ligands towards transition-metal ions [4], new drugs [5], and 
significant intermediates for the synthesis of important vitamins [6] such as nicotinic 
acids [7] and nicotinamides [8].  
 
The pharmacological and physiological activity of 3-cyanopyridines has 
attracted much attention in recent years with the synthesis and the study of the non-
glycosidic cardiotonic agent milrinone [9, 10], as well as with a number of 3-
cyanopyridine derivatives which proved to be active against the herpes virus and the 
human immunodeficiency virus [11, 12]. The 3-cyanopyridin-2-one nucleus is also 
the structural basis of the alkaloid ricinine-the first known alkaloid containing a 
cyano-group. 
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N
H
O
N
Milrinone
N
N O
N
Ricinine
O
 
 
3-cyanopyridines with different alkyl and aryl/heteroaryl groups were found to 
have anti-tubercular [13], antimicrobial [14], anti-cancer [15, 16], A2A adenosine 
receptor antagonists [17], antihypertensive [18, 19], anti-histaminic [20], anti-
inflammatory, analgesic & antipyretic properties [21] as well as 1KK-β inhibitor 
properties [22]. Some examples of published derivatives of 3-cyanopyridines with 
their biological activities are as following. 
Activity: Aurora A kinase inhibitory [23]
N
N
N
H
NHN
HN
HO .HCl
N
CN
NH2
Br
Br
H3CO OCH3
Activity: Anti-tubercular [26]
N
NH2
CN
N
Activity: Herbicidal [24]
N
N
O
O
Activity: Cardiotonic [25]
N
CN
NH2
H
N
O
OH
N
CN
OCH2CONHNH2
OCH3
Activity: Antimicrobial [27]
N
CN
O
OCH3
Activity: Anticancer [28]
N
HN N
S
H2N
Activity: Anti-inflammatory [29] Activity: anti-HIV [30]
NH
S
O
O
O
O
O O
O
O
O
N
O OH
O
N
H
O
N
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2.1.2 Reported synthetic strategies 
 
2.1.2.1. From α,β-unsaturated synthons 
Large number of publications describe the synthesis of 3-cyanopyridines from 
α,β-unsaturated synthons. The Michael-type condensation of α,β-unsaturated ketones 
or 1,3-diaryl-prop-2-en-1-ones with malononitrile and ammonium acetate is probably 
the most reported strategy for the synthesis of 4,6-diaryl/heteroaryl-2-amino-3-cyano 
pyridines [26, 36-38] (Scheme  2.1.1). The reaction is generally carried out in alcohol 
in presence of excess of ammonium acetate. Recently, Sarda et al. have reported the 
reaction using ionic liquid ethylammonium nitrate [39]. 
 
+R1
O
NH4OAc
N
R
R1 NH2
CN
R
N
N
R, R1 = aryl or heteroaryl
Scheme  2.1.1
 
 
Reaction of arylidene malononitrile with alkyl and aryl ketones in presence of 
ammonium acetate is reported to yield 6-alkyl/aryl substituted 2-amino-3-cyano 
pyridines [40, 41] (Scheme  2.1.2). 
 
CN
CN
+
R R1
O
NH4OAc
N
R
R1 NH2
CN
R = aryl or heteroaryl, R1 = alkyl or aryl
Scheme  2.1.2
 
 
Number of multi-component approaches for the synthesis of 2-amino-3-cyano 
pyridines has also been reported involving one pot reaction of different aldehydes, 
ketones, malononitrile and ammonium acetate [22, 29, 42-44]. Heravi et al. have reported 
the green one-pot synthesis of 2-amino-3-cyano pyridines from 3,4-dimethoxyaceto- 
phenone, different aromatic aldehydes, malonitrile and ammonium acetate using hetero- 
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 polyacid as heterogeneous and recyclable catalyst [45] (Scheme  2.1.3).  
 
+R H
O
NH4OAc
N
R
R1 NH2
CN
N
N
R, R1 = aryl or heteroaryl
Scheme  2.1.3
+ R1
O
 
 
Reaction of arylidene malononitriles with 2-amino-thiophenol yielded 2-
amino-3,5-dicyano-6-substitutedthioxo-pyridines [46]. Recently, multi-component 
reactions involving aldehydes, malononitrile and 2-aminothiophenol using boric acid 
[47] as well as potassium fluoride on alumina (KF-Al2O3) [48] as green catalysts have 
been described (Scheme  2.1.4). 
 
CN
CN
+R
N
R
S NH2
CN
R = aryl or heteroaryl
Scheme  2.1.4
SH
NH2 R H
O
+
SH
NH2
+
N
N
NC
NH2
 
 
Condensation of ethyl cyanoacetate with α,β-unsaturated ketones in presence 
of excess ammonium acetate afforded 3-cyanopyridin-2-ones [31, 49-51] (Scheme  
2.1.5). Also, a green chemistry approach describing reaction of α,β-unsaturated 
ketones with ethyl cyanoacetate using samarium iodide as catalyst has been reported 
recently [52]. 
 
+R1
O
NH4OAc
N
H
R
R1 O
CN
R
COOEt
CN
R, R1 = aryl or heteroaryl
Scheme  2.1.5
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Barat reported first that condensation of cyanoacetamide with α,β-unsaturated 
ketones also affords 3-cyanopyridin-2-ones [53]. Number of reports following this 
approach have been reported till date [54-56] (Scheme 2.1.6). 
 
+R1
O
NH4OAc
N
H
R
R1 O
CN
R
R, R1 = aryl or heteroaryl
Scheme  2.1.6
C
CN
O
H2N
 
 
Chase et al. have synthesized 6-amino-5-phenyl-3-cyanopyridin-2-one by the 
reaction of 3-isobutoxy-2-phenylacrylonitrile with cyanoacetamide [57] (Scheme 
2.1.7). Recently, Melikyan et al. have reported synthesis of novel N-substituted-3-
cyanopyridin-2-ones from ylidenecyanoacetic acid ethyl esters in two steps [58] 
(Scheme 2.1.7).  
 
CN
Ph
O +
N
H
H2N O
CN
Scheme  2.1.7
Ph
R1
CN
COOEt
N
O
O+ R1
CN
COOEt
N(Me)2
N O
CN
R1
R2
R1, R2 = alkyl
R2NH2
C
CN
O
H2N
 
 
Reaction of ethyl-(2,3,4-trimethoxybenzoyl)-pyruvate with cyanoacetamide in 
ethanol in presence of  piperidine gave 4-carbehtoxy-6-(2,3,4-trimethoxybenzyl)-3 
cyanopyridin-2-one [59]  (Scheme  2.1.8). 
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OOCH3
OEt
O
+
OCH3
H3CO
H3CO
H3CO
H3CO
HN
O
CN
COOEt
Scheme  2.1.8
C
CN
O
H2N
 
 
Chalcones react with cyanothioacetamide in the presence of sodium ethoxide 
to afford 3-cyano-pyridin-2-thiones [60, 61]. A one pot approach has also been 
reported to afford the 3-cyano-pyridin-2-thiones involving reaction of chalcones, 
malononitrile and elemental sulfur [62] (Scheme 2.1.9). 
 
+R1
O
N
H
R
R1 S
CN
R
R, R1 = aryl or heteroaryl
Scheme  2.1.9
+R1
O
R
N
N
+ S8
EtONa MorpholineC
CN
S
H2N
 
The 6-amino-4-methylthio-3-cyano-2(1H)-pyridinethione was prepared by the 
reaction of 1,1-dimethylthio-1-thiocarbamoyl-2-cyanoethylene with cyanoacetamide 
[63] (Scheme  2.1.10). 
 
SMe
MeS
CN
CSNH2
+ C
CN
N
H
S
CN
SMe
H2N
S
H2N
Scheme  2.1.10
 
 
The reaction of 4-butoxybenzalcyanoacetic ester with cyanothioacetamide 
yielded 6-amino-4-(4-butoxyphenyl)-3,5-dicyano-2(1H)-pyridinethione [64] (Scheme  
2.1.11). 
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+
RO
Scheme  2.1.11
C
CN
S
H2N
CN
OCH3
O
N
H
S
CN
H2N
NC
OR
R = butyl
 
 
Synthesis of 2-alkoxy-3-cyanopyridines is generally achieved by the reaction 
of chalcones with malononitrile in corresponding sodium alkoxide [65-68] (Scheme 
2.1.12).  
 
+R1
O
R2ONa
N
R
R1 OR2
CN
R
N
N
R, R1 = aryl or heteroaryl
Scheme  2.1.12
R2OH
 
 
Another frequently used approach for the synthesis of 2-alkoxy-3-cyano-pyridi-
nes is the O-alkylation of 3-cyanopyridin-2-ones by the reaction with appropriate alkyl 
/aryl halide [69, 70] (Scheme 2.1.13). 
 
N
H
O
CN
R + R1Br
N
H
OR1
CN
R
R = substituent/substituents on 4, 5 and/or 6 position of pyridine
R1 = alkyl or aryl
Scheme  2.1.13
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2.1.2.2. From 1,3-dicarbonyl synthons  
Literature survey revealed many reports on synthesis of 3-cyanopyridin-2-one and 3-
cyanopyridin-2-thione by reaction of 1,3-dicarbonyl compounds with cyanoacetamide 
[71-74] and cyanothioacetamide [75-77] respectively (Scheme  2.1.14).  
 
+ C
CN
X
H2NO
R1
O
N
H
X
CN
R1
R1 = H [69, 70], R1 = -COOCH3 [71], R1 = heteroaryl [72],         ; X = O [69-72], S [73-75]
R1 = benzoyl [73], R1 = CH3, -OC2H5 [74], R1 = -OC2H5 [75]
Scheme  2.1.14
 
 
2.1.2.3. Miscellaneous 
 Enaminones have been attractive starting materials for chemists for the 
synthesis of diverse functionalized 3-cyanopyridines [78-83]. Abu-Elmaati has 
reported reaction of enaminone 1-(N-pchlorophenyl)-2-(N-dimethylaminomethino)-3-
oxobutanamide with cyanothioacetamide in ethanol/sodium ethoxide to yield 3-
cyano-4-methylpyridin-2(1H)one [80] (Scheme  2.1.15). 
 
CONHPh
N(CH3)2
+
C
CN NH
S
CN
S
H2N
Scheme  2.1.15
O
PhHNOC
EtONa
 
 
Literature survey also revealed a few ring transformation reactions of 4-
amino-1H-1,5-benzodiazepine-3-carbonitrile [84] and substituted uracil [85] yielding 
3-cyanopyridines. Nohara et al. have reported that heating 2-cyano-3-(6-ethyl-4-oxo-
4H-1-benzopyran-3-yl)acrylamide in pyridine yields 3-cyano-5-(5-ethyl-2-
hydroxybenzoyl)-2(1H)-pyridones [86] (Scheme  2.1.16). 
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O
NH2
O
O
N
C5H5N
NH
CN
O
OOH
Scheme 2.1.16  
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2.1.3 Current work 
The chemistry of pyridine and its derivatives has been studied for over a 
century due to their diverse biological activities. 3-cyanopyridine or pyridine-3-
carbonitrile derivatives draw a special attention for their wide spectrum biological 
activities viz. anti-tubercular, anti-cancer, cardiovascular, anti-histaminic, anti-
inflammatory, analgesic and antipyretic properties along with their importance and 
utility as intermediates in preparing variety of heterocyclic compounds.  
Keeping in mind various biomedical applications and with a view to further 
assess the pharmacological profile of this class of compounds, two novel series of 
pyridine-3-carbonitriles (DDK-A-01 to DDK-A-20) have been synthesized. The 
synthesis of pyridine-3-carbonitriles (DDK-A-01 to DDK-A-10) and (DDK-A-11 to 
DDK-A-20) was achieved by Michael addition of α,β-unsaturated ketones (chalcones) 
to malononitrile in sodium methoxide/methanol and sodium ethoxide/ethanol systems 
resepectively. 3-(2,7-dichloroquinolin-3-yl)-1-(aryl)-prop-2-en-1-ones (chalcones) 
were prepared by the reaction of 2,7-dichloroquinoline-3-carbaldehyde with different 
substituted acetophenones s using 40% sodium hydroxide as a catalyst [87]. The 
products were characterized by FT-IR, mass, 1H NMR spectroscopy and elemental 
analyses. The newly synthesized compounds were subjected to antimicrobial activity. 
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2.1.4 Reaction scheme 
N
CN
OR2
N ClCl
R1
R1
O
NCl Cl
a
+
N
N
DDK-A-01 to DDK-A-20
Reagents and conditions: (a) R2ONa, R2OH, reflux, 6-8 h.
 
Code R1 R2 M.F. M.W. M.P. ºC Yield % Rf1 Rf2 
DDK-A-01 H CH3 C22H13Cl2N3O 406 215-217 69 0.47 0.68 
DDK-A-02 3-NO2 CH3 C22H12Cl2N4O3 451 233-235 62 0.48 0.71
DDK-A-03 4-NO2 CH3 C22H12Cl2N4O3 451 247-249 60 0.53 0.72 
DDK-A-04 4-Cl CH3 C22H12Cl3N3O 439 211-213 70 0.54 0.74 
DDK-A-05 2-OH CH3 C22H13Cl2N3O2 422 189-191 65 0.47 0.69
DDK-A-06 4-OH CH3 C22H13Cl2N3O2 422 195-197 73 0.52 0.70 
DDK-A-07 2-OCH3 CH3 C23H15Cl2N3O2 436 198-200 65 0.55 0.76 
DDK-A-08 4-OCH3 CH3 C23H15Cl2N3O2 436 206-208 75 0.51 0.66
DDK-A-09 4-F CH3 C22H12Cl2FN3O 424 265-267 78 0.56 0.69 
DDK-A-10 4-Br CH3 C22H12BrN3O 485 228-231 62 0.49 0.73 
DDK-A-11 H C2H5 C23H15Cl2N3O 420 128-130 68 0.53 0.61
DDK-A-12 3-NO2 C2H5 C23H14Cl2N4O3 465 241-243 74 0.58 0.67 
DDK-A-13 4-NO2 C2H5 C23H14Cl2N4O3 465 178-180 70 0.49 0.58 
DDK-A-14 4-Cl C2H5 C23H14Cl3N3O 454 239-241 80 0.53 0.60
DDK-A-15 2-OH C2H5 C23H15Cl2N3O2 436 256-258 69 0.59 0.70 
DDK-A-16 4-OH C2H5 C23H15Cl2N3O2 436 263-265 56 0.51 0.59 
DDK-A-17 2-OCH3 C2H5 C24H17Cl2N3O2 450 229-231 63 0.54 0.61
DDK-A-18 4-OCH3 C2H5 C24H17Cl2N3O2 450 234-236 68 0.56 0.63 
DDK-A-19 4-F C2H5 C23H14Cl2FN3O 438 173-175 52 0.48 0.57 
DDK-A-20 4-Br C2H5 C22H12BrN3O 499 238-240 50 0.58 0.68 
 
TLC Solvent system Rf1: Hexane: Ethyl acetate – 6:4,  
TLC Solvent system Rf2: Chloroform:Methanol – 9.5:0.5. 
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2.1.5 Mechanism 
+R1
O
R2ONaR
CN
CN
R = substituted phenyl  ;
R2OH
Cyclization
-H2O N
R
R1 OR2
CN
N ClCl
R1 = R2 = -CH3 or  -C2H5;
R
CN
C OR2
N
B
R
CN
C N
Na R2OA
OR1
OR1
 
 
The reaction proceeds through Michael addition of α,β-unsaturated ketones to the 
malononitrile to afford adduct A which undergoes a nucleophilic attack by alkoxide 
anion followed by cyclization and subsequent dehydration of the cyclized product 
leads to the 2-alkoxycyanopyridines as suggested by Radwan et al. [68] 
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2.1.6 Experimental 
 
2.1.6.1 Materials and Methods 
 
Melting points were determined in open capillary tubes and are uncorrected. 
Formation of the compounds was routinely checked by TLC on silica gel-G plates of 
0.5 mm thickness and spots were located by iodine. IR spectra were recorded 
Shimadzu FT-IR-8400 instrument using KBr pellet method. Mass spectra were 
recorded on Shimadzu GC-MS-QP-2010 model using Direct Injection Probe 
technique. 1H NMR was determined in DMSO-d6 solution on a Bruker Avance II 400 
MHz spectrometer. Elemental analysis of the all the synthesized compounds was 
carried out on Elemental Vario EL III Carlo Erba 1108 model and the results are in 
agreements with the structures assigned. 
 
2.1.6.2 Synthesis of 3-(2,7-dichloroquinolin-3-yl)-1-(aryl)-prop-2-en-1-ones 
 
Synthesis of 3-(2,7-dichloroquinolin-3-yl)-1-(aryl)-prop-2-en-1-ones was achieved 
using previously published method [87]. 
 
2.1.6.3 General procedure for the synthesis of 4-(2,7-dichloroquinolin-3-yl)-2-
methoxy-6-(aryl)-pyridine-3-carbonitriles  (DDK A-01 to DDK-A-10) 
 
3-(2,7-dichloroquinolin-3-yl)-1-(aryl)-prop-2-en-1-one (0.01 mol) was added to a 
freshly prepared sodium methoxide solution (0.015 mol of sodium in 15 mL of 
methanol). Malononitrile (0.01 mol) was then added to this solution. The resulting 
mixture was heated under reflux for 6-8 h. The progress of the reaction was monitored 
by TLC. Upon completion of the reaction, the separated solid was collected by 
filtration, washed with cold methanol and crystallized from ethanol.  
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2.1.6.3.1 4-(2,7-dichloroquinolin-3-yl)-2-methoxy-6-phenylpyridine-3-carbonitrile 
(DDK-A-01) 
Yield: 69%; m.p. 215-217 ºC; IR (cm-1): 3022 
(C-H stretching of aromatic ring), 2951 (C-H 
asymmetrical stretching of CH3 group), 2864 
(C-H symmetrical stretching of CH3 group), 
2218 (C≡N stretching of nitrile group), 1616, 
1585 & 1548 (C=C stretching of aromatic ring), 1462 (C-H asymmetrical deformation 
of CH3 group), 1359 (C-H symmetrical deformation of CH3 group), 1261 (C-O-C 
asymmetrical stretching of OCH3 group), 1074 (C-O-C symmetrical stretching OCH3 
group), 1020 (C-H in plane bending for aromatic ring), 769 (C-Cl stretching), 704  & 
769 (C-H out of plane bending for mono-substituted aromatic ring); 1H NMR 
(DMSO-d6) δ ppm: 4.03 (s, 3H, Ha), 7.95 (s, 1H, Hb), 7.67-7.71 (d, 1H, Hd), 7.83-7.85 
(m, 2H, Hc, f), 8.14-8.15 (d, 1H, He), 7.42-7.47 (m, 3H, Hg, h, h’), 8.03-8.05 (m, 2H, Hi, i’); 
MS: m/z 406; Anal. Calcd. for C22H13Cl2N3O: C, 65.04; H, 3.23; N, 10.34. Found: C, 
64.06; H, 3.16; N, 10.27. 
 
2.1.6.3.2 4-(2,7-dichloroquinolin-3-yl)-2-methoxy-6-(3-nitrophenyl)pyridine-3-
carbonitrile (DDK-A-02) 
Yield: 62%; m.p. 233-235 ºC; MS: m/z 451; 
Anal. Calcd. for C22H12Cl2N4O3: C, 58.55; H, 
2.68; N, 12.42. Found: C, 58.46; H, 2.61; N, 
12.33%. 
 
 
2.1.6.3.3 4-(2,7-dichloroquinolin-3-yl)-2-methoxy-6-(4-nitrophenyl)pyridine-3-
carbonitrile (DDK-A-03) 
Yield: 60%; m.p. 247-249 ºC; MS: m/z 451; Anal. 
Calcd. for C22H12Cl2N4O3: C, 58.55; H, 2.68; 
N, 12.42. Found: C, 58.47; H, 2.61; N, 12.34%. 
 
 
N
CN
OCH3
N ClCl
a
f
h'
h
b c
d
e
i
i'
g
 
N
CN
OCH3
N ClCl
NO2
N
CN
OCH3
N ClClO2N
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2.1.6.3.4 6-(4-chlorophenyl)-4-(2,7-dichloroquinolin-3-yl)-2-methoxypyridine-3-
carbonitrile (DDK-A-04) 
Yield: 70%; m.p. 211-213 ºC; IR (cm-1): 3043 
(C-H stretching of aromatic ring), 2922 (C-H 
asymmetrical stretching of CH3 group), 2852 
(C-H symmetrical stretching of CH3 group), 
2218 (C≡N stretching of nitrile group), 1546, 
1506 & 1456 (C=C stretching of aromatic ring), 1402 (C-H asymmetrical deformation 
of CH3 group), 1348 (C-H symmetrical deformation of CH3 group), 1257 (C-O-C 
asymmetrical stretching of OCH3 group), 1089 (C-O-C symmetrical stretching OCH3 
group), 1010 (C-H in plane bending for aromatic ring), 725 (C-Cl stretching), 821 (C-
H out of plane bending for 1,4-disubstituted aromatic ring); 1H NMR (DMSO-d6) δ 
ppm: 4.02 (s, 3H, Ha), 7.96 (s, 1H, Hb), 7.88-7.89 (d, 1H, Hc), 7.43-7.44 (m, 1H, Hd), 
8.28-8.29 (d, 1H, He), 7.66 (s, 1H, Hf), 7.33-7.35 (d, 2H, Hg, g’, J = 8.36 Hz), 8.17-8.19 
(d, 2H, Hh, h’, J = 8.32 Hz),; MS: m/z 439; Anal. Calcd. for C22H12Cl3N3O: C, 59.96; H, 
2.74; N, 9.53. Found: C, 59.89; H, 2.66; N, 9.43%. 
 
2.1.6.3.5 4-(2,7-dichloroquinolin-3-yl)-6-(2-hydroxyphenyl)-2-methoxypyridine-3-
carbonitrile (DDK-A-05) 
Yield: 65%; m.p. 189-191 ºC; MS: m/z 422; 
Anal. Calcd. for C22H13Cl2N3O2: C, 62.58; H, 
3.10; N, 9.95. Found: C, 62.50; H, 3.01; N, 
9.87%. 
 
2.1.6.3.6 4-(2,7-dichloroquinolin-3-yl)-6-(4-hydroxyphenyl)-2-methoxypyridine-3-
carbonitrile (DDK-A-06) 
Yield: 73%; m.p. 195-197 ºC; MS: m/z 422; 
Anal. Calcd. for C22H13Cl2N3O2: C, 62.58; H, 
3.10; N, 9.95. Found: C, 62.48; H, 3.02; N, 
9.87%. 
 
 
N
CN
OCH3
N ClCl
a
f
g'
g
b c
d
e
h
h'
Cl
N
CN
OCH3
N ClClOH  
N
CN
OCH3
N ClClHO
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2.1.6.3.7 4-(2,7-dichloroquinolin-3-yl)-2-methoxy-6-(2-methoxyphenyl)pyridine-3-
carbonitrile (DDK-A-07) 
Yield: 65%; m.p. 198-200 ºC; MS: m/z 436; Anal. 
Calcd. for C23H15Cl2N3O2: C, 63.32; H, 3.47; N, 
9.63. Found: C, 63.24; H, 3.39; N, 9.53%. 
 
 
2.1.6.3.8 4-(2,7-dichloroquinolin-3-yl)-2-methoxy-6-(4-methoxyphenyl)pyridine-3-
carbonitrile (DDK-A-08) 
Yield: 75%; mp 254-256 ºC; MS: m/z 436; 
Anal. Calcd. for C23H15Cl2N3O2: C, 63.32; H, 
3.47; N, 9.63. Found: C, 63.25; H, 3.38; N, 
9.54%. 
 
2.1.6.3.9 4-(2,7-dichloroquinolin-3-yl)-6-(4-fluorophenyl)-2-methoxypyridine-3-
carbonitrile (DDK-A-09) 
Yield: 78%; m.p. 265-267 ºC; IR (cm-1): 3057 (C-
H stretching of aromatic ring), 2999 (C-H 
asymmetrical stretching of CH3 group), 2899 (C-
H symmetrical stretching of CH3 group), 2216 
(C≡N stretching of nitrile group), 1579 & 1558, 
(C=C stretching of aromatic ring), 1465 (C-H asymmetrical deformation of CH3 
group), 1352 (C-H symmetrical deformation of CH3 group), 1255 (C-O-C 
asymmetrical stretching of OCH3 group), 1022 (C-O-C symmetrical stretching of 
OCH3 group), 987 (C-H in plane bending for aromatic ring), 725 (C-Cl stretching), 
839 (C-H out of plane bending for 1,4-disubstituted aromatic ring); 1H NMR (DMSO-
d6) δ ppm: 3.98 (s, 3H, Ha), 7.96 (s, 1H, Hb), 7.73-7.78 (m, 2H, Hc, f), 7.40-7.44 (m, 1H, 
Hd), 8.16-8.18 (d, 1H, He), 7.18-7.23 (m, 2H, Hg, g’), 8.25-8.28 (t, 2H, Hh, h’); MS: m/z 
424; Anal. Calcd. for C22H12Cl2FN3O: C, 62.28; H, 2.85; N, 9.90. Found: C, 62.19; H, 
2.78; N, 9.83%. 
 
 
N
CN
OCH3
N ClCl
OCH3
 
N
CN
OCH3
N ClClH3CO
N
CN
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2.1.6.3.10 6-(4-bromophenyl)-4-(2,7-dichloroquinolin-3-yl)-2-methoxypyridine-3-
carbonitrile (DDK-A-10) 
Yield: 62%; m.p. 228-231 ºC; MS: m/z 485; 
Anal. Calcd. for C22H12BrN3O: C, 54.46; H, 
2.49; N, 8.66. Found: C, 54.37; H, 2.40; N, 
8.58%. 
 
 
2.1.6.4 General procedure for the synthesis of 4-(2,7-dichloroquinolin-3-yl)-2-
ethoxy-6-(aryl)pyridine-3-carbonitriles  (DDK-A-11 to DDK-A-20) 
 
3-(2,7-dichloroquinolin-3-yl)-1-(aryl)-prop-2-en-1-one (0.01 mol) was added to a 
freshly prepared sodium ethoxide solution (0.015 mol of sodium in 15 mL of ethanol). 
Malononitrile (0.01 mol) was then added to this solution. The resulting mixture was 
heated under reflux for 6-8 h. The progress of the reaction was monitored by TLC. 
Upon completion of the reaction, the separated solid was collected by filtration, 
washed with cold methanol and crystallized from ethanol. 
 
2.1.6.4.1 4-(2,7-dichloroquinolin-3-yl)-2-ethoxy-6-phenylpyridine-3-carbonitrile 
(DDK-A-11) 
Yield: 67%; m.p. 209-211 ºC; IR (cm-1): 3068 
(C-H stretching of aromatic ring), 2956 (C-H 
asymmetrical stretching of CH3 and CH2 group), 
2872 (C-H symmetrical stretching of CH3 and 
CH2 group), 2214 (C≡N stretching of nitrile 
group), 1529 & 1481 (C=C stretching of aromatic ring), 1458 (C-H asymmetrical 
deformation of CH3 group), 1348 (C-H symmetrical deformation of CH3 group), 1257 
(C-O-C asymmetrical stretching of OC2H5 group), 1074 (C-O-C symmetrical 
stretching OC2H5 group), 1016 (C-H in plane bending for aromatic ring), 738 (C-Cl 
stretching), 690 & 738 (C-H out of plane bending for mono-substituted aromatic ring); 
1H NMR (DMSO-d6) δ ppm: 4.71-4.73 (t, 3H, Ha), 1.53-1.56 (q, 2H, Hb), 7.97 (s, 1H, 
Hc), 7.68-7.70 (d, 1H, Hd), 7.85-7.91(m, 2H, He, g); 8.29-8.30 (d, 1H, Hf), 7.49-7.53 (m, 
N
CN
OCH3
N ClClBr
N
CN
O
N ClCl
g
h
i'
i
d
e
f
j
j'
b
a
c
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3H, Hh, i,  i’), 8.14-8.17 (m, 2H, H j, j’); MS: m/z 420; Anal. Calcd. for C23H15Cl2N3O: C, 
65.73; H, 3.60; N, 10.00. Found: C, 65.66; H, 3.51; N, 09.94%. 
 
2.1.6.4.2 4-(2,7-dichloroquinolin-3-yl)-2-ethoxy-6-(3-nitrophenyl)pyridine-3-
carbonitrile (DDK-A-12) 
 Yield: 62%; m.p. 242-244 ºC; MS: m/z 465; 
Anal. Calcd. for C23H14Cl2N4O3: C, 59.37; H, 
3.03; N, 12.04;. Found: C, 59.27; H, 2.94; N, 
11.95%. 
 
 
2.1.6.4.3 4-(2,7-dichloroquinolin-3-yl)-2-ethoxy-6-(4-nitrophenyl)pyridine-3-
carbonitrile (DDK-A-13) 
Yield: 70%; m.p. 178-180 ºC; MS: m/z 465; 
Anal. Calcd. for C23H14Cl2N4O3: C, 59.37; H, 
3.03; N, 12.04;. Found: C, 59.28; H, 2.94; N, 
11.96%. 
 
2.1.6.4.4 6-(4-chlorophenyl)-4-(2,7-dichloroquinolin-3-yl)-2-ethoxypyridine-3-
carbonitrile (DDK-A-14) 
Yield: 71%; m.p. 233-235 ºC; IR (cm-1): 3048 
(C-H stretching of aromatic ring), 2991 (C-H 
asymmetrical stretching of CH3 and CH2 group), 
2822 (C-H symmetrical stretching of CH3 and 
CH2 group), 2220 (C≡N stretching of nitrile 
group), 1616 & 1581 (C=C stretching of aromatic ring), 1467 (C-H asymmetrical 
deformation of CH3 group), 1340 (C-H symmetrical deformation of CH3 group), 1255 
(C-O-C asymmetrical stretching of OC2H5 group), 1109 (C-O-C symmetrical 
stretching OC2H5 group), 1024 (C-H in plane bending for aromatic ring), 761 (C-Cl 
stretching), 835 (C-H out of plane bending for 1,4-disubstituted aromatic ring); 1H 
NMR (DMSO-d6) δ ppm: 4.66-4.70 (t, 3H, Ha), 1.50-1.54 (q, 2H, Hb), 7.96 (s, 1H, Hc), 
7.44-7.47 (m, 1H, Hd), 7.88-7.90 (m, 1H, He), 8.28-8.29 (d, 1H, Hf), 7.66 (s, 1H, Hg), 
7.22-7.25 (d, 2H, Hh, h’, J = 8.60 Hz), 8.18-8.20 (d, 2H, H i, i’, J = 8.28 Hz);  MS: m/z 
N
CN
O
N ClCl
NO2
N
CN
O
N ClClO2N
N
CN
O
N ClCl
g
h'
h
d
e
f
i
i'
b
a
c
Cl
 
Chapter 2-Section 1                                                                    Pyridine-3-carbonitriles  
   
   25
454; Anal. Calcd. for C23H14Cl3N3O: C, 60.75; H, 3.10; N, 9.24. Found: C, 60.69; H, 
3.03; N, 9.17%. 
 
2.1.6.4.5 4-(2,7-dichloroquinolin-3-yl)-2-ethoxy-6-(2-hydroxyphenyl)pyridine-3-
carbonitrile (DDK-A-15) 
Yield: 61%; m.p. 169-171 ºC; MS: m/z 436; 
Anal. Calcd. for C23H15Cl2N3O2: C, 63.32; H, 
3.47; N, 9.63. Found: C, 63.23; H, 3.39; N, 
9.55%. 
 
2.1.6.4.6 4-(2,7-dichloroquinolin-3-yl)-2-ethoxy-6-(4-hydroxyphenyl)pyridine-3-
carbonitrile (DDK-A-16) 
Yield: 62%; m.p. 183-185 ºC; MS: m/z 436; 
Anal. Calcd. for C23H15Cl2N3O2: C, 63.32; H, 
3.47; N, 9.63. Found: C, 63.25; H, 3.38; N, 
9.56%. 
 
2.1.6.4.7 4-(2,7-dichloroquinolin-3-yl)-2-ethoxy-6-(2-methoxyphenyl)pyridine-3-
carbonitrile (DDK-A-17) 
Yield: 63%; m.p. 211-213 ºC; MS: m/z 450; Anal. 
Calcd. for C24H17Cl2N3O2: C, 64.01; H, 3.81; N, 
9.33; Found: C, 63.93; H, 3.75; N, 9.27%. 
 
 
2.1.6.4.8 4-(2,7-dichloroquinolin-3-yl)-2-ethoxy-6-(4-methoxyphenyl)pyridine-3-
carbonitrile (DDK-A-18) 
Yield: 77%; m.p. 268-272 ºC; MS: m/z 450; 
Anal. Calcd. for C24H17Cl2N3O2: C, 64.01; H, 
3.81; N, 9.33; Found: C, 63.93; H, 3.74; N, 
9.25%. 
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2.1.6.4.9 4-(2,7-dichloroquinolin-3-yl)-2-ethoxy-6-(4-fluorophenyl)pyridine-3-
carbonitrile (DDK-A-19) 
Yield: 78%; m.p. 265-267 ºC; IR (cm-1): 3041 (C-
H stretching of aromatic ring), 2991 (C-H 
asymmetrical stretching of CH3 group), 2947 (C-
H asymmetrical stretching of CH2 group), 2854 
(C-H symmetrical stretching of CH3 and CH2 
group), 2214 (C≡N stretching of nitrile group), 1585, 1556, 1504 (C=C stretching of 
aromatic ring), 1467 (C-H asymmetrical deformation of CH3 group), 1435 (C-H 
asymmetrical deformation of CH3 group), 1348 (C-H symmetrical deformation of CH3 
group), 1238 (C-O-C asymmetrical stretching of OC2H5 group), 1076 (C-O-C 
symmetrical stretching OC2H5 group), 1020 (C-H in plane bending for aromatic ring), 
748 (C-Cl stretching), 839 (C-H out of plane bending for 1,4-disubstituted aromatic 
ring); 1H NMR (DMSO-d6) δ ppm: 4.66-4.69 (t, 3H, Ha), 1.49-1.53 (q, 2H, Hb), 8.07 
(s, 1H, Hc), 7.44-7.47 (m, 1H, He), 8.20-8.23 (m, 1H, Hi, i), 8.34-8.35 (d, 1H, Hf), 7.72 
(s, 1H, Hg), 7.22-7.27 (t, 2H, Hh, h’), 7.84-7.93 (m, 2H, Hd,g); MS: m/z 438; Anal. Calcd. 
for C23H14Cl2FN3O: C, 63.03; H, 3.22; N, 9.59. Found: C, 62.95; H, 3.15; N, 9.51%. 
 
2.1.6.4.10 6-(4-bromophenyl)-4-(2,7-dichloroquinolin-3-yl)-2-methoxypyridine-3-
carbonitrile (DDK-A-20) 
Yield: 66%; m.p. 226-228 ºC; MS: m/z 499; 
Anal. Calcd. for C22H12BrN3O: C, 55.34; H, 
2.83; N, 8.42. Found: C, 55.27; H, 2.76; N, 
8.36%. 
 
 
 
 
 
 
 
 
 
N
CN
O
N ClCl
g
h'
h
d
e
f
i
i'
b
a
c
F
N
CN
O
N ClClBr
 
Chapter 2-Section 1                                                                    Pyridine-3-carbonitriles  
   
   27
2.1.7 Spectral discussion 
2.1.7.1 Mass spectral study 
Mass spectra were recorded on Shimadzu GC-MS-QP-2010 model using Direct 
Injection Probe technique. Systematic fragmentation pattern was observed in mass 
spectral analysis. Molecular ion peak was observed in agreement with molecular 
weight of respective compound. Mass fragmentation pattern for a representative 
compound of each series is depicted below. 
 
2.1.7.1.1 Mass fragmentation pattern for DDK-A-04 
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2.1.7.1.2 Mass fragmentation pattern for DDK-A-19 
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2.1.7.2 IR spectral study 
IR spectra were recorded on Shimadzu FT-IR-8400 model using KBr pellet method. 
Various functional groups present in molecule were identified by characteristic 
frequency obtained for them. For 3-cyanopyridines (DDK-A-01 to DDK-A-20), a 
characteristic band of nitrile group was observed in the range of 2214-2220 cm-1. 
Confirmatory bands of C-O-C asymmetrical stretching at 1238-1261 cm-1 and C-O-C 
symmetrical stretching at 1022-1109 cm-1 were observed for methoxy and ethoxy 
groups.  
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2.1.7.3 1H NMR spectral study 
1H NMR spectra were recorded in DMSO-d6 solution on a Bruker Ac 400 MHz 
spectrometer using TMS as an internal standard. Number of protons and their 
chemical shifts were found to support the structure of the synthesized compounds. 
For 3-cyanopyridines (DDK-A-01 to DDK-A-10), characteristic singlet was 
observed for methoxy group at 4.02-4.03 δ ppm. The aromatic ring protons were 
observed at 7.18-8.28 δ ppm and J value were found to be in accordance with 
substitution pattern on phenyl ring.  
While, for 3-cyanopyridines (DDK-A-11 to DDK-A-20), characteristic triplet-
quartet pattern was observed for ethoxy group. A signal as triplet at 1.49-1.56 δ ppm 
corresponding to three methyl (O-CH2-CH3) protons and a quartet at 4.66-4.73 δ ppm 
corresponding to two methylene (O-CH2-CH3) protons was observed confirming the 
formation of 2-ethoxy-3-cyanopyridines. The aromatic ring protons were observed at 
7.22-8.35 δ ppm and J value were found to be in accordance with substitution pattern 
on phenyl ring.  
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IR spectrum of DDK-A-01 
 
 
Mass spectrum of DDK-A-01 
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1H NMR spectrum of DDK-A-01 
 
 
Expanded 1H NMR spectrum of DDK-A-01 
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IR spectrum of DDK-A-04 
 
 
Mass spectrum of DDK-A-04 
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1H NMR spectrum of DDK-A-04 
 
 
Expanded 1H NMR spectrum of DDK-A-04 
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IR spectrum of DDK-A-09 
 
 
Mass spectrum of DDK-A-09 
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1H NMR spectrum of DDK-A-09 
 
 
Expanded 1H NMR spectrum of DDK-A-09 
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IR spectrum of DDK-A-11 
 
 
Mass spectrum of DDK-A-11 
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1H NMR spectrum of DDK-A-11 
 
 
Expanded 1H NMR spectrum of DDK-A-11 
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Expanded 1H NMR spectrum of DDK-A-11 
 
 
IR spectrum of DDK-A-14 
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Mass spectrum of DDK-A-14 
 
 
1H NMR spectrum of DDK-A-14 
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Expanded 1H NMR spectrum of DDK-A-14 
 
 
Expanded 1H NMR spectrum of DDK-A-14 
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IR spectrum of DDK-A-19 
 
 
Mass spectrum of DDK-A-19 
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1H NMR spectrum of DDK-A-19 
 
 
Expanded 1H NMR spectrum of DDK-A-19 
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Expanded 1H NMR spectrum of DDK-A-19 
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2.1.8 Biological evaluation 
2.1.8.1 Antimicrobial evaluation 
All of the synthesized compounds (DDK-A-01 to DDK-A-20) were tested for their 
antibacterial and antifungal activity (MIC) in vitro by broth dilution method [88] with 
two Gram-positive bacteria Staphylococcus aureus MTCC-96, Streptococcus 
pyogenes MTCC 443, two Gram-negative bacteria Escherichia coli MTCC 442, 
Pseudomonas aeruginosa MTCC 441 and three fungal strains Candida albicans 
MTCC 227, Aspergillus Niger MTCC 282, Aspergillus clavatus MTCC 1323 taking 
Ampicillin, Chloramphenicol, Ciprofloxacin, Norfloxacin, Nystatin, and Griseofulvin 
as standard drugs. The standard strains were procured from the Microbial Type 
Culture Collection (MTCC) and Gene Bank, Institute of Microbial Technology, 
Chandigarh, India.  
 The minimal inhibitory concentration (MIC) values for all the newly 
synthesized compounds, defined as the lowest concentration of the compound 
preventing the visible growth, were determined by using microdilution broth method 
according to NCCLS standards [88(a)].  Serial dilutions of the test compounds and 
reference drugs were prepared in Muellere-Hinton agar. Drugs (10 mg) were 
dissolved in dimethylsulfoxide (DMSO, 1 mL). Further progressive dilutions with 
melted Muellere-Hinton agar were performed to obtain the required concentrations. In 
primary screening 1000 μg mL-1, 500 μg mL-1 and 250 μg mL-1 concentrations of the 
synthesized drugs were taken. The active synthesized drugs found in this primary 
screening were further tested in a second set of dilution at 125 μg mL-1, 62.5 μg mL-1, 
50 μg mL-1, 25 μg mL-1, 12.5 μg mL-1, and 6.250 μg mL-1 concentration against all 
microorganisms. The tubes were inoculated with 108 cfu mL-1 (colony forming 
unit/mL) and incubated at 37 ºC for 24 h. The MIC was the lowest concentration of 
the tested compound that yields no visible growth (turbidity) on the plate. To ensure 
that the solvent had no effect on the bacterial growth, a control was performed with 
the test medium supplemented with DMSO at the same dilutions as used in the 
experiments and it was observed that DMSO had no effect on the microorganisms in 
the concentrations studied. The results obtained from antimicrobial susceptibility 
testing are depicted in Table 1. 
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Table 1. Antibacterial and antifungal activity of synthesized compounds DDK-A-
01to DDK-A-20 
 
Code Minimum inhibition concentration (µg mL-1 ) 
Gram-positive Gram-negative Fungal species 
S.a. S. p. E.c. P.a. C. a. A. n. A.c. 
DDK-A-01 500 500 500 500 500 500 >1000 
DDK-A-02 1000 1000 1000 1000 1000 500 500 
DDK-A-03 >1000 500 250 500 1000 250 250 
DDK-A-04 100 62.5 125 100 500 500 500 
DDK-A-05 1000 1000 1000 1000 1000 >1000 500 
DDK-A-06 25 100 200 100 1000 500 500 
DDK-A-07 125 200 500 250 500 500 250 
DDK-A-08 100 125 100 100 1000 500 500 
DDK-A-09 50 100 25 100 >1000 500 1000 
DDK-A-10 25 50 100 50 500 500 1000 
DDK-A-11 1000 500 100 1000 >1000 500  >1000 
DDK-A-12 500 >1000 500 100 500 250 1000 
DDK-A-13 500 500 500 1000 >1000 500 125 
DDK-A-14 125 100 50 250 250 1000 500 
DDK-A-15 500 >1000 500 500 500 500 1000 
DDK-A-16 50 125 100 200 >1000 500 >1000 
DDK-A-17 125 100 250 125 500 500 >1000 
DDK-A-18 125 250 125 50 500 1000 500 
DDK-A-19 100 125 100 250 500 1000 >1000 
DDK-A-20 50 125 250 100 100 1000 500 
Ampicillin 250 100 100 100 - - - 
Chloramphenicol 50 50 50 50 - - - 
Ciprofloxacin 50 50 25 25 - - - 
Norfloxacin 10 10 10 10 - - - 
Nystatin - - - - 100 100 100 
Griseofulvin - - - - 500 100 100 
 
2.1.8.2 Antimycobacterial, anticancer and antiviral evaluation 
Antimycobacterial, anticancer and antiviral screening of all the newly synthesized 
compounds (DDK-A-01 to DDK-A-20) is currently under investigation and results 
are awaited.  
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2.2: Synthesis and biological evaluation 
       of 6-alkoxy-3-methyl-4-aryl-1H- 
       pyrazolo[3,4-b]pyridine-5- 
       carbonitriles        
 
2.2.1 Introduction 
Fused pyridines continue to attract considerable attention of researchers in different 
countries because of their great practical usefulness, primarily, due to a very wide 
spectrum of their biological activities. Pyrazolopyridines occupy a special position 
among these compounds. Along with some other pyridine systems containing an 
annelated five membered heteroaromatic ring, pyrazolopyridines are isosters of 
bioactive indoles or indazoles [89, 90] and have been reported to possess useful 
properties as antimetabolites in the biochemical synthesis of purine [91]. 
When pyrazole and pyridine rings are fused together, five isomeric 
pyrazolopyridines arise from such fusion corresponding to the five possible types of 
annulations of pyrazole to the pyridine ring as shown below. 
 
N N N NH
N
N
N
H
N
N N
H
N
N
N
H
N
   (1) Pyrazolo[1,5-a]pyridine  (2) Pyrazolo[3,4-b]pyridine (3) Pyrazolo[4,3-b]pyridine
   (4) Pyrazolo[3,4-c]pyridine (5) Pyrazolo[4,3-c]pyridine  
 
Pyrazolo[3,4-b]pyridines have been reported to possess wide variety of 
biological activities. Analgesic [92], anxiolytic [93], hypnotic [94], xanthine oxidase 
inhibitory [95, 96], antiviral [97], anti-HIV [98], Corticotropin-Releasing Factor (CRF) 
antagonist [99, 100], antidiabetic [101], antiarrhythmic [102], antitumor [103] 
activities have been reported for certain pyrazolopyridine derivatives. Some examples 
of published derivatives of pyrazolo[3,4-b]pyridines with their biological activities are 
as follows. 
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2.2.2 Reported synthetic strategies 
Synthetic approaches towards pyrazolo[3,4-b]pyridines can be divided conceptually 
into two main groups: (a) appropriately substituted pyrazoles onto which a pyridine 
ring is annelated, and (b) suitably substituted pyridines onto which a pyrazole ring is 
annelated as summarized in the figure below. 
 
N
N
R1
NH2
R2
N
R3
X
R
Route A
Route B
N N
NR
R2
R1
R1= H, Ph
R2=Me, Ar, OH, NH2
R3=CN, COMe, COAr, COOMe
R=Approiate Substituent(s)
X=Leaving Group
 
 
 
2.2.2. 1. ANNELATION OF PYRIDINE RING ONTO PYRAZOLE 
2.2.2.1.1  From 3(5)-Aminopyrazoles 
2.2.2.1.1.1 Use of α, β- unsaturated reagents (as bifunctional synthons) 
By far the most pyrazolo[3,4-b]pyridine synthesis are condensations of aminopyrazole 
with α, β- unsaturated synthons. Reactions of aminopyrazole as 1,3-binucleophiles with 
variety of such α, β- unsaturated synthons have been reported proving this method highly 
useful for the construction of pyrazolo[3,4-b]pyridine core with versatile substituents. 
Examples of pyrazolo[3,4-b]pyridine synthesis published in the relevant period 
are listed in Table below, arranged according to the synthons used.  
 
Entry Aminopyrazole α, β- unsaturated 
synthon 
Pyrazolo[3,4-b]pyridine Ref. 
1 
N
N
R
R'
NH2
 
R1
O
R2
 
N
N N
R' R1
R2
R  
[114] 
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2 
N
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[115] 
3 
N
N
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R
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N
N N
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COOEt
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[116] 
4 
N
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[116] 
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[117] 
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[118] 
7 
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[118] 
8 
N
H
N NH2
 
R
COOEt
COOEt  
N
N
H NH
O
R
COOEt
 
[120] 
aR and R’ means (substituted) aryl or heteroaryl substituent. 
An interesting variation in this type of reactions is the use of β-
aminocrotononitrile or its derivatives resulting in generation of bioactive substituted 
dihydropyrazolo[3,4-b]pyridines with 4-amino and 6-methyl substituents available for 
further synthetic explorations [121] (Scheme 2.2.1).  
 
NC
NH2
CH3 HN
N N
H
O NH2
AcOH
N
HN
O
NH2
+
Scheme 2.2.1  
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Generally, the cyclizations are accomplished in acidic medium [121, 122] or in 
presence of base catalysts like triethyl amine or piperidine [116]. New green chemistry 
approaches recently described involve solvent-free reaction under microwave irradiation 
with or without catalyst [123, 124] as well as reactions in aqueous media [125], which are 
environmentally benign and afford high yields (Scheme 2.2.2). 
 
R
CN
CN R
O
R'N
N N
R
NH2
CN
N
N N
R
R'H2O, SDS ZNCl2, MWI
N
N
Ph
NH2
Ph Ph
R = 4-OMeC6H4, 4-ClC6H4, 4-BrC6H4, 4-NO2C6H4,
       4-MeC6H4, 4-FC6H4, 3-ClC6H4, 3, 4-Cl2C6H4
a R = 4-BrC6H4,     R' = 2-ClC6H4;       f R = 4-ClC6H4,      R' =2-OMeC6H4
b R = 4-BrC6H4,     R' = 4-MeC6H4;     g R = 4-OMeC6H4,  R' = 4-MeC6H4
c R = 4-FC6H4,       R' = 4-MeC6H4;     h R = 4-ClC6H4,      R' = 4-FC6H4
d R = 3,4-Cl2C6H4, R' = 4-OMeC6H4;  i R = 4-OMeC6H4,   R' = 2-ClC6H4
e R = 3-NO2C6H4,  R' = 4-OMeC6H4;   j R = 4-ClC6H4,       R' = 2,4-Cl2C6H4
Scheme 2.2.2
 
Several efficient multi-component reaction (MCR) approaches have been reported 
attractively replacing the use of α, β- unsaturated synthons with their synthetic precursors. 
MCR approaches avoid the synthesis of α, β- unsaturated synthons, thereby reduce the 
reaction steps. The MCRs generally involve the one-pot reaction of aminopyrazole with 
aldehyde and 1,3-bifunctional reagents such as pyruvic acid [118], malononitrile [126], 
ethyl cyanoacetate [127] etc. 
Unraveling site selectivity in these additions is not an easy task unless an acyclic 
intermediate can be isolated or the same reaction products can be synthesized by alternate 
routes. In several cases, modern NMR techniques studies were used to corroborate the 
structures of reaction products.  
Lipson et al. reported that on boiling 3-methyl-5-aminopyrazole with an 
equimolar amount of 2,2-dimethyl-1,3-dioxane-4,6-dione (Meldrum’s acid) and ketones, 
both in methanol and in DMF, only the corresponding pyrazolo[3,4-b]pyridin-6-ones 
were formed and other possible isomeric products were not formed [128]. The structures 
of compounds were established 1H NMR spectra signals and Nuclear Overhauser 
Experiment (NOE) (Scheme 2.2.3). 
Rahmati investigated a one-pot, three-component condensation reaction of 3-
amino-5-methylpyrazole, aldehyde, ethyl cyanoacetate under reflux conditions in ethanol 
using p-toluenesulfonic acid (p-TsOH) as the catalyst [129] (Scheme 2.2.4). The 1H NMR 
spectra of the products indicated the formation of two diastereoisomers (cis and trans).  
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In some cases, a choice of multicomponent or linear protocol allows obtaining 
different heterocycles. For instance, MCR involving 5-aminopyrazole, aldehyde and 
pyruvic acid afforded positional isomer of product obtained from sequence pathway via 
preliminary synthesis of arylidenpyruvic acids [118] (Scheme 2.2.5). 
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Different products of the three-component and linear treatments in the case of 5- 
aminopyrazole can be the evidence that this MCR follows independent pathway without 
in situ formation of α, β- unsaturated compound. 
 
2.2.2.1.1.2 Use of 1,3-dicarbonyl reagents (1,3-dielectrophiles) and other C-H 
acids 
Cyclocondensations of aminopyrazoles with 1,3-dielectrophiles are extensively used 
for preparation of bicyclic nitrogen heterocycles viz. pyrazolo[1,5-a]pyrimidines and 
pyrazolo[3,4-b]pyridines. N1-unsubstituted 3(5)- aminopyrazoles usually react with 
1,3-dicarbonyl compounds providing pyrazolo[1,5-a]pyrimidines [130-132]. The 
reaction of N1-substituted 5-aminopyrazoles with 1,3-dielectrophiles forms 
substituted pyrazolo[3,4-b]pyridines; as bifunctional reagents 1,3-ketoesters [133-
136] as well as symmetric 1,3-diketones [135] are generally employed. The reaction is 
generally accomplished using acetic acid as a solvent [133], but cyclizations using 
hydrochloric acid in ethanol [134] or using zinc chloride and hydrochloric acid in 
ethanol [135] are also documented. 
Microwave-assisted reaction of 1,3-dimethyl-5-amino-pyrazole with activated 
aryl malonates is reported by Rivkin et al. [137] (Scheme 2.2.6). Reaction of 5-
aminopyrazole with aryl 1,3-ketoester is also documented [133]. 
 
N
N NH2
+
O O
OR'OR'
Ph
N
N N
H
OH
O
Ph
MWI
250oC
a R' = Et; b R' = 2,4,6-Cl-C6H2
Scheme 2.2.6  
 
Literature survey also revealed few examples involving use of trifluoromethyl 
containing 1,3-ketoesters [135, 138] and symmetric 1,3-diketones [134], which 
exclusively lead to formation of a single pyrazolo[3,4-b]pyridine isomer as a product. 
Volochnyuk et al. have reported the synthesis of pyrazolo[3,4-b]pyridine using 
trifluoroacetic acid [139] (Scheme 2.2.7). 
However, the application of unsymmetrical 1,3-diketones to the synthesis of 
pyrazolo[3,4-b]pyridines is poorly documented evidently because two regioisomeric 
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products may form in the reaction. The problem of regiodirection of the reaction is 
still urgent for the molecules of 3(5)-aminopyrazoles and unsymmetrical 1,3-
dielectrophiles.  
 
N
N
Ph
NH2
AcOH
N
N N
H
CF3
O
Ph
CF3COOH
Scheme 2.2.7  
 
Emelina et al. investigated the direction of reaction between N1-substituted 
aminopyrazoles and trifluoromethyl-containing unsymmetrical 1,3-diketones [140]. 
The study established characteristic spectral distinctions of individual regioisomers 
using 1H and 13C NMR spectroscopy. It was proved that the regioisomer was formed 
having trifluoromethyl group attached at the C-4 (Scheme 2.2.8). 
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Scheme 2.2.8
 
 
The same research group further published the studies on regiodirection of the 
reaction of N1-unsubstituted 5-amino-3-methyl-pyrazole with hexafluoroacetyl- 
acetone under different reaction conditions [141]. They established the structure of 
intermediate compound leading to the formation of pyrazolo[3,4-b]pyridine by 2D 
NMR by means of homo and heteronuclear correlation procedures: DQF-COSY, J-
COSY, NOESY, and HSQC without decoupling from 13C (Scheme 2.2.9).  
Three component reaction of 5-aminopyrazole with aldehydes and ethyl 
acetoaceate under microwave irradiation is recently reported [116]. As CH-acids in 
the MCRs with 5-aminopyrazoles and aldehydes, aroylacetonitriles have been 
efficiently employed affording 4,6-diaryl-5-cyanopyrazolo[3,4-b]pyridines. Zhu et 
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al.have reported microwave-assisted synthesis of 3-methyl-5-aminopyrazole with 3-
cyanoacetyl indole and aldehydes in glycol as a reaction medium [142]. The same 
reaction was effected regioselectively by Quiroga et al. using solvent-free approach 
under microwave irradiation [117] (Scheme 2.2.10). A solvent-free green chemistry 
approach was adopted in one pot cyclocondensation of 5-amino-3-aryl-1H-
phenylpyrazole, p-substituted benzoylacetonitriles, and some aldehydes using 
ammonium acetate as a reaction medium [143] as well as under neat conditions for 5-
amino-3-pyrazolone, aldehydes and aroylacetonitriles [144].  
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N
N
Ph
NH2 + RO
N
H
CN
O
R1
+
MWI, glycol, 150oC
or
MWI
N
N
N
R
Ph
CN
NH
R1
R = C6H5, 2-ClC6H4, 4-ClC6H4, 2-BrC6H4, 3-BrC6H4, 4-FC6H4, 4-MeC6H4, 4-OMeC6H4, 4-OHC6H4, 2-thienyl, 2-pyridyl, n-propyl, n-butyl
R1= H, 2-C6H5, 2-Me, 4-Me, 7-MeC6H4
Scheme 2.2.10
 
Shaabani et al. have reported novel four-component reaction of aryl/alkyl 
amines, diketene, aldehydes and 1,3-diphenyl-5-aminopyrazole in the presence of p-
toluene sulfonyl chloride as a catalyst in dry dichloromethane at ambient temperature 
[145] (Scheme 2.2.11). 
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Scheme 2.2.11  
 
2.2.2.1.1.3 Gould-Jacobs reaction 
The classical Gould-Jacobs reaction for quinoline synthesis involves reaction between 
aniline and diethyl ethoxymethylene malonate. This reaction is widely documented in 
recent literature for the synthesis of 4-hydroxy- or 4-chloro-pyrazolo[3,4-b]pyridine-
5-carboxylates using 5-aminopyrazole as a substitute for aniline in the classical 
Gould-Jacobs method [109, 146-149]. The first step of the reaction involves the 
addition of diethyl ethoxymethylene malonate to 5-aminopyrazole and the reaction is 
effected in solvents like ethanol [148, 149], or under solvent-free conditions at higher 
temperatures (120-130oC) [109, 147]. The adduct is further cyclized in diphenyl ether 
at 240o C to give 4-hydroxy-pyrazolo[3,4-b]pyridine-5-carboxylate [109] or in 
phosphorus oxychloride to give the 4-chloro-pyrazolo[3,4-b]pyridine-5-carboxylates 
[146-149]. The scope of the reaction is extended by employing novel N1-substituted 
5-aminopyrazoles [109, 146] (Scheme 2.2.12). 
 
EtO
COOEt
COOEt
N
N NH2
H2C
CH
Ph
OH
+ N
N N
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2.2.2.1.1.4 Reactions with β-dimethyl-aminopropiophenones 
Quiroga et al. have reported an interesting synthesis from 5-aminopyrazoles and β-
dimethyl aminopropiophenones yielding 6-aryl-4,5-dihydropyrazolo[3,4-b]pyridines, 
which are aromatized upon treatment with N-bromo succinimide (NBS) to give [150] 
(Scheme 2.2.13).  
Also of interest is the microwave promoted synthesis of 5-aroyl-pyrazolo[3,4- 
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b]pyridines by hetero-Diels-Alder reaction of N-[(dimethylamino)methylene]-3-
methyl-1-phenyl-5-pyrazolamine with β-dimethyl aminopropiophenones in dry media 
in just one step [151] (Scheme 2.2.13).  
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Scheme 2.2.13
 
2.2.2.1.1.5 Ring opening reactions 
Recently, ring opening reactions of variety of reagents with aminopyrazoles have 
drawn considerable attention for the complexity-generating synthesis of pyrazolo[3,4-
b]pyridines baring versatile substituents. 
Synthesis of pyrazolo[3,4-b]pyridine derivatives, which contain synthetically 
useful hydroxyl and carbonyl groups, was achieved from aminopyrazole and 3-formyl 
chromone via opening of the γ-pyrone ring  of 3-formyl chromone [152] (Scheme 
2.2.14). Similar reaction was efficiently achieved from 3-formyl chromone and 
aminopyrazole in presence of chlorotrimethylsilane in DMF [153]. Reaction of 6-
methyl-4-oxo-4H-[1]-benzopyran-3-carboxaldehyde with 5-amino-3-methyl-1-
phenylpyrazole is also reported to furnish 5-(2-hydroxy-5-methylbenzoyl)-3-methyl-
1-phenyl-1H-pyrazolo[3,4-b]pyridine [154]. 
 
R = a-f -C6H5, g-j 4-NO2C6H4, k-o Me,
R1 = a -H, b 5-Me, c 5-F, d 5-Br, e 5-Cl, f 5-NO2, g 5-Me, h 5-F,
         i 5-Br, j 5-Cl, k 5-Me, l 5-F, m 5-Br, n 5-Cl, o 5-NO2
Scheme 2.2.14
O
O
CHO
N
N
R
NH2
+
EtOH, H+
-10oC
N
N N
R
O OH
R1 R1
 
 
 
 
Chapter 2-Section 2                                           Pyrazolo[3,4-b]pyridine-5-carbonitriles   
   57
2.2.2.1.1.6 Miscellaneous reactions with 3(5)-aminopyrazoles 
Abdel-Khalik et al. have reported reaction of 2-Arylhydrazonopropanals with 5-
methyl-1H-pyrazol-3-amine yielding novel 3-substituted pyrazolo[3,4-b] pyridines 
[155] (Scheme 2.2.15).  
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Scheme 2.2.15  
 
While microwave-assisted reaction of 5-amino-3-methyl-1-phenylpyrazole 
with aldehydes under solvent-free conditions furnished bispyrazolo[3,4-b:4',3'-
e]pyridines [156]. Bispyrazolo[3,4-b:4',3'-e]pyridines were also obtained by refluxing 
3-methyl-5-aminopyrazole with arylidenemalonic acid derivatives in nitrobenzene or 
bromobenzene [157] (Scheme 2.2.16). 
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Scheme 2.2.16
 
 
2.2.2.1.2 Friedlander Reaction 
The classical Friedlander quinoline synthesis is an acid or base catalyzed 
condensation followed by a cyclodehydration between an aromatic 2-aminoaldehyde 
or ketone with the carbonyl compound containing a reactive α-methylene group [158, 
159]. Friedlander reaction of various 5-amino-pyrazole-4-carboxaldehydes have been 
efficiently employed in literature for the synthesis of pyrazolo[3,4-b]pyridines with 
versatile substituents. As active methylene compounds with 5-amino-pyrazole-4-
carboxaldehydes; ethyl acetoacetate [160], ethyl 3-oxo-3-phenylpropanoate [161], 
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acetone [161, 167], acetyl acetone [160, 167], acetophenones [161, 167], diethyl 
malonate [161], aroylacetonitriles [161-163], aryl/heteroaryl acetonitrile [161, 162], 
malononitrile [160, 164] have been employed. Abd-El-Latif et al. have reported an 
interesting condensation between 3-phenyl-5-chloro-1-phenylpyrazole-4-
carbaldehyde and cyanoacetamide/cyano-thioacetamide furnishing Friedlander type 
product 1,3-diphenylpyrazolo[3,4-b]pyridine derivatives [165]. Reactions are usually 
effected in presence of base catalysts like pyridine [160], piperidine [161, 162] or 
potassium hydroxide [161, 167].  
The starting 5-amino-pyrazole-4-carboxaldehydes are generally synthesized 
by Vilsmeier-Haack formylation of 5-aminopyrazoles [161] or by reduction of 5-
azidopyrazole-4-carboxaldehyde with hydrogen sulphide [160, 166] or sodium 
dithionite [166]. However, Zheng et al.have reported a facile one-pot conversion of 5-
azidopyrazole-4-carboxaldehyde to pyrazolo[3,4-b]pyridines in presence of alcoholic 
potassium hydroxide [167] (Scheme 2.2.17). 
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2.2.2.1.3 From 4-cyano-5-amino-pyrazoles 
Reactions of different substituted 4-cyano-5-amino-pyrazoles with variety of active 
methylenes or C-H acids are reported as valuable tool for obtaining highly 
functionalized pyrazolo[3,4-b]pyridines. Reactions of 4-cyano-5-amino-pyrazoles 
with ethyl acetoacetate [168, 169], acetyl acetone [168], diethyl malonate [168, 169], 
cyanoacetone [170], malononitrile [169] have been reported. The cyclocondensation 
is generally achieved in basic media like sodium ethoxide [170] or in presence of base 
like triethyl amine [169].  
One interesting report using SnCl4 as a catalyst in toluene for 
cyclocondensation is published by Zhao et al. [168] (Scheme 2.2.18). 
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2.2.2. 2.  ANNELATION OF PYRAZOLE RING ONTO PYRIDINE 
Annelation of pyridine onto pyrazole ring (Route A) is the most commonly employed 
protocol and offers a degree of flexibility in terms of substitution about the pyridine 
ring. While Annelation of pyrazole onto pyridine ring (Route B) has remained 
relatively unexplored and has been confined to pyrazoles containing a methyl-, aryl-, 
hydroxy- or an amino- group at the 3-position [171]. Route B involves the formation 
of pyrazole ring from a 3-acetyl-, 3-carboxy- or 3-cyanopyridines bearing a leaving 
group in the 2-position. 
 
2.2.2. 2.1 From 3-Cyanopyridines 
2.2.2. 2.1.1 From 2-halo-3-cyanopyridines 
Reaction of 2-chloro-3-cyanopyridines with hydrazine hydrate or its derivatives is 
widely employed strategy in literature furnishing 3-amino-pyrazolo[3,4-b]pyridines 
(for Route B) [171, 173-178]. Reaction is generally carried out by refluxing 2-chloro-
3-cyanopyridines and hydrazine hydrate in suitable solvents viz. EtOH, BuOH, DMF 
etc (Scheme 2.2.19). However, base catalyst CS2CO3 in DMF has been used for 
cyclization by Lavecchia et al. [173]. 
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Scheme 2.2.19  
 
2.2.2. 2.1.2 From 2-thioxo-3-cyanopyridines 
Literature survey also revealed several reports involving reaction of 2-thioxo-3-
cyanopyridines [179-182] or its S-methyl derivatives [181, 183, 184] with hydrazine 
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hydrate for the synthesis of 3-amino-pyrazolo[3,4-b]pyridines. Variety of 2-thioxo-3-
cyanopyridines have been used by different researchers as shown below. 
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2.2.2.2.1.3 From 2-alkoxy-3-cyanopyridines 
3-amino-pyrazolo[3,4-b]pyridines can also be synthesized by the reaction of 2-
alkoxy-3-cyanopyridines with hydrazine hydrate or its derivatives [99, 185]. Goda et 
al. have synthesized 3-amino-pyrazolo[3,4-b]pyridines from 2-alkoxy-3-
cyanopyridine using BF3 as a catalyst [185] (Scheme 2.2.20). 
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Scheme 2.2.20  
 
2.2.2.2.2. From 3-Carboxylpyridines 
Recent literature survey revealed only one report involving reaction starting from 2-
chloro-nicotinic acid derivatives yielding 3-oxo-pyrazolo[3,4-b]pyridines in three steps 
[186] (Scheme 2.2.21). 
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2.2.2.2.3 From 3-Acetylpyridines (or 3-Benzoylpyridines) 
Tucker et al. have reported synthesis of 3-methyl-pyrazolo[3,4-b]pyridines from 1-(2,6-
Difluoropyridin-3-yl)ethanone in two steps [98] (Scheme 2.2.22). 
Similar reaction have been reported by Zhong et al.via double SNAr reaction of 
and its derivatives with hydrazine hydrate in one pot using n-BuLi as a base [187] The 
compound and derivatives have also been synthesized from 1-(2-amino-6-fluoropyridin-
3-yl)ethanone [188] (Scheme 2.2.22). 
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Scheme 2.2.22
 
Recently, number of synthetic approaches starting from 3-benzoylpyridines have also 
been published [189, 190]. For instance, Sweeny et al. have reported synthesis of 3-
(substitutedbenzyl)-1H-pyrazolo[3,4-b]pyridine from reaction of 1-(2-chloropyridin-3-
yl)-2-(aryl)ethanone with hydrazine hydrate [190] (Scheme 2.2.23).  
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2.2.2.3  MISCELLANEOUS SYNTHESIS 
Kolosov et al. have reported synthesis of pyrazolo[3,4-b]pyridines by reaction of α-
cyanochalcones with phenylhydrazine [191] (Scheme 2.2.24). 
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2.2.3 Current work 
Pyrazolopyridines occupy a special position among fused pyridines due to their 
diverse biological activities. Pyrazolo[3,4-b]pyridine ring system is of special 
biological interest as isosters of bioactive indoles or indazoles. It has numerous 
pharmacological and medicinal applications viz. antiviral, antidiabetic, antiarrythmic,  
antitumour, anti-inflammatory etc.  
Keeping in mind various biomedical applications and with a view to further 
assess the pharmacological profile of this class of compounds, two novel series of 
pyrazolo[3,4-b]pyridine-5-carbonitriles (DDK-A-21 to DDK-A-40) have been 
synthesized. The synthesis of pyrazolo[3,4-b]pyridine-5-carbonitriles (DDK-A-21 to 
DDK-A-30) and (DDK-A-31 to DDK-A-40) was achieved by the reaction of 
arylidene malononitrile and  3-methyl-1H-pyrazol-5H-one in sodium 
methoxide/methanol and sodium ethoxide/ethanol systems resepectively. Arylidene 
malononitriles were prepared via the Knoevenagel condensation reaction between 
different aromatic aldehydes and malononitrile [192]. The products were 
characterized by FT-IR, mass spectra, 1H NMR and elemental analysis. The newly 
synthesized compounds were subjected to antimicrobial activity. 
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2.2.4 Reaction scheme 
N
H
N O NN
H N OR2
CN
CN
+
a
R1
R1
Reagents and conditions: (a) R2ONa, R2OH, reflux, 10-12 h.
CN
DDK-A-21 to DDK-A-40
 
 
Code R1 R2 M.F. M.W. M.P. ºC Yield % Rf1 Rf2 
DDK-A-21 H CH3 C13H11N3OS 264 222-224 68 0.49 0.66
DDK-A-22 2-Cl CH3 C15H11ClN4O 298 218-220 61 0.47 0.73 
DDK-A-23 3-Cl CH3 C15H11ClN4O 298 237-239 65 0.49 0.71 
DDK-A-24 4-Cl CH3 C15H11ClN4O 298 193-195 60 0.52 0.74
DDK-A-25 3- NO2 CH3 C15H11N5O3 309 234-236 60 0.50 0.67 
DDK-A-26 4- NO2 CH3 C15H11N5O3 309 228-230 65 0.54 0.68 
DDK-A-27 4-OCH3 CH3 C16H14N4O4 294 181-183 65 0.53 0.74
DDK-A-28 4- CH3 CH3 C16H14N4O 278 261-263 69 0.48 0.65 
DDK-A-29 4-F CH3 C15H11FN4O 282 236-238 65 0.55 0.66 
DDK-A-30 4-OH CH3 C15H12N4O2 280 237-239 60 0.49 0.70
DDK-A-31 H C2H5 C16H14N4O 278 218-220 66 0.53 0.61 
DDK-A-32 2-Cl C2H5 C16H13ClN4O 312 229-231 60 0.57 0.65 
DDK-A-33 3-Cl C2H5 C16H13ClN4O 312 244-246 64 0.49 0.58 
DDK-A-34 4-Cl C2H5 C16H13ClN4O 312 208-210 63 0.52 0.60 
DDK-A-35 3- NO2 C2H5 C16H15N3O2S 323 248-250 61 0.59 0.70 
DDK-A-36 4- NO2 C2H5 C15H11N5O3 323 236-238 65 0.50 0.58 
DDK-A-37 4-OCH3 C2H5 C17H16N4O2 308 196-198 69 0.54 0.61 
DDK-A-38 4- CH3 C2H5 C16H14N4O 292 213-215 65 0.55 0.63 
DDK-A-39 4-F C2H5 C16H13FN4O 296 229-231 61 0.48 0.57 
DDK-A-40 4-OH C2H5 C16H14N4O2 294 193-195 62 0.49 0.62 
 
TLC Solvent system Rf1: Hexane: Ethyl acetate – 5:5,  
TLC Solvent system Rf2: Chloroform: Methanol – 9:1.  
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2.2.5 Mechanism 
1 2
3
N
H
N O
R CN
CN
R2ONa
R2OH NH
N O
R
CN
C N
Na R2OA
N
H
N O
R
CN
C OR2
N
B
H2O
2H
N
N
H N OR2
CN
R
R = substituted phenyl ; R2 = -CH3 or  -C2H5  
 
The proposed mechanism involves the Michael addition between 1 and 2 to generate 
intermediate A, followed by alkoxide nucleophilic attack at one of the nitrile groups 
of A with dehydration and subsequent dehydrogenation to give the pyrazolo[3,4-b] 
pyridine 3 [193].  
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2.2.6 Experimental 
 
2.2.6.1 Materials and Methods 
 
Melting points were determined in open capillary tubes and are uncorrected. 
Formation of the compounds was routinely checked by TLC on silica gel-G plates of 
0.5 mm thickness and spots were located by iodine. IR spectra were recorded 
Shimadzu FT-IR-8400 instrument using KBr pellet method. Mass spectra were 
recorded on Shimadzu GC-MS-QP-2010 model using Direct Injection Probe 
technique. 1H NMR was determined in DMSO-d6 solution on a Bruker Avance II 400 
MHz (for compounds DDK-A-23, DDK-A-29, DDK-A-34, DDK-A-39) and Bruker 
DRX 300 MHz (for compounds DDK-A-24, DDK-A-37) spectrometer. Elemental 
analysis of the all the synthesized compounds was carried out on Elemental Vario EL 
III Carlo Erba 1108 model and the results are in agreements with the structures 
assigned. 
 
2.2.6.2 Synthesis of 2-(arylidene)malononitriles 
 
Synthesis of 2-(arylidene)malononitriles was achieved using previously published 
method [192]. 
 
2.2.6.3 General procedure for the synthesis of 6-methoxy-3-methyl-4-(aryl)-1H-
pyrazolo[3,4-b]pyridine-5-carbonitriles (DDK-A-21 to DDK-A-30) 
 
 2-(arylidene)malononitrile (0.01 mol) was added to a freshly prepared sodium 
methoxide solution (0.015 mol of sodium in 15 mL of methanol). 3-methyl-1H-
pyrazol-5H-one (0.01 mol) was then added to this solution. The resulting mixture was 
heated under reflux for 10-12 h. The progress of the reaction was monitored by TLC. 
Upon completion of the reaction, the separated solid was collected by filtration, 
washed with cold methanol and crystallized from ethanol.  
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2.2.6.3.1 6-methoxy-3-methyl-4-phenyl-1H-pyrazolo[3,4-b]pyridine-5-carbonitrile 
(DDK-A-21) 
Yield: 68%; m.p. 222-224 ºC; MS: m/z 264; 
Anal. Calcd. for C15H12N4O: C, 68.17; H, 4.58; 
N, 21.20. Found: C, 68.08; 4.14; N, 21.13%. 
 
 
2.2.6.3.2 4-(2-chlorophenyl)-6-methoxy-3-methyl-1H-pyrazolo[3,4-b]pyridine-5-
carbonitrile (DDK-A-22) 
Yield: 61%; m.p. 218-220 ºC; MS: m/z 298; 
Anal. Calcd. for C15H11ClN4O: C, 60.31; H, 3.71; 
N, 18.76. Found: C, 60.24; H, 3.63; N, 18.70%. 
 
 
2.2.6.3.3 4-(3-chlorophenyl)-6-methoxy-3-methyl-1H-pyrazolo[3,4-b]pyridine-5-
carbonitrile (DDK-A-23) 
Yield: 65%; m.p. 237-239 ºC; IR (cm-1): 3286 (N-
H stretching of secondary amine), 3041 (C-H 
stretching of aromatic ring), 2947 (C-H 
asymmetrical stretching of CH3 group), 2852 (C-H 
symmetrical stretching of CH3 group), 2218 (C≡N 
stretching of nitrile group), 1637 (C=N stretching of 
pyridine ring), 1599, 1546 and 1510 (C=C stretching of aromatic ring), 1452 (C-H 
asymmetrical deformation of CH3 group), 1377 (C-H symmetrical deformation of CH3 group), 
1301 (C-N stretching of secondary amine), 1232 (C-O-C asymmetrical stretching of OCH3 
group), 1095 (C-O-C symmetrical stretching OCH3 group), 995 (C-H in plane 
bending for aromatic ring), 794 (C-Cl stretching), 727 (C-H out of plane bending for 
1,3-disubstituted aromatic ring); 1H NMR (DMSO-d6) δ ppm: 2.53 (s, 3H, Ha), 3.98 (s, 3H, 
Hb), 7.4 (s, 1H, Hc), 7.50-7.53 (m, 2H, Hd, f), 7.39-7.42 (m, 1H, He), 8.00 (s, 1H, Hg); MS: m/z 
298; Anal. Calcd. for C15H11ClN4O: C, 60.31; H, 3.71; N, 18.76. Found: C, 60.231; H, 3.64; N, 
18.69%. 
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2.2.6.3.4 4-(4-chlorophenyl)-6-methoxy-3-methyl-1H-pyrazolo[3,4-b]pyridine-5-
carbonitrile (DDK-A-24) 
Yield: 60%; m.p. 193-195 ºC; IR (cm-1): 3240 
(N-H stretching of secondary amine), 3039 (C-H 
stretching of aromatic ring), 2947 (C-H 
asymmetrical stretching of CH3 group), 2884 (C-H 
symmetrical stretching of CH3 group), 2218 (C≡N 
stretching of nitrile group), 1645 (C=N stretching of 
pyridine ring), 1597, 1548 and 1512 (C=C stretching of aromatic ring), 1454 (C-H 
asymmetrical deformation of CH3 group), 1379 (C-H symmetrical deformation of CH3 group), 
1305 (C-N stretching), 1230 (C-O-C asymmetrical stretching of OCH3 group), 1091 (C-
O-C symmetrical stretching OCH3 group), 727 (C-Cl stretching), 840 (C-H out of 
plane bending for para-substituted aromatic ring); 1H NMR (DMSO-d6) δ ppm: 2.50 (s, 
3H, Ha), 3.85 (s, 3H, Hb), 7.33-7.36 (d, 2H, Hc, c’, J = 8.4 Hz), 7.50-7.53 (d, 2H, Hd, d’, J = 8.4 
Hz), 7.90 (s, 1H, He); MS: m/z 298; Anal. Calcd. for C15H11ClN4O: C, 60.31; H, 3.71; N, 
18.76. Found: C, 60.24; H, 3.64; N, 18.68%. 
 
2.2.6.3.5 6-methoxy-3-methyl-4-(3-nitrophenyl)-1H-pyrazolo[3,4-b]pyridine-5-
carbonitrile (DDK-A-25) 
Yield: 60%; m.p. 234-236 ºC; MS: m/z 309; 
Anal. Calcd. for C15H11N5O3: C, 58.25; H, 3.58; 
N, 22.64. Found: C, 58.18; H, 3.52; N, 22.57%. 
 
 
 
2.2.6.3.6 6-methoxy-3-methyl-4-(4-nitrophenyl)-1H-pyrazolo[3,4-b]pyridine-5-
carbonitrile (DDK-A-26) 
Yield: 65%; m.p. 228-230 ºC; MS: m/z 309; 
Anal. Calcd. for C15H11N5O3: C, 58.25; H, 3.58; 
N, 22.64. Found: C, 58.17; H, 3.50; N, 22.56%. 
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2.2.6.3.7 6-methoxy-4-(4-methoxyphenyl)-3-methyl-1H-pyrazolo[3,4-b]pyridine-5-
carbonitrile (DDK-A-27) 
 Yield: 65%; m.p. 181-183 ºC; MS: m/z 294; 
Anal. Calcd. for C16H14N4O4: C, 65.30; H, 4.79; 
N, 19.04. Found: C, 65.23; H, 4.73; N, 18.96%. 
 
 
 
2.2.6.3.8 6-methoxy-3-methyl-4-p-tolyl-1H-pyrazolo[3,4-b]pyridine-5-carbonitrile 
(DDK-A-28) 
Yield: 69%; m.p. 261-263 ºC; MS: 
m/z 278; Anal. Calcd. for C16H14N4O: C, 69.05; 
H, 5.07; N, 20.13. Found: C, 68.96; H, 4.99; N, 
20.06%. 
 
 
2.2.6.3.9 4-(4-fluorophenyl)-6-methoxy-3-methyl-1H-pyrazolo[3,4-b]pyridine-5-
carbonitrile (DDK-A-29) 
Yield: 65%; m.p. 236-238 ºC; IR (cm-1): 3271 (N-
H stretching of secondary amine), 3032 (C-H 
stretching of aromatic ring), 2918 (C-H 
asymmetrical stretching of CH3 group), 2858 (C-H 
symmetrical stretching of CH3 group), 2218 (C≡N 
stretching of nitrile group), 1599, 1545 and 1516 
(C=C stretching of aromatic ring), 1437 (C-H asymmetrical deformation of CH3 group), 1301 
(C-H symmetrical deformation of CH3 group), 1232 (C-O-C asymmetrical stretching of 
OCH3 group), 1090 (C-O-C symmetrical stretching OCH3 group), 1020 (C-F 
stretching), 839 (C-H out of plane bending for 1,4-disubstituted aromatic ring); 1H 
NMR (DMSO-d6) δ ppm: 2.53 (s, 3H, Ha), 3.91 (s, 3H, Hb), 7.32-7.36 (t, 2H, Hc, c’), 7.48-7.52 
(m, 2H, Hd, d’), 7.93 (s, 1H, He); MS: m/z 282; Anal. Calcd. for C15H11FN4O: C, 63.83; H, 
3.93; N, 19.85. Found: C, 63.77; H, 3.87; N, 19.77%. 
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2.2.6.3.10 4-(4-hydroxyphenyl)-6-methoxy-3-methyl-1H-pyrazolo[3,4-b]pyridine-
5-carbonitrile (DDK-A-30) 
 Yield: 60%; m.p. 237-239 ºC; MS: m/z 280; 
Anal. Calcd. for C15H12N4O2: C, 64.28; H, 4.32; 
N, 19.99. Found: C, 64.19; H, 4.26; N, 19.91%. 
 
 
 
 
2.2.6.4 General procedure for the synthesis of 6-ethoxy-3-methyl-4-phenyl-1H-
pyrazolo[3,4-b]pyridine-5-carbonitriles (DDK-A-31 to DDK-A-40) 
 
2-(arylidene)malononitrile (0.01 mol) was added to a freshly prepared sodium 
methoxide solution (0.015 mol of sodium in 15 mL of ethanol). 3-methyl-1H-pyrazol-
5H-one (0.01 mol) was then added to this solution. The resulting mixture was heated 
under reflux for 10-12 h. The progress of the reaction was monitored by TLC. Upon 
completion of the reaction, the separated solid was collected by filtration, washed 
with cold methanol and crystallized from ethanol.  
 
2.2.6.4.1 6-ethoxy-3-methyl-4-phenyl-1H-pyrazolo[3,4-b]pyridine-5-carbonitrile 
(DDK-A-31) 
Yield: 66%; m.p. 218-220 ºC; MS: m/z 278; 
Anal. Calcd. for C16H14N4O: C, 69.05; H, 5.07; 
N, 20.13. Found: C, 68.97; H, 4.99; N, 20.07%. 
 
 
2.2.6.4.2 4-(2-chlorophenyl)-6-ethoxy-3-methyl-1H-pyrazolo[3,4-b]pyridine-5-
carbonitrile (DDK-A-32) 
 
Yield: 60%; m.p. 229-231 ºC; MS: m/z 312; 
Anal. Calcd. for C16H13ClN4O: C, 61.44; H, 4.19; 
N, 17.91. Found: C, 61.38; H, 4.14; N, 17.84%. 
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2.2.6.4.3 4-(3-chlorophenyl)-6-ethoxy-3-methyl-1H-pyrazolo[3,4-b]pyridine-5-
carbonitrile (DDK-A-33) 
Yield: 64%; m.p. 244-246 ºC; MS: m/z 312; Anal. 
Calcd. for C16H13ClN4O: C, 61.44; H, 4.19; N, 
17.91. Found: C, 61.37; H, 4.12; N, 17.85%. 
 
 
 
2.2.6.4.4 4-(4-chlorophenyl)-6-ethoxy-3-methyl-1H-pyrazolo[3,4-b]pyridine-5-
carbonitrile (DDK-A-34) 
Yield: 63%; m.p. 208-210 ºC; IR (cm-1): 3236 
(N-H stretching of secondary amine), 3043 (C-H 
stretching of aromatic ring), 2985 (C-H 
asymmetrical stretching of CH3 and CH2 group), 
2860 (C-H symmetrical stretching of CH3 and CH2 
group), 2218 (C≡N stretching of nitrile group), 
1635 (C=N stretching of pyridine ring), 1539 and 1494 (C=C stretching of aromatic ring), 1440 
(C-H asymmetrical deformation of CH3 group), 1330 (C-H symmetrical deformation of CH3 
group), 1301 (C-N stretching), 1247 (C-O-C asymmetrical stretching of OCH3 group), 
1091 (C-O-C symmetrical stretching OCH3 group), 719 (C-Cl stretching), 833 (C-H 
out of plane bending for 1,4-disubstituted aromatic ring); 1H NMR (DMSO-d6) δ ppm: 
1.53-1.56 (t, 1H, Ha), 2.53 (s, 3H, Hb), 4.51-4.53 (q, 2H, Hc), 7.33-7.35 (d, 2H, Hd, d’, J = 8.32 
Hz), 7.56-7.58 (d, 2H, He, e’, J = 8.52 Hz), 8.00 (s, 1H, Hf); MS: m/z 312; Anal. Calcd. for 
C16H13ClN4O: C, 61.44; H, 4.19; N, 17.91. Found: C, 61.38; H, 4.12; N, 17.82%. 
 
2.2.6.4.5 6-ethoxy-3-methyl-4-(3-nitrophenyl)-1H-pyrazolo[3,4-b]pyridine-5-
carbonitrile (DDK-A-35) 
Yield: 61%; m.p. 248-250 ºC; MS: m/z 323; 
Anal. Calcd. for C16H13N5O3: C, 59.44; H, 4.05; 
N, 21.66;. Found: C, 59.39; H, 3.98; N, 21.59;%. 
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2.2.6.4.6 6-ethoxy-3-methyl-4-(4-nitrophenyl)-1H-pyrazolo[3,4-b]pyridine-5-
carbonitrile (DDK-A-36) 
Yield: 65%; m.p. 236-238 ºC; MS: m/z 323; 
Anal. Calcd. for C15H11N5O3: C, 58.25; H, 3.58; 
N, 22.64. Found: C, 58.17; H, 3.50; N, 22.56%. 
 
 
 
2.2.6.4.7 6-ethoxy-4-(4-methoxyphenyl)-3-methyl-1H-pyrazolo[3,4-b]pyridine-5-
carbonitrile (DDK-A-37) 
 Yield: 69%; m.p. 196-198 ºC; IR (cm-1): 3285 
(N-H stretching of secondary amine), 3010 (C-H 
stretching of aromatic ring), 2972 (C-H 
asymmetrical stretching of CH3 group), 2933 (C-H 
asymmetrical stretching of CH2 group), 2843 (C-H 
symmetrical stretching of CH3 and CH2 group), 
2218 (C≡N stretching of nitrile group), 1597 & 1541 (C=C stretching of aromatic ring), 1452 
(C-H asymmetrical deformation of CH3 group), 1311 (C-H symmetrical deformation of CH3 
group), 1301 (C-N stretching), 1251 (C-O-C asymmetrical stretching of OCH3 group), 
1026 (C-O-C symmetrical stretching OCH3 group), 977 (C-H in plane bending for 
aromatic ring), 837 (C-H out of plane bending for 1,4-disubstituted aromatic ring); 1H 
NMR (DMSO-d6) δ ppm: 1.31-1.36 (t, 1H, Ha), 2.49 (s, 3H, Hb), 3.83 (s, 1H, Hg), 4.39-4.45 (q, 
2H, Hc), 7.09-7.11 (d, 2H, Hd, d’, J = 8.4 Hz), 7.46-7.49 (d, 2H, He, e’, J = 8.1 Hz), 7.90 (s, 1H, Hf); 
MS: m/z 308; Anal. Calcd. for C17H16N4O2: C, 66.22; H, 5.23; N, 18.17. Found: C, 
66.16; H, 5.18; N, 18.09%. 
 
2.2.6.4.8 6-ethoxy-3-methyl-4-p-tolyl-1H-pyrazolo[3,4-b]pyridine-5-carbonitrile 
(DDK-A-38) 
Yield: 65%; m.p. 213-215 ºC; MS: 
m/z 292; Anal. Calcd. for C16H14N4O: C, 69.85; 
H, 5.52; N, 19.17. Found: C, 69.79; H, 5.44; N, 
19.09%. 
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2.2.6.4.9 4-(4-fluorophenyl)-6-ethoxy-3-methyl-1H-pyrazolo[3,4-b]pyridine-5-
carbonitrile (DDK-A-39) 
Yield: 61%; m.p. 229-231 ºC; IR (cm-1): 3246 (N-
H stretching of secondary amine), 3032 (C-H 
stretching of aromatic ring), 2989 (C-H 
asymmetrical stretching of CH3 and CH2 group), 
2868 (C-H symmetrical stretching of CH3 and CH2 
group), 2218 (C≡N stretching of nitrile group), 1637 
(C=N stretching of pyridine ring), 1599, 1546 and 1510 (C=C stretching of aromatic ring), 
1452 (C-H asymmetrical deformation of CH3 group), 1377 (C-H symmetrical deformation of 
CH3 group), 1301 (C-N stretching), 1232 (C-O-C asymmetrical stretching of OCH3 
group), 1095 (C-O-C symmetrical stretching OCH3 group), 1027 (C-F stretching), 
995 (C-H in plane bending for aromatic ring), 840 (C-H out of plane bending for 1,4-
disubstituted aromatic ring); 1H NMR (DMSO-d6) δ ppm: 1.41-1.44 (t, 1H, Ha), 2.58 (s, 3H, 
Hb), 4.45-4.51 (q, 2H, Hc), 7.21-7.25 (t, 2H, Hd, d’), 7.51-7.54 (m, 2H, He, e’), 8.00 (s, 1H, Hf); 
MS: m/z 296; Anal. Calcd. for C16H13FN4O: C, 64.86; H, 4.42; N, 18.91. Found: C, 
64.78; H, 4.35; N, 18.85%. 
 
2.2.6.4.10 4-(4-hydroxyphenyl)-6-methoxy-3-methyl-1H-pyrazolo[3,4-b]pyridine-
5-carbonitrile (DDK-A-40) 
 Yield: 62%; m.p. 193-195 ºC; MS: m/z 294; 
Anal. Calcd. for C16H14N4O2: C, 65.30; H, 4.79; 
N, 19.04. Found: C, 65.23; H, 4.72; N, 18.97%. 
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2.2.7 Spectral discussion 
2.2.7.1 Mass spectral study 
Mass spectra were recorded on Shimadzu GC-MS-QP-2010 model using Direct 
Injection Probe technique. Systematic fragmentation pattern was observed in mass 
spectral analysis. Molecular ion peak was observed in agreement with molecular 
weight of respective compound. Mass fragmentation pattern for a representative 
compound of each series is depicted below. 
 
2.2.7.1.1 Mass fragmentation pattern for DDK-A-29 
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2.2.7.1.2 Mass fragmentation pattern for DDK-A-37 
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2.2.7.2. IR spectral study 
IR spectra were recorded on Shimadzu FT-IR-8400 model using KBr pellet method. 
Various functional groups present in molecule were identified by characteristic 
frequency obtained for them. For pyrazolo[3,4-b]pyridine-5-carbonitriles (DDK-A-21 
to DDK-A-40), a characteristic band of nitrile group was observed in the range of 
2191-2218 cm-1. Confirmatory bands of C-O-C asymmetrical stretching at 1232-1247 
cm-1 and C-O-C symmetrical stretching at 1076-1095 cm-1 were observed for methoxy 
and ethoxy groups. Also, N-H stretching band of secondary amine was observed at 
3246-3285 cm-1 suggesting formation of desired products (DDK-A-21 to DDK-A-
40).     
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2.2.7.3 1H NMR spectral study 
1H NMR spectra were recorded in DMSO-d6 solution on a Bruker Ac 400 MHz 
spectrometer using TMS as an internal standard. Number of protons and their 
chemical shifts were found to support the structure of the synthesized compounds. 
For pyrazolo[3,4-b]pyridine-5-carbonitriles (DDK-A-21 to DDK-A-30), 
characteristic singlet was observed for methoxy group at 3.85-3.98 δ ppm confirming 
the formation of 2-methoxy-pyrazolo[3,4-b]pyridine-5-carbonitriles.. The aromatic 
ring protons were observed at 7.32-7.53 δ ppm and J value were found to be in 
accordance with substitution pattern on phenyl ring. The singlet for secondary amine 
(-NH) proton was observed at 7.90-8.00 δ ppm. 
While, for pyrazolo[3,4-b]pyridine-5-carbonitriles (DDK-A-31 to DDK-A-
40), characteristic triplet-quartet pattern was observed for ethoxy group. A signal as 
quartet at 1.31-1.56 δ ppm corresponding to three methyl (O-CH2-CH3) protons and a 
triplet at 4.39-4.53 δ ppm corresponding to two methylene (O-CH2-CH3) protons was 
observed confirming the formation of 2-ethoxy-pyrazolo[3,4-b]pyridine-5-
carbonitriles. The aromatic ring protons were observed at 7.09-7.58 δ ppm and J value 
were found to be in accordance with substitution pattern on phenyl ring. The singlet 
for secondary amine (-NH) proton was observed at 7.90-8.00 δ ppm. 
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IR spectrum of DDK-A-23 
 
 
Mass spectrum of DDK-A-23 
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1H NMR spectrum of DDK-A-23 
 
 
Expanded 1H NMR spectrum of DDK-A-23 
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IR spectrum of DDK-A-24 
 
 
Mass spectrum of DDK-A-24 
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1H NMR spectrum of DDK-A-24 
 
 
Expanded 1H NMR spectrum of DDK-A-24 
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IR spectrum of DDK-A-29 
 
 
Mass spectrum of DDK-A-29 
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1H NMR spectrum of DDK-A-29 
 
 
Expanded 1H NMR spectrum of DDK-A-29 
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IR spectrum of DDK-A-34 
 
 
Mass spectrum of DDK-A-34 
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1H NMR spectrum of DDK-A-34 
 
 
Expanded 1H NMR spectrum of DDK-A-34 
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Expanded 1H NMR spectrum of DDK-A-34 
 
 
IR spectrum of DDK-A-37 
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Mass spectrum of DDK-A-37 
 
 
1H NMR spectrum of DDK-A-37 
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Expanded 1H NMR spectrum of DDK-A-37 
 
 
Expanded 1H NMR spectrum of DDK-A-37 
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IR spectrum of DDK-A-39 
 
 
Mass spectrum of DDK-A-39 
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1H NMR spectrum of DDK-A-39 
 
 
Expanded 1H NMR spectrum of DDK-A-39 
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Expanded 1H NMR spectrum of DDK-A-39 
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2.2.8 Biological evaluation 
2.2.8.1 Antimicrobial evaluation 
All of the synthesized compounds (DDK-A-21 to DDK-A-40) were tested for their 
antibacterial and antifungal activity (MIC) in vitro by broth dilution method [88] with 
two Gram-positive bacteria Staphylococcus aureus MTCC-96, Streptococcus 
pyogenes MTCC 443, two Gram-negative bacteria Escherichia coli MTCC 442, 
Pseudomonas aeruginosa MTCC 441 and three fungal strains Candida albicans 
MTCC 227, Aspergillus Niger MTCC 282, Aspergillus clavatus MTCC 1323 taking 
ampicillin, chloramphenicol, ciprofloxacin, norfloxacin, nystatin, and griseofulvin as 
standard drugs. The standard strains were procured from the Microbial Type Culture 
Collection (MTCC) and Gene Bank, Institute of Microbial Technology, Chandigarh, 
India.  
 The minimal inhibitory concentration (MIC) values for all the newly 
synthesized compounds, defined as the lowest concentration of the compound 
preventing the visible growth, were determined by using microdilution broth method 
according to NCCLS standards [88(a)].  Serial dilutions of the test compounds and 
reference drugs were prepared in Muellere-Hinton agar. Drugs (10 mg) were 
dissolved in dimethylsulfoxide (DMSO, 1 mL). Further progressive dilutions with 
melted Muellere-Hinton agar were performed to obtain the required concentrations. In 
primary screening 1000 μg mL-1, 500 μg mL-1 and 250 μg mL-1 concentrations of the 
synthesized drugs were taken. The active synthesized drugs found in this primary 
screening were further tested in a second set of dilution at 125 μg mL-1, 62.5 μg mL-1, 
50 μg mL-1, 25 μg mL-1, 12.5 μg mL-1, and 6.250 μg mL-1 concentration against all 
microorganisms. The tubes were inoculated with 108 cfu mL-1 (colony forming 
unit/mL) and incubated at 37 ºC for 24 h. The MIC was the lowest concentration of 
the tested compound that yields no visible growth (turbidity) on the plate. To ensure 
that the solvent had no effect on the bacterial growth, a control was performed with 
the test medium supplemented with DMSO at the same dilutions as used in the 
experiments and it was observed that DMSO had no effect on the microorganisms in 
the concentrations studied. The results obtained from antimicrobial susceptibility 
testing are depicted in Table 1. 
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Table 1. Antibacterial and antifungal activity of synthesized compounds (DDK-
A-21 to DDK-A-40) 
 
Code Minimum inhibition concentration (µg mL-1 ) 
Gram-positive Gram-negative Fungal species 
S.a. S. p. E.c. P.a. C. a. A. n. A.c. 
DDK-A-21 50 25 125 500 1000 1000 500 
DDK-A-22 250 250 100 500 100 500 500 
DDK-A-23 100 500 125 1000 500 1000 1000 
DDK-A-24 250 1000 250 500 500 250 250 
DDK-A-25 50 125 250 62.5 1000 1000 500 
DDK-A-26 500 500 500 >1000 100 500 250 
DDK-A-27 1000 500 1000 1000 500 500 100 
DDK-A-28 500 1000 1000 500 500 100 500 
DDK-A-29 62.5 100 250 125 1000 >1000 1000 
DDK-A-30 1000 500 500 1000 500 100 500 
DDK-A-31 500 1000 250 1000 500 500 >1000 
DDK-A-32 1000 250 500 500 500 100 250 
DDK-A-33 100 125 100 62.5 >1000 1000 1000 
DDK-A-34 100 >1000 500 1000 >1000 500 1000 
DDK-A-35 25 500 250 100 500 1000 >1000 
DDK-A-36 1000 100 100 500 250 100 250 
DDK-A-37 125 100 100 500 500 250 1000 
DDK-A-38 500 500 1000 >1000 1000 500 125 
DDK-A-39 125 100 50 250 500 1000 500 
DDK-A-40 100 1000 250 1000 1000 500 1000 
Ampicillin 250 100 100 100 - - - 
Chloramphenicol 50 50 50 50 - - - 
Ciprofloxacin 50 50 25 25 - - - 
Norfloxacin 10 10 10 10 - - - 
Nystatin - - - - 100 100 100 
Griseofulvin - - - - 500 100 100 
 
2.2.8.2 Antimycobacterial, anticancer and antiviral evaluation 
Antimycobacterial, anticancer and antiviral screening of all the newly synthesized 
compounds (DDK-A-21 to DDK-A-40) is currently under investigation and results 
are awaited.  
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 Chapter 3 
 Microwave assisted synthesis of 
 heterocycles-an overview 
 
 
 
3.1 Microwave-Assisted Organic Synthesis (MAOS) – A Brief History 
While fire is now rarely used in synthetic chemistry, it was not until Robert Bunsen 
invented the burner in 1855 that the energy from this heat source could be applied to a 
reaction vessel in a focused manner. The Bunsen burner was later superseded by the 
isomantle, the oil bath or the hot plate as a means of applying heat to a chemical 
reaction. In the past few years, heating and driving chemical reactions by microwave 
energy has been an increasingly popular theme in the scientific community [1, 2]. 
 Microwave energy, originally applied for heating foodstuffs by Percy Spencer 
in the 1940s, has found a variety of technical applications in the chemical and related 
industries since the 1950s, in particular in the food-processing, drying and polymer 
industries. Other applications range from analytical chemistry (microwave digestion, 
ashing and extraction) [3] to biochemistry (protein hydrolysis, sterilization) [3], 
pathology (histoprocessing, tissue fixation) [4] and medical treatments (diathermy) [5]. 
Somewhat surprisingly, microwave heating has only been implemented in organic 
synthesis since the mid-1980s. The first reports on the use of microwave heating to 
accelerate organic chemical transformations (MAOS) were published by the groups of 
Richard Gedye (Scheme 3.1) [6] and Raymond J. Giguere/George Majetich [7] in 
1986.  
 
NH2
O
OH
O
20% H2SO4
MW or thermal
Thermal: 1h, 90% yield  (reflux)
MW: 10 min, 99% yield  (sealed vessel)
Scheme 3.1 Hydrolysis of benzamide: The first published example (1986) of 
microwave-assisted organic synthesis.  
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In those early days, experiments were typically carried out in sealed teflon or 
glass vessels in a domestic household microwave oven without any temperature or 
pressure measurements. The results were often violent explosions due to the rapid 
uncontrolled heating of organic solvents under closed-vessel conditions. In the 1990s, 
several groups started to experiment with solvent-free microwave chemistry (so-
called dry-media reactions), which eliminated the danger of explosions [8]. Here, the 
reagents were pre-adsorbed onto either an essentially microwave-transparent (i.e., 
silica, alumina or clay) or strongly absorbing (i.e., graphite) inorganic support, that 
additionally may have been doped with a catalyst or reagent. Particularly in the early 
days of MAOS, the solvent-free approach was very popular since it allowed the safe 
use of domestic microwave ovens and standard open-vessel technology. While a large 
number of interesting transformations using “dry-media” reactions have been 
published in the literature [8], technical difficulties relating to non-uniform heating, 
mixing and the precise determination of the reaction temperature remained unresolved, 
in particular when scale-up issues needed to be addressed. 
 Alternatively, microwave-assisted synthesis has been carried out using 
standard organic solvents under open-vessel conditions. If solvents are heated by 
microwave irradiation at atmospheric pressure in an open vessel, the boiling point of 
the solvent typically limits the reaction temperature that can be achieved. In order to 
nonetheless achieve high reaction rates, high-boiling microwave-absorbing solvents 
have been frequently used in open-vessel microwave synthesis [9]. However, the use 
of these solvents presented serious challenges in relation to product isolation and 
recycling of the solvent. Because of the recent availability of modern microwave 
reactors with on-line monitoring of both temperature and pressure, MAOS in 
dedicated sealed vessels using standard solvents-a technique pioneered by Christopher 
R. Strauss in the mid-1990s [10]-has been celebrating a comeback in recent years. 
This is clearly evident surveying the recently published (since 2001) literature in the 
area of controlled microwave-assisted organic synthesis (MAOS). It appears that the 
combination of rapid heating by microwaves with sealed-vessel (autoclave) 
technology will most likely be the method of choice for performing MAOS on a 
laboratory scale in the future. Importantly, recent innovations in microwave reactor 
technology now allow controlled parallel and automated sequential  
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processing under sealed-vessel conditions, and the use of continuous- or stop-flow 
reactors for scale-up purposes. 
 Since the early days of microwave synthesis, the observed rate accelerations 
and sometimes altered product distributions compared to oil-bath experiments have 
led to speculation on the existence of so-called “specific” or “non-thermal” 
microwave effects [11]. Historically, such effects were claimed when the outcome of 
a synthesis performed under microwave conditions was different from that of the 
conventionally heated counterpart at the same apparent temperature. Reviewing the 
present literature [12], it appears that today most scientists agree that in the majority 
of cases the reason for the observed rate enhancements is a purely thermal/kinetic 
effect, i.e., a consequence of the high reaction temperatures that can rapidly be 
attained when irradiating polar materials in a microwave field, although effects that 
are caused by the unique nature of the microwave dielectric heating mechanism 
(“specific microwave effects”) clearly also need to be considered. While for the 
medicinal chemist in industry this discussion may seem largely irrelevant, the debate 
on “microwave effects” is undoubtedly going to continue for many years in the 
academic world. Regardless of the nature of the observed rate enhancements, 
microwave synthesis has now truly matured and has moved from a laboratory 
curiosity in the late 1980s to an established technique in organic synthesis, heavily 
used in both academia and industry. 
The initially slow uptake of the technology in the late 1980s and 1990s has 
been attributed to its lack of controllability and reproducibility, coupled with a general 
lack of understanding of the basics of microwave dielectric heating. The risks 
associated with the flammability of organic solvents in a microwave field and the lack 
of available dedicated microwave reactors allowing for adequate temperature and 
pressure control were major concerns. Important instrument innovations now allow 
for careful control of time, temperature and pressure profiles, paving the way for 
reproducible protocol development, scale-up and transfer from laboratory to 
laboratory and from scientist to scientist. Today, microwave chemistry is as reliable as 
the vast arsenal of synthetic methods that preceded it. Since 2001, therefore, the 
number of publications related to MAOS has increased dramatically, to such a level 
that it might be assumed that, in a few years, most chemists will probably use 
microwave energy to heat chemical reactions on a laboratory scale [1, 2]. Not only is 
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direct microwave heating able to reduce chemical reaction times significantly, but it is 
also known to reduce side reactions, increase yields and improve reproducibility. 
Therefore, many academic and industrial research groups are already using MAOS as 
a technology for rapid reaction optimization, for the efficient synthesis of new 
chemical entities or for discovering and probing new chemical reactivity. 
 
3.2 Applications of microwaves in heterocyclic ring formation 
3.2.1 Five-membered heterocyclic rings 
3.2.1.1 Pyrroles 
The classical Paal-Knorr cyclization of 1,4-diketones to give pyrroles is dramatically 
speeded- up under microwave irradiation and high yields are obtained as shown in 
Scheme 3.2 [13]. 
 
O
O
RNH2
N
R
R = CH2C6H5,
4-MeOC6H4, 
2-ClC6H4
MW, 100-200 W, 0.5-2.0 min., solvent-free
Microwave: 2 min., Convential: Lewis acid activation, 12h.
Scheme 3.2  
 
3.2.1.2 Pyrazoles 
Another recent application of microwaves in cyclization is the preparation of 
pyrazoles from hydrazones using the Vilsmeier cyclization method by treatment with  
 
MW, 210 W, 30-50 sec., DMF
Microwave: 35-50 sec., 45-78%
 Convential: 4-5 h, 41-76%
Scheme 3.3
R2 R1
R5
N
NH
R3
R4
POCl3
R2 R1
N N
R5
R4R3
R1 = H, OH; R2 = H, CH3; R3 = H, NO2; 
R4 = NO2; R5 = CH3, C2H5,
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POCl3 and DMF [14].
 
As shown in Scheme 3.2, once again the reaction is speeded-up 
by factors of several 100-fold. 
 
3.2.1.3 Imidazoles 
An important classical preparation of imidazoles is from an α-diketone, an aldehyde 
and ammonia. Here again, excellent yields can be obtained in reaction times of a few 
minutes as shown in Scheme 3.4 [15]. 
 
Scheme 3.4
R1 H
O
+
R2
O
R3
O
N NH
R3 R2
R1
MW, 130 W, 10 min., solvent-free
Microwave: 10 sec., 45-78%
 Convential: 4h, AcOH, reflux
R1 = C6H5; 4-ClC6H4, 2-thiophenyl etc.
R2 = R3 =  C6H5; 4-MeC6H4
Al2O3
NH4OAc
 
 
3.2.1.4 Oxazolines 
The example of Scheme 3.5, the preparation of oxazolines shows that partially 
saturated five-membered rings can also be prepared advantageously using 
microwaves [16]. 
 
+
R OH
O
NH2
OH
HO
OH
NH
OH
HO
HO
O
R
N
OR
OH
OH
80-95%
MW, 850 W, 200 ºC, 5 min., solvent-free
 Convential: 15-16 h
R = 2-Furyl, Phenyl, Heptadecenyl
Scheme 3.5
-H2O -H2O
 
 
3.2.1.5 Triazoles and Tetrazoles 
Schemes 3.6 and 3.7 show the overview of five-membered rings with illustrations of 
the advantageous preparation of 1,2,4–triazoles [17] and tetrazoles [18]
 
respectively 
using microwaves. Notice that in Scheme 3.6 the starting aryl cyanides are also made 
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by a Pd-catalyzed but microwave-enhanced replacement of aryl bromides using zinc 
cyanide. 
 
Ar C N
NH2NH2-H2O
NN
N
NH2
Ar Ar
MW: 60 W, 130 ºC, 36-96%
Convential: 60 min., 130 ºC, 45-60%
Ar = C6H5; 4-OCH3C6H4,  4-NH2C6H4,  
4-OHC6H4, 4-CH3C6H4 etc.
Scheme 3.6
Br
R
CN
R R
N
N
NHN
R = OCH3, NO2, CH3 etc.
MW: 60 W, 175 ºC, 2 min., DMF, 78-93%
Convential: 2-16 h, 71-97%
MW: 20 W, 220 ºC, 10-25 min., DMF, 36-96%
Convential: 3-96 h, 35-97%
Scheme 3.7
NH2NH2-2HCl
Zn(CN)2
Pd(PPh3)4
NaN3
NH4Cl
 
 
3.2.1.6 Oxadiazoles 
The dehydration of unsymmetrical diacylhydrazines (themselves prepared by a 
conventional Mitsunobu reaction) using Burgess’s reagent is shown in Scheme 3.8 to 
give 1,3,4-oxadiazoles rapidly under microwave irradiation [19]. 
 
MW: 150 ºC, 5 min., DMF
 Convential :90 min., 150 ºC
R = alkyl, aryl; R2 = Cl, OMe
Scheme 3.8
+
R1 OH
O
N
H
O
H2N
R2
N
H
OH
N
R2
R1
O
MeO N
S
NEt3
O O
O
NN
OR1
100%
DDC
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3.2.1.7 Isoxazolines and pyrazolines 
The acceleration of 1,3-dipolar cycloaddition reactions to give isoxazolines and 
pyrazolines by the addition of activated olefins to nitrile oxides or nitrile imides, 
respectively, is illustrated in Scheme 3.9; the resulting compounds are obtained in far  
high yield than under conventional conditions [20]. 
 
N
XH
ClAr
Ar C N X
Ar C N X
RC CY
RHC C(Y)(Z)
O N Me
N
X
YR
Ar
+
N
X
RY
Ar
25-73% 0-22%
N
X
YR
Ar
Z
MW: 110-140 ºC, 30 min., xylene, 50-85%
 Convential :22-40%
R = H, Ph, CO2Me;
Y = CO2Me, CO2Et;
Z = H, CN
Scheme 3.9
Al2O3
 
3.2.2 Benzo-derivatives of five-membered rings 
3.2.2.1 Benz- imidazoles, -oxazoles, and –thiazoles 
Ring closure reactions of appropriate o-substituted anilines to give benzimidazoles, 
benzoxazoles, and benzthiazoles takes place much faster and in significantly high 
yield under microwave conditions  than conventionally [21] as shown in Scheme 3.10.  
 
NH2
Z
+
EtO CF3
OEt O
Y
N
F3C
O
Z = NH2, OH, SH MW: 980 W, 9-11 min., toluene, 86-96%
 Convential : 3-5 h, 40-80%
Scheme 3.10
Y = NH, O, S
 
 
3.2.2.2 Indoles 
The classical Fischer-indole synthesis from an aryl hydrazine and a ketone is speeded-
up by several 100-fold as documented in Scheme 3.11 [22].  
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H
N
NH2 +
O
N
H
MW:30 Sec., AcOH
 Convential : AcOH rerflux, 2h
Scheme 3.11  
 
3.2.2.3 γ-Carbolines 
The Graebe-Ullmann synthesis which converts 1-arylbenzotriazoles into carbazoles or 
their heterocyclic analogs is also accelerated under microwave conditions as shown in 
Scheme 3.12 where the 1-(4-pyridyl)benzotriazole is converted into a γ-carboline [23].  
 
N
H
N
NR2
R3
+
N
Cl
R1
N
N
NR2
R3
N
R1
H2P2O7
N
H
R2
R3
N
R1
MW, 160W, 10 min., solvent-free
MW, 160W, 5 min., solvent-free
MW: 15 min., 30-76%
Convential: 150 min., 28-80%
R1 = H, Me
R2 = R3 = H, Me
Scheme 3.12
 
 
3.2.3 Six-membered rings 
3.2.3.1 Dihydropyridines   
Me OEt
O O
+
Ar H
O
25% aq NH4OH
N
H
CO2EtEtO2C
Me Me
Ar
(5 equiv)
MW: 140 ºC, 10-15 min., Solvent-free, 51-92%
Convential:12 h, 15-61%
Ar = C6H5, 2-NO2C6H4,
2-CH3OC6H4, 2-ClC6H4
Scheme 3.13  
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The Hantzsch dihydropyridine synthesis remains one of the most important routes to 
pyridine ring systems. Under conventional conditions long periods of heating are 
required and yields are poor to moderate. Microwaves dramatically reduce the heating 
times and also significantly increase the yields as shown in Scheme 3.13 [24].  
 
3.2.3.2 Dihydropyridopyrimidinones  
Dihydropyridopyrimidinones have been produced by ring annulations of 
aminopyrimidinones. Once again the reaction time is dramatically reduced and yields 
are much better with the solvent-free microwave conditions (Scheme 3.14) [25]. 
 
N
N
O
NH2X
Me
R
+ Ph
O
CN + Ar H
O
N
H
N
N
Ar
CN
Ph
R
X
Me
O
X = O, S; R = H, CH3;
Ar = C6H5, 2-CH3OC6H4, 2-ClC6H4
MW: 600 W, 20 min., Solvent-free, 70-75%
Convential: EtOH reflux, 40-48 h, 21-25 %
Scheme 3.14  
 
3.2.3.3 Dihydropyrimidines 
The Biginelli reaction is important for the preparation of dihydropyrimidine 
derivatives and excellent results are found for reactions carried out with microwave 
enhancement (Scheme 3.15) [19].  
 
MW: 5 min., 60-90%
Convential:12-24 h, 15-60%
R1 OEt
O O
+
H2N
O
NH2 R2 H
O
+ HN
N
H
O
O
OEt
R1
R2
R1 = H, CH3 R2 =  C6H5, 2-CH3OC6H4,   2-ClC6H4
Scheme 3.15  
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3.2.3.4 Tetrazines 
The Diels-Alder reaction between aza-olefins and aza-dicarboxylic ester to give 
tetrazines is speeded-up by a factor of 1000 by microwave enhancement as shown in 
Scheme 3.16 [26]. 
 
Ph
N
N
R
+ N N CO2EtEtO2C
N
N
N
N
Ph
CO2Et
CO2Et
R = Carbohydrate MW: 300 W, 15 min., 80-96%
Convential: 30 days
Scheme 3.16
R
 
 
3.2.4 Polycyclic six-membered rings 
3.2.4.1 Quinolines 
The Skraup synthesis has a bad reputation as it involves very messy conditions and 
gives only low yields of quinolines when carried out conventionally. Recently, it has 
been reported that microwave enhancement reduces the reaction time to a few minutes 
and allows high yields to be isolated (Scheme 3.17) [27]. 
 
NH2
R + R1
R2
R3
O
InCl3/SiO2
N
R3
R2
R1
R
R = H,  o-CH3, m-CH3, p-CH3, o-OMe, p-OMe, m-OH, m-Cl etc.
R1 = H, CH3, n-C3H7; R2 = H, C2H5;
R3 = CH3, p-MeOC6H4
MW: 600 W, 5-12 min., Solvent-free, 80-87%
Convential: H2SO4/150 ºC, low yileds
Scheme 3.17  
 
3.2.4.2 Pyrimido[1,2-a]pyrimidines 
Pyrimido[1,2-a]pyrimidines are prepared from dihydroaminopyrimidines and 
chromone-3-aldehydes as is shown in Scheme 3.18 [28].
 
Although the conventional 
reaction must proceed in refluxing ethanol, reactions are much faster and better yields 
have been obtained with microwaves. 
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N
H
N
NH2
EtO2C
Ph
HAr
+
O
O
O
H N
N
EtO2C
Ph
HAr
N
H
H
OH
O
N
N
EtO2C
Ph
Ar
N
H
H
OH
O
H
4H
2H
Ar = C6H5, 4-CH3C6H4, 4-CH3OC6H4, 
4-ClC6H4, 2-thienyl
MW: 400 W, 20 min., Solvent-free, >95%
Convential: EtOH reflux, 4 h, 60-70 %
Scheme 3.18
 
 
3.2.5 Nucleophilic Substitutions 
3.2.5.1 Heterocyclic C-alkylations 
Nucleophilic substitution reactions can be speeded-up very considerably as is 
illustrated in Scheme 3.19 for a chloro-naphthyridine derivative [29]. 
 
N N
O
F
F
F
Cl
NH
N N
O
F
F
F
N
COOEt
COOEt
NH2
N N
O
F
F
F
HN
COOEtF3C
NH2
N N
O
F
F
F
HN
COOEt
CF3
NH2
N N
O
F
F
F
HN
COOEt
NH2
OMe
N N
O
F
F
F
HN
COOEt
OMe
Microwave: 175 ºC, 10 min, 100%
Convential: 100 ºC, 12-24 h, 35-60%
Scheme 3.19  
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3.2.5.2 Heterocyclic N-alkylations 
Another class of nucleophilic substitution is involved in heterocyclic N-alkylation 
which we have illustrated in Scheme 3.20. This shows that nucleophilic substitution 
on the nitrogen atom of saccharin is significantly speeded-up by microwave 
irradiation [19].  
 
Microwave: 750 W, 2-10 min, solvent-free, 71-92%
Convential: DMF reflux, 30 min.
Scheme 3.20
S
NH
O
O O
NaOH, RX
silica gel S
NR
O
O O
R = CH2C6H5, n-C16H33, CH2COOC2H5 etc.
 
 
3.2.5.3 Selective-alkylation 
In Scheme 3.21, the results presented indicate that selectivity is achieved in the N 
alkylation of 1,2,4-triazole under microwave conditions where only the N1-alkyl 
derivative was formed in contradistinction to the conventional conditions which give 
a considerable amount of the di-1,4-benzylated compound [30]. 
 
N
N
H
N + PhCH2Br
N
N
N
CH2Ph
+
N
N
N
CH2Ph
PhH2C Br
molar ratio 1:1 N1 N1,4
Microwave: 90-165 ºC, 1.5-5 min, 70%
Convential: 14%; only N1,4 isolated
Scheme 3.21  
 
3.2.5.4 Transition metal cross-coupling 
An important type of nucleophilic substitution reactions which are recently much 
exploited are comprised of transition metal cross-coupling. A Suzuki coupling is 
shown at the top of Scheme 3.22 to give significantly better yield in the presence of 
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microwave irradiation [31].
 
At the bottom of Scheme 3.22 another Suzuki coupling is 
shown, which was speeded-up by a factor of 100 [32]. 
 
N Br
Pd(OAC)2, (C6H5)4BNa
N Ph
Microwave:160 W, 105 ºC, 12 min, H2O, 73%
Convential: 42%
N
N
H
HN
O1
+
B
HO OH
Me
Cu(OAc)2, pyr-NMP
TFA
N
N
H2N
O
MeMicrowave: 30 sec., 60%
Convential: 48h
Scheme 3.22
Na2CO3
 
 
3.2.6 Hetero-Diels−Alder reactions 
3.2.6.1 Intramolecular reactions 
We have already seen one example of a hetero-Diels−Alder reaction involving acyclic 
components. Hetero-Diels−Alder reactions involving cyclic components which lead 
to polycyclic ring systems are of great importance. An intramolecular example shown 
in Scheme 3.23 indicates that the reaction was accelerated by a factor of around 1000 
by microwave irradiation [33]. 
 
N
N
R
Cl
O
O
(CH2)n N
N
O
R Cl
O
(CH2)n
+H2O
N
NH
O
R O
O
(CH2)n
Microwave: 300 W, 190 ºC, 8-15 min., DCE, bmimPF6 Microwave: 300 W, 130 ºC, 5 min., 57-77%
Convential: PhCl reflux, 2-3 days
R = Butyl, Ph; n = 2,3
Scheme 3.23
 
3.2.6.2 Intermolecular reactions 
Scheme 3.24 shows two impressive examples of rate enhancement for intermolecular 
hetero-Diels−Alder reactions [33]. In the first example on the top of Scheme 3.24 the  
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initial reaction is followed by elimination thus involving the conversion of a pyrazine 
derivative into a pyridine. Perhaps more impressive is the lower example in Scheme 
3.24 where an autoclave is required under conventional conditions but which can be 
dispensed with when microwave acceleration is utilized. 
 
CO2MeMeO2C
N
N
O
Ph Cl
MeO2C
MeO2C
CN -ClCN
N
CO2Me
O
NC CO2Me
Ph
N
CO2Me
CO2Me
Cl CN
-PhNCO
N
N
Ph
Cl
O
CN
Microwave: 300 W, 190 ºC, 5 min., DCE, bmimPF6
Convential: 30 min.
N
N
Ph
Cl
O
R
ethene
N
N
O
Ph Cl
R
Microwave: 300 W, 190 ºC, 40-190 min., DCB, 86-89%
Convential: Autoclave, 25 atm., 110 ºC, 12h
Scheme 3.24  
 
3.2.7 1,3-Dipolar cycloaddition reactions 
3.2.7.1 Synthesis of C-carbamoyl-1,2,3-triazoles 
 
N3 4 or 5
NN
N
R1
R2
R
N34 or 5
1 2
7-12
O N3
4 or 5
O
NH
Ph4
O
N
5 3
Microwave: 120-170 W, 55-85 ºC, 30 min., solvent-free, 62-80%
Convential: 24h to 1 week, 120 ºC
Ph
Ph
Ph(CH2)2
7
8
9
Ph(CH2)210
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R R1 R2
CONHCH2Ph
COpiperidinyl
COpiperidinyl
CONHCH2Ph
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Scheme 3.25
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There is one recent report which has involved microwave induced 1,3-dipolar 
cycloaddition of organic azides to acetylenic amides. As shown in Scheme 3.25, these 
reactions were achieved under microwave conditions in a reasonable time at 
temperatures of around 70±15 ºC [34]. Under conventional conditions the times were 
roughly 100 times as long and the temperature had to be taken up to 120 ºC [35]. 
 
3.2.8 Oxidation 
The osmium-catalyzed dihydroxylation reaction, the addition of osmium tetroxide to 
olefins to produce a vicinal diol, is one of the most selective and reliable organic 
transformations. Recent work by Sharpless, Fokin, and coworkers [36] has uncovered 
that electron-deficient olefins can be converted into the corresponding diols much 
more efficiently when the reaction medium is kept acidic (Scheme 3.26). 
 
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
K2OsO2(OH)4, NMO
citric acid/BuOH/H2O
Microwave: 120 ºC, 150 min., 81%
Scheme 3.26
OH
OH
 
 
3.3. Concluding remarks 
For more than a century, heterocycles have constituted one of the largest areas of 
research in organic chemistry. The presence of heterocycles in all kinds of organic 
compounds of interest in biology, pharmacology, optics, electronics, material sciences, 
and so on is very well known. Among them, sulfur and nitrogen-containing 
heterocyclic compounds have maintained the interest of researchers and their unique 
structures led to several applications in different areas.  
The presence of heteroatoms results in significant changes in the cyclic 
molecular structure, due to the availability of unshared pairs of electrons, and in the 
reactivity, compared with the parent aromatic hydrocarbons. In contrast to the number 
and variety of such heterocycles, the number of synthetic methods to afford sulfur and 
nitrogen-containing molecules is, in practice, restricted to the availability of the 
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appropriate sulfur or nitrogen reagent. Sometimes the preparation of theses 
heterocyclic systems by conventional ways is difficult work that implies many 
synthetic steps and extensive starting material.  
For all these reasons, the various possibilities offered by the microwave 
technology are particularly attractive where fast, high-yielding protocols and the 
avoidance or facilitation of purification are highly desirable. Despite the area of 
microwave-assisted chemistry being about 20 years old, the technique has only 
recently received widespread global acceptance of microwave-assisted synthesis of 
sulfur and nitrogen-containing heterocycles in the academic and industrial 
communities [37]. This is a consequence of the recent availability of commercial 
microwave systems specific for synthesis, which offers improved opportunities for 
reproducibility, rapid synthesis, rapid reaction optimization and the potential 
discovery of new chemistries. The beneficial effects of microwave irradiation are 
finding an increased role in process chemistry, especially in cases when usual 
methods require forcing conditions or prolonged reaction times. Microwaves have 
also shown an advantage where processes involve sensitive reagents or when products 
may decompose under prolonged reaction conditions. 
All above observations led us to explore microwave-assisted synthesis of our 
aimed heterocyclic scaffolds viz. acridine-1,8-diones, 5,6,7,8-tetrahydroquinolines 
and 7,8-dihydroquinolines. The results are described in the following chapters: 
 
Chapter 4:  Studies on Microwave Assisted Synthesis of Acridines 
 
Chapter 5:  Studies on Microwave Assisted Synthesis of Polyhydroquinolines 
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 Chapter 4 
 Studies on microwave assisted  
 synthesis of acridines 
 
 
 
4.1 Introduction 
Acridine (C13H9N) is a nitrogen heterocycle, which is structurally related to 
anthracene with one of the central CH groups replaced by nitrogen.  
 
N
Acridine  
 
The acridines were first developed as dyes and during the early 20th century 
their pharmacological properties were evaluated. At this time, proflavin was used as a 
topical antibacterial and antifungal agent [1]. In the 1940’s and to the present day, the 
acridines (e.g., quinacrine, pyronaridine and acranil) have been used as anti-malarial 
drugs [2]. The first acridine-based therapeutic agents specifically designed for cancer 
treatment were developed during the 1970’s. These efforts led to the development of 
m-amsacrine, a 9-anilinoacridine introduced into clinical use in 1976 [3]. Accordingly, 
this acridine has been clinically utilized as a single agent or in combination with other 
antineoplastic drugs in the treatment of acute nonlymphocytic, lymphocytic [4, 5], and 
acute myeloid [6, 7] leukemias. However, m-amsacrine has not generally been 
effective in the treatment of solid tumors [8]. 
 
Asulacrine is an inhibitor of topoisomerase II, which has shown potential 
against breast and lung cancer [9, 10]. Nitracrine (Ledakrin) is another acridine 
antineoplastic agent used in mammary and ovarian tumors. It also inhibits RNA 
synthesis [11].  
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Acridines and their fused derivatives posses wide spectrum biological 
activities viz. antibacterial [12], fungicidal [13], antimicrobial [14], anti-tubercular 
[15-17], antimalarial [18], anti-tumor [19, 20], anti-cancer [21], acetylcholinesterase 
inhibitory [22, 23], vasorelaxing [24], anti-viral [25]. The antitumor and anti-
infectious activities of acridines are mainly related to their capacity to reversibly bind 
with DNA [26]. Due to their planar polycyclic structure, they have been shown to 
intercalate between DNA double-strands, to interfere with DNA regulatory enzymes 
such as topoisomerase I and II and to disrupt DNA functions in cells [27]. Some 
examples of published derivatives of acridines with their biological activities are 
shown in following figure. 
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4.2 Reported synthetic strategies 
Acridine is prepared from either anthranilic acid derivatives and aryl halides or from 
2-chlorobenzoic acid and aryl amines in four steps [1] (Scheme 4.2.1).  
 
COOH
NH2
+
X
Cu
Cu
Cyclization
N
H
O
Oxidation
N
H
Reduction
N
H
COOH
COOH
X
+
H2N
N
Acridone2-carboxy-diphenyl
         amine
Scheme 4.2.1
Acridine
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Other general synthetic strategies include Bernthsen’s method, Pfitzinger’s 
method, Friedlander’s method, Ullman’s method and Goldberg’s method [1] (Scheme 
4.2.2). 
 
N
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COOH
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+
H2N
N
H
O
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+
OH
OHHO
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4 h N
COOH OH
OH
NH3Cl
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+
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N
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O
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+
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Ph
Ph
O2N
H2N
NaOAc
Br
O
+
Cu, CuI NH2N
K2CO3
OMe
OMe
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OMe
K2CO3
Cu
COOH
N
POCl3
reflux
Cl
Pfitzinger's method:
Friedlander's method:
Ullman's method:
Goldberg's method:
Scheme 4.2.2
N
H 200-270 oC
RCOOH
ZnCl2 N
Bernthsen's method: R
 
The above mentioned strategies have been modified by different researchers to 
obtain diversely functionalized acridines or to improve the reaction conditions. 
Bernthsen’s method was modified by Seijas et al. using microwave assistance, which 
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reduced the reaction time drastically from hours to minutes and avoided the use of 
higher temperatures (200-270 ºC) [33]. 
Buu-Hoi et al. synthesized 2-chloro-5,6-dihydro-9-methylbenz]acridine-7-
carboxylic acid by Pfitzinger’s method using 5-methylisatin and 7-Chloro-3,4-
dihydro-l(2H)-naphthalenone as starting materials [34]. While Cromwell and Bell 
have reported synthesis of 11-chloro-5,5-dimethyl-5,6-dihydro-benzo[c]acridine by 
Pfitzinger’s method by the reaction of 7-chloroisatin with 4,4-dimethyl-3,4-dihydro-
2H-naph- thalen-1-one [35] (Scheme 4.2.3). Recent literature survey also revealed 
few examples of acridine synthesis by Pfitzinger’s method [36, 37]. 
 
N
H
N
O
O
+
O ClCl
Scheme 4.2.3  
 
Palimkar et al. have reported ionic liquid 1-n-butylimidazolium 
tetrafluoroborate ([Hbim]BF4) promoted Friedlander annulation between 2-
aminoacetophenone and cyclic ketones [38] (Scheme 4.2.4). Other researchers have 
also utilised Friedlander reaction for the synthesis of different fused acridines [39-41]. 
 
NH2
O
+
O
Scheme 4.2.4
N
[Hbim]BF4
100oC
 
 
A recent report on synthesis of 2-(2-Arylidenaminothiazol-4-yl)acridines has 
utilized Goldberg’s method sequence [42]. Literature survey also revealed number of 
examples of acridine synthesis using Ullman reaction at one or other stages of the 
reaction [43-45]. 
Several other synthetic approaches have been reported by different 
researchers, few of which [39, 46-48] are summarized in (Scheme 4.2.5). 
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(1) Via aza-Diels-Alder reaction: [39]
NH
+
CH3CN, 70oC
N
N
N(CH3)2
O
O
NaOH, 43%
N
F3C O
O
(2) From acylated diphenylamines: [46]
N
H
I2, HI, hv
O Ph N
Ph
(3) By ring contraction: [47]
N
H
H3PO4, I2, AcOH
N
(4) From 2-oxo-substituted aryl azides: [48]
CO(R)
N3 N
R
C6H6
BF3O(Et)2
Scheme 4.2.5
R = H, CH3
 
 
Polyhydroacridines and polyhydroacridine-1,8-diones are polyfunctionalized 
1,4-dihydropyridine type derivatives. 1,4-Dihydropyridines (1,4-DHPs) are well-
known compounds because of their biological activities [49, 50]. The chemical 
modifications on the DHP ring, such as different substituents [49] or heteroatoms [51], 
have allowed the study of the extended structure and activity relationship and also 
provided some insight into the molecular interactions at the receptor level. In this 
context, polyhydroacridine-1,8-diones are also increasingly receiving attention due to 
their likeness in properties with those of 1,4-dihydropyridines. As a consequence, the 
interest of organic chemists in the synthesis or structure modifications of 
acridinedione derivatives remains high. Several reports describing the synthesis of 
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polyhydroacridines have been published recently. The synthesis of  
polyhydroacridine-1,8-diones by the reaction of 5,5-dimethylcyclohexane-1,3-dione 
(dimedone) with different aldehydes and ammonium acetate (Scheme 4.2.6) by 
heating in conventional solvents [52], by solvent-free conventional heating [53], by 
microwave-assisted synthesis [54], by reactions in aqueous media using ammonium 
chloride, or Zn(OAc)2·2H2O or L-proline as catalysts [55], and by using ionic liquids 
[56] have been reported. 
 
O
O
+ R
NH4OAc2
N
H
RO OO
Scheme 4.2.6
R = aryl or heteroaryl
 
 
The synthesis of N-aryl-polyhydroacridine-1,8-diones by the reaction of 5,5-
dimethylcyclohexane-1,3-dione (dimedone) with different aldehydes and amines 
(Scheme 4.2.7) using microwave-assisted synthesis [57, 58], by reactions in aqueous 
media using p-dodecylbenezenesulfonic acid [59], sodium dodecyl sulfate (SDS) [60] 
or proline [61] as catalysts, and by using ionic liquids [62, 63] have been reported.  
 
O
O
+ R
R1-NH2
2
N
RO OO
Scheme 4.2.7
R = aryl or heteroaryl R1
 
 
Reactions of enaminoketones with aldehydes in 20% P2O5 solution in 
isopropyl alocohol also furnish N-aryl-polyhydroacridine-1,8-diones [64, 65]. 
Reactions of enaminones with aldehydes and dimedone also furnished the same 
products under microwave irradiation using solvent acetic acid [66] (Scheme 4.2.8). 
Reaction of methylene-bis(5,5-dimethylcyclohexane-1,3-dione) with amines also 
affords N-substituted-polyhydroacridine-1,8-diones [67, 68] (Scheme 4.2.9).  
Synthesis of polyhydroacridine-1,8-diones from Schiff base derivatives of 
amines with dimedone is also well documented [69-71] (Scheme 4.2.10).  
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3.3 Current Work 
The chemistry of acridine and its derivatives has been studied for over a century due 
to their diverse biological activities viz, antitubercular, antimalarial, antitumour, 
vasorelaxing, antiviral etc. Polyhydroacridine-1,8-diones are polyfunctionalized 1,4-
dihydropyridine type derivatives. 1,4-Dihydropyridines (1,4-DHPs) are well-known 
compounds because of their biological activities [49-51]. The chemical modifications 
on the DHP ring, such as different substituents [49] or heteroatoms [51], have allowed 
the study of the extended structure and activity relationship and also provided some 
insight into the molecular interactions at the receptor level. In this context, 
polyhydroacridine-1,8-diones are also increasingly receiving attention due to their 
likeness in properties with those of 1,4-dihydropyridines. 
In view of these observations and with a view to further assess the 
pharmacological profile of this class of compounds; two novel series of acridines 
(DDK-B-01 to DDK-B-20) are synthesized. The synthesis of pyridine-3-carbonitriles 
(DDK-B-01 to DDK-B-10) and (DDK-B-11 to DDK-B-20) was achieved by 
microwave-assisted one pot reaction of two moles of 5,5-dimethylcyclohexane-1,3-
dione (dimedone) with one mole of substituted 2-chloro-quinoline-3-carbaldehyde 
and 3-(aryl)-1-phenyl-1H-pyrazole-4-carbaldehyde respectively in presence of excess 
of ammonium acetate. The products were characterized by FT-IR, mass, 1H NMR 
spectroscopy and elemental analyses. The newly synthesized compounds were 
subjected to antimicrobial activity. 
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4.4 Reaction scheme 
O
O
+2
 Reagents and conditions: (a) NH4OAc, MWI, 4-5 mins. ; (b) NH4OAc, MWI, 2-3 mins.
NN
N
H
NN
CHO
a
OO
O
O
+2 b
DDK-B-01 to DDK-B-10
N
H
OO
N
Cl
DDK-B-11 to DDK-B-20
N
CHO
Cl
R1
R1
R1
R1
 
 
Code R1 M.F. M.W. M.P. ºC Yield % Rf1 Rf2 
DDK-B-01 H C32H33N3O2 491 203-205 75 0.45 0.64 
DDK-B-02 4-Cl C32H32ClN3O2 526 196-198 81 0.48 0.68 
DDK-B-03 3-NO2 C32H32ClN4O4 536 216-218 78 0.51 0.69 
DDK-B-04 4-NO2 C32H32ClN4O4 536 233-235 77 0.50 0.65 
DDK-B-05 2-OCH3 C33H35N3O3 521 191-193 70 0.47 0.67 
DDK-B-06 4-OCH3 C33H35N3O3 521 218-220 83 0.54 0.71 
DDK-B-07 2-OH C32H33N3O3 507 179-181 68 0.53 0.72 
DDK-B-08 4-OH C32H33N3O3 507 193-195 69 0.51 0.67 
DDK-B-09 4-F C32H32FN3O2 509 254-256 82 0.54 0.71 
DDK-B-10 4-Br C32H32BrN3O2 570 244-246 79 0.52 0.69 
DDK-B-11 4-F C26H26ClFN2O2 452 209-211 75 0.51 0.63 
DDK-B-12 3-Cl C26H26Cl2N2O2 469 237-239 72 0.54 0.67 
DDK-B-13 4-Cl C26H26Cl2N2O2 469 243-245 79 0.51 0.56 
DDK-B-14 2-OCH3 C27H29ClN2O3 464 228-230 69 0.53 0.60 
DDK-B-15 3-OCH3 C27H29ClN2O3 464 249-251 71 0.59 0.70 
DDK-B-16 4-OCH3 C27H29ClN2O3 464 238-240 78 0.53 0.59 
DDK-B-17 3-CH3 C27H29ClN2O2 448 182-184 70 0.51 0.62 
DDK-B-18 4-CH3 C27H29ClN2O2 448 217-219 76 0.53 0.65 
DDK-B-19 4-NO2 C26H26ClN3O4 479 226-228 72 0.52 0.60 
DDK-B-20 4-Br C26H26BrClN2O2 513 247-249 74 0.57 0.67 
 
     TLC Solvent system Rf1: Hexane: Ethyl acetate – 4:6,  
     TLC Solvent system Rf2: Chloroform:Methanol – 9.0:1.0. 
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4.5 Mechanism 
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The probable mechanism involves the synthesis of acridines via formation of two 
intermediates A & B as suggested by Da-quing et al. [60 ] and Venkatesan et al. [61]. 
It is likely that the first step is Knoevenagel reaction between dimedone and aldehyde 
resulting in the formation of intermediate A. While condensation of another dimedone 
molecule with ammonium ion results in the formation of enamine intermediate B. 
Then, the Michael additation, cyclization, and dehydration between intermediates A 
and B take place respectively and give the product acridine. 
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4.6 Experimental 
4.6.1 Materials and Methods 
 
Melting points were determined in open capillary tubes and are uncorrected. 
Formation of the compounds was routinely checked by TLC on silica gel-G plates of 
0.5 mm thickness and spots were located by iodine. Microwave assisted reactions 
were carried out in QPro-M microwave synthesizer. IR spectra were recorded 
Shimadzu FT-IR-8400 instrument using KBr pellet method. Mass spectra were 
recorded on Shimadzu GC-MS-QP-2010 model using Direct Injection Probe 
technique. 1H NMR was determined in DMSO-d6 solution on a Bruker Avance 400 
MHz (for compounds DDK-B-02, DDK-B-06, DDK-B-09, DDK-B-11 and DDK-B-
18) and Varian 400 MHz (for compound B-13) spectrometer. Elemental analysis of 
the all the synthesized compounds was carried out on Elemental Vario EL III Carlo 
Erba 1108 model and the results are in agreements with the structures assigned. 
 
4.6.2 Synthesis of 3-(aryl)-1-phenyl-1H-pyrazole-4-carbaldehydes 
 
Synthesis of substituted 3-(aryl)-1-phenyl-1H-pyrazole-4-carbaldehydes was achieved 
using previously published method [72]. 
 
4.6.3 General procedure for the synthesis of 9-(3-(aryl)-1-phenyl-1H-pyrazol-4-yl)-
3,4,6,7-tetrahydro-3,3,6,6-tetramethylacridine-1,8(2H,5H,9H,10H)-diones (DDK-B-
01 to DDK-B-10) 
 
A mixture of the 5,5-dimethylcyclohexane-1,3-dione (dimedone) (0.01 mol), 3-(aryl)-
1-phenyl-1H-pyrazole-4-carbaldehyde (0.005 mol) and ammonium acetate (0.08 mol) 
was irradiated under microwave irradiation at 120 °C for 4-5 min. The microwave 
irradiation was operated in 30-second cycles. The progress of the reaction was 
monitored by TLC. Upon completion of the reaction, the reaction mass was poured 
into ice-cold water, the product was filtered, washed with water, dried and crystallized 
from ethanol-DMF (9:1) mixture. 
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4.6.3.1 9-1,3-diphenyl-1H-pyrazol-4-yl)-3,4,6,7-tetrahydro-3,3,6,6-tetramethyl 
acridine-1,8(2H,5H,9H,10H)-dione (DDK-B-01) 
Yield: 73%; m.p. 203-205 ºC; MS: m/z 491; 
Anal. Calcd. for C32H33N3O2: C, 78.18; H, 6.77; 
N, 8.55. Found: C, 78.09; H, 6.69; N, 8.48% 
 
 
 
 
4.6.3.2 9-(3-(4-chlorophenyl)-1-phenyl-1H-pyrazol-4-yl)-3,4,6,7-tetrahydro-3,3,6,6 
-tetramethylacridine-1,8(2H,5H,9H,10H)-dione (DDK-B-02) 
Yield: 77%; m.p. 196-198 ºC; IR (cm-1): 3288 
(N-H stretching of secondary amine), 3070 (C-
H stretching of aromatic ring), 2956 (C-H 
asymmetrical stretching of CH3 group), 2874 
(C-H symmetrical stretching of CH3 group), 
1678 (C=O stretching of carbonyl group), 1629 
(N-H deformation of -NH group), 1602, 1570 
and 1502 (C=C stretching of aromatic ring), 1406 (C-H asymmetrical deformation of 
CH3 group), 1359 (C-H symmetrical deformation of CH3 group), 1003 (C-H in plane 
bending for aromatic ring), 756 (C-Cl stretching); 1H NMR (DMSO-d6) δ ppm: 0.96 
(s, 6H, Ha, a’), 1.04 (s, 6H, Hb, b’), 2.02-2.16 (m, 4H, Hc, c’), 2.29-2.38 (m, 4H, Hd, d’), 
5.01 (s, 1H, He), 7.20-7.24 (m, 1H, Hf), 7.39-7.43 (m, 2H, Hg, g’), 7.64-7.67 (m, 2H, Hh, 
h’), 7.13-7.15 (d, 2H, Hi, i’, J = 8.8 Hz), 8.12-8.14(d, 2H, Hj, j', J = 7.88 Hz), 7.83 (s, 1H, 
Hk), 9.10 (s, 1H, Hl); MS: m/z 523; Anal. Calcd. for C32H32ClN3O2: C, 73.06; H, 6.13; 
N, 7.99. Found: C, 72.97; H, 6.05; N, 7.90%. 
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4.6.3.3 3,4,6,7-tetrahydro-3,3,6,6-tetramethyl-9-(3-(3-nitrophenyl)-1-phenyl-1H- 
pyrazol-4-yl)acridine-1,8(2H,5H,9H,10H)-dione 
(DDK-B-03)Yield: 71%; m.p. 216-218 ºC; MS: m/z 
536; Anal. Calcd. for C32H32N4O4: C, 71.62; H, 6.01; N, 
10.44. Found: C, 71.54; H, 5.95; N, 10.37%. 
 
 
 
4.6.3.4 3,4,6,7-tetrahydro-3,3,6,6-tetramethyl-9-(3-(4-nitrophenyl)-1-phenyl-1H-  
pyrazol-4-yl)acridine-1,8(2H,5H,9H,10H)-dione 
(DDK-B-04) Yield: 77%; m.p. 233-235 ºC; MS: 
m/z 536; Anal. Calcd. for C32H32N4O4: C, 71.62; H, 
6.01; N, 10.44. Found: C, 71.55; H, 5.94; N, 10.36%. 
 
 
 
4.6.3.5 3,4,6,7-tetrahydro-9-(3-(2-methoxyphenyl)-1-phenyl-1H-pyrazol-4-yl)-  
3,3,6,6-tetramethylacridine-1,8(2H,5H,9H,10H)-
dione (DDK-B-05) Yield: 70%; m.p. 191-193 ºC; 
MS: m/z 521; Anal. Calcd. for C33H35N3O3: C, 
75.98; H, 6.76; N, 8.06. Found: C, 75.91; H, 6.69; 
N, 7.97%. 
 
 
4.6.3.6  3,4,6,7-tetrahydro-9-(3-(4-methoxyphenyl)-1-phenyl-1H-pyrazol-4-yl)- 
3,3,6,6-tetramethylacridine-1,8(2H,5H,9H,10H)-
dione (DDK-B-06) Yield: 83%; m.p. 218-220 ºC; 
IR (cm-1): 3265 (N-H stretching of secondary 
amine), 3067 (C-H stretching of aromatic ring), 
2958 (C-H asymmetrical stretching of CH3 group), 
2877 (C-H symmetrical stretching of CH3 group), 
1680 (C=O stretching of carbonyl group), 1639 
(N-H deformation of -NH group), 1597 and 1487  (C=C stretching of aromatic ring), 
NN
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1487 (C-H asymmetrical deformation of CH3 group), 1367 (C-H symmetrical 
deformation of CH3 group), 1222 (C-O-C asymmetrical stretching of OCH3 group), 
1062 (C-O-C symmetrical stretching of OCH3 group), 995 (C-H in plane bending for 
aromatic ring); 1H NMR (DMSO-d6) δ ppm: 0.94 (s, 6H, Ha, a’), 1.00 (s, 6H, Hb, b’), 
2.01-2.17 (m, 4H, Hc, c’), 2.29-2.38 (m, 4H, Hd, d’), 5.01 (s, 1H, He), 7.37-7.40 (m, 1H, 
Hf), 7.50-7.54 (m, 2H, Hg, g’), 7.87-7.93 (m, 2H, Hh, h’), 7.00-7.02 (d, 2H, Hi, i’, J = 8.92 
Hz), 7.93-7.95 (d, 2H, Hj, j', J = 8.8 Hz), 8.13 (s, 1H, Hk), 9.11 (s, 1H, Hl), 3.85 (s, 3H, 
Hm); MS: m/z 521; Anal. Calcd. for C33H35N3O3: C, 75.98; H, 6.76; N, 8.06. Found: C, 
75.90; H, 6.70; N, 7.97%. 
 
4.6.3.7 3,4,6,7-tetrahydro-9-(3-(2-hydroxyphenyl)-1-phenyl-1H-pyrazol-4-yl)- 
3,3,6,6-tetramethylacridine-1,8(2H,5H,9H,10H)-
dione (DDK-B-07) Yield: 68%; m.p. 179-181 ºC; 
MS: m/z 507; Anal. Calcd. for C32H33N3O3: C, 
75.71; H, 6.55; N, 8.28. Found: C, 75.63; H, 6.49; 
N, 8.22%. 
 
 
4.6.3.8 3,4,6,7-tetrahydro-9-(3-(4-hydroxyphenyl)-1-phenyl-1H-pyrazol-4-yl)- 
3,3,6,6-tetramethylacridine-1,8(2H,5H,9H,10H)-
dione (DDK-B-08) Yield: 69%; m.p. 193-195 ºC; 
MS: m/z 507; Anal. Calcd. for C32H33N3O3: C, 
75.71; H, 6.55; N, 8.28. Found: C, 75.64; H, 6.49; 
N, 8.20%. 
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4.6.3.9 9-(3-(4-fluorophenyl)-1-phenyl-1H-pyrazol-4-yl)-3,4,6,7-tetrahydro- 
3,3,6,6-tetramethylacridine-1,8(2H,5H,9H,10H)-
dione (DDK-B-09) Yield: 82%; m.p. 254-256 ºC; 
IR (cm-1): 3282 (N-H stretching of secondary 
amine), 3074 (C-H stretching of aromatic ring), 
2955 (C-H asymmetrical stretching of CH3 group), 
2875 (C-H symmetrical stretching of CH3 group), 
1629 (C=O stretching of carbonyl group), 1616 (N-
H deformation of -NH group), 1599, 1491 and 1454 (C=C stretching of aromatic ring), 
1454 (C-H asymmetrical deformation of CH3 group), 1359 (C-H symmetrical 
deformation of CH3 group), 1066 (C-H in plane bending for aromatic ring), 1018 (C-F 
stretching); 1H NMR (DMSO-d6) δ ppm: 0.96 (s, 6H, Ha, a’), 1.04 (s, 6H, Hb, b’), 2.02-
2.17 (m, 4H, Hc, c’), 2.29-2.38 (m, 4H, Hd, d’), 5.02 (s, 1H, He), 7.39-7.43 (m, 2H, Hg, g’), 
7.63-8.66 (m, 2H, Hh, h’), 7.11-7.15 (t, 2H, Hi, i’), 8.10-7.11 (t, 2H, Hj, j'), 7.92 (s, 1H, Hk), 
9.07 (s, 1H, Hl); MS: m/z 509; Anal. Calcd. for C32H32FN3O2: C, 75.42; H, 6.33; N, 
8.25. Found: C, 75.34; H, 6.27; N, 8.19%. 
 
4.6.3.10 9-(3-(4-bromophenyl)-1-phenyl-1H-pyrazol-4-yl)-3,4,6,7-tetrahydro- 
3,3,6,6-tetramethylacridine-1,8(2H,5H,9H,10H)-
dione (DDK-B-10)Yield: 79%; m.p. 244-246 ºC; 
MS: m/z 570; Anal. Calcd. for C32H32BrN3O2: C, 
67.37; H, 5.65; N, 7.37, Found: C, 67.28; H, 5.57; N, 
7.28%. 
 
 
 
4.6.4 Synthesis of substituted 2-chloro-quinoline-3-carbaldehydes  
Synthesis of substituted 2-chloro-quinoline-3-carbaldehydes was achieved using 
previously published methods [73]. 
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4.6.5 General procedure for the synthesis of 9-(2-chloro-6-substituted-quinolin-3-
yl)-3,4,6,7-tetrahydro-3,3,6,6-tetramethylacridine-1,8(2H,5H,9H,10H)-dione (DDK-
B-11 to DDK-B-20) 
 
A mixture of the 5,5-dimethylcyclohexane-1,3-dione (dimedone) (0.01 mol), 
substituted 2-chloro-quinoline-3-carbaldehyde (0.005 mol) and ammonium acetate 
(0.08 mol) was irradiated under microwave irradiation at 120 °C for 2-3 min. The 
microwave irradiation was operated in 30-second cycles. The progress of the reaction 
was monitored by TLC. Upon completion of the reaction the reaction mass was 
poured into ice-cold water, the product was filtered, washed with water, dried and 
crystallized from ethanol-DMF (9:1) mixture. 
 
4.6.5.1  9-(2-chloro-6-fluoroquinolin-3-yl)-3,4,6,7-tetrahydro-3,3,6,6-tetramethyl  
acridine-1,8(2H,5H,9H,10H)-dione (DDK-B-11) 
Yield: 75%; m.p. 209-211 ºC; IR (cm-1): 3282 (N-H 
stretching of secondary amine), 3074 (C-H 
stretching of aromatic ring), 2955 (C-H 
asymmetrical stretching of CH3 group), 2875 (C-H 
symmetrical stretching of CH3 group), 1629 (C=O 
stretching of carbonyl group), 1599, 1491 and 1454 
(C=C stretching of aromatic ring), 1454 (C-H asymmetrical deformation of CH3 
group), 1359 (C-H symmetrical deformation of CH3 group), 1018 (C-F stretching), 
958 (C-H in plane bending for aromatic ring); 1H NMR (DMSO-d6) δ ppm: 0.98 (s, 
6H, Ha, a’), 1.08 (s, 6H, Hb, b’), 2.07-2.24 (m, 4H, Hc, c’), 2.41-2.51 (m, 4H, Hd, d’), 4.62 
(s, 1H, He), 7.74-7.77 (m, 1H, Hf), 7.11-7.16 (m, 1H, Hg), 7.30-7.33 (m, 1H, Hh), 8.00 (s, 
1H, Hi), 11.43 (s, 1H, Hj); MS: m/z 452; Anal. Calcd. for C26H26ClFN2O2: C, 68.94; H, 
5.79; N, 6.18. Found: C, 68.86; H, 5.72; N, 6.11% 
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4.6.5.2 9-(2,7-dichloroquinolin-3-yl)-3,4,6,7-tetrahydro-3,3,6,6-tetramethylacridine- 
1,8(2H,5H,9H,10H)-dione (DDK-B-12) Yield: 
72%; m.p. 237-239 ºC; MS: m/z 469; Anal. Calcd. 
for C26H26Cl2N2O2: C, 66.53; H, 5.58; N, 5.97. 
Found: C, 66.46; H, 5.50; N, 5.88% 
 
 
 
4.6.5.3 9-(2,6-dichloroquinolin-3-yl)-3,4,6,7-tetrahydro-3,3,6,6-tetramethylacridine- 
1,8(2H,5H,9H,10H)-dione (DDK-B-13) Yield: 
79%; m.p. 243-245 ºC; ; IR (cm-1): 3290 (N-H 
stretching of secondary amine), 3079 (C-H 
stretching of aromatic ring), 2958 (C-H 
asymmetrical stretching of CH3 group), 2872 (C-H 
symmetrical stretching of CH3 group), 1653 (C=O 
stretching of carbonyl group), 1614 (N-H 
deformation of -NH group), 1577 and 1450 (C=C stretching of aromatic ring), 1425 
(C-H asymmetrical deformation of CH3 group), 1363 (C-H symmetrical deformation 
of CH3 group), 1004 (C-H in plane bending for aromatic ring), 735 (C-Cl stretching) ); 
1H NMR (DMSO-d6) δ ppm: 0.87 (s, 6H, Ha, a’), 0.99 (s, 6H, Hb, b’), 1.98-2.53 (m, 8H, 
Hc, c’,  d, d’), 4.49 (s, 1H, He), 7.79-7.83 (d, 2H, Hf, i), 7.40-7.42 (m, 1H, Hg), 7.17-7.19 (d, 
1H, Hh), 11.59 (s, 1H, Hj); MS: m/z 469; Anal. Calcd. for C26H26Cl2N2O2: C, 66.53; H, 
5.58; N, 5.97. Found: C, 66.47; H, 5.49; N, 5.89% 
 
4.6.5.4  9-(2-chloro-8-methoxyquinolin-3-yl)-3,4,6,7-tetrahydro-3,3,6,6-tetramethyl  
acridine-1,8(2H,5H,9H,10H)-dione (DDK-B-14) 
Yield: 69%; m.p. 228-230 ºC; MS: m/z 464; Anal. 
Calcd. for C27H29ClN2O3: C, 69.74; H, 6.29; N, 6.02. 
Found: C, 69.67; H, 6.21; N, 5.95% 
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4.6.5.5  9-(2-chloro-7-methoxyquinolin-3-yl)-3,4,6,7-tetrahydro-3,3,6,6-tetramethyl  
acridine-1,8(2H,5H,9H,10H)-dione (DDK-B-15) 
Yield: 71%; m.p. 249-251 ºC; MS: m/z 464; Anal. 
Calcd. for C27H29ClN2O3: C, 69.74; H, 6.29; N, 6.02. 
Found: C, 69.66; H, 6.21; N, 5.96% 
 
 
 
4.6.5.6  9-(2-chloro-6-methoxyquinolin-3-yl)-3,4,6,7-tetrahydro-3,3,6,6-tetramethyl  
acridine-1,8(2H,5H,9H,10H)-dione (DDK-B-16) 
Yield: 78%; m.p. 238-240 ºC; MS: m/z 464; Anal. 
Calcd. for C27H29ClN2O3: C, 69.74; H, 6.29; N, 
6.02. Found: C, 69.67; H, 6.20; N, 5.94% 
 
 
 
4.6.5.7  9-(2-chloro-7-methylquinolin-3-yl)-3,4,6,7-tetrahydro-3,3,6,6-tetramethyl  
acridine-1,8(2H,5H,9H,10H)-dione (DDK-B-17) 
Yield: 70%; m.p. 182-184 ºC; MS: m/z 448; Anal. 
Calcd. for C27H29ClN2O2: C, 72.23; H, 6.51; N, 
6.24. Found: C, 72.16; H, 6.43; N, 6.17% 
 
 
 
4.6.5.8  9-(2-chloro-6-methylquinolin-3-yl)-3,4,6,7-tetrahydro-3,3,6,6-tetramethyl  
acridine-1,8(2H,5H,9H,10H)-dione (DDK-B-18) 
Yield: 76%; m.p. 217-219 ºC; ; IR (cm-1): 3252 (N-
H stretching of secondary amine), 3045 (C-H 
stretching of aromatic ring), 2955 (C-H 
asymmetrical stretching of CH3 group), 2879 (C-H 
symmetrical stretching of CH3 group), 1660 (C=O 
stretching of carbonyl group), 1566, 1500 and 1467 
(C=C stretching of aromatic ring), 1427 (C-H asymmetrical deformation of CH3 
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group), 1365 (C-H symmetrical deformation of CH3 group), 1066 (C-H in plane 
bending for aromatic ring); 1H NMR (DMSO-d6) δ ppm: 0.93 (s, 6H, Ha, a’), 1.03 (s, 
6H, Hb, b’), 2.01-2.19 (m, 4H, Hc, c’), 2.36-2.50 (m, 4H, Hd, d’), 4.55 (s, 1H, He), 7.90-
7.91 (d, 1H, Hf), 7.09-7.15 (m, 2H, H g, h), 8.13 (s, 1H, Hi), 11.25 (s, 1H, Hj), 2.31 (s, 3H, 
Hk); MS: m/z 448; Anal. Calcd. for C27H29ClN2O2: C, 72.23; H, 6.51; N, 6.24. Found: 
C, 72.15; H, 6.44; N, 6.15% 
 
4.6.5.9  9-(2-chloro-7-nitroquinolin-3-yl)-3,4,6,7-tetrahydro-3,3,6,6-tetramethyl  
acridine-1,8(2H,5H,9H,10H)-dione (DDK-B-19) 
Yield: 72%; m.p. 226-228 ºC; MS: m/z 479; Anal. 
Calcd. for C26H26ClN3O4: C, 65.06; H, 5.46; N, 
8.76. Found: C, 64.97; H, 5.39; N, 8.70% 
 
 
 
 
4.6.5.10  9-(6-bromo-2-chloroquinolin-3-yl)-3,4,6,7-tetrahydro-3,3,6,6-tetramethyl  
acridine-1,8(2H,5H,9H,10H)-dione (DDK-B-20) 
Yield: 74%; m.p. 247-249 ºC; MS: m/z 513; Anal. 
Calcd. for C26H26BrClN2O2: C, 60.77; H, 5.10; N, 
5.45. Found: C, 60.69; H, 5.03; N, 5.38% 
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4.7 Spectral discussion 
4.7.1 Mass spectral study 
Mass spectra were recorded on Shimadzu GC-MS-QP-2010 model using Direct 
Injection Probe technique. Systematic fragmentation pattern was observed in mass 
spectral analysis. Molecular ion peak was observed in agreement with molecular 
weight of respective compound. Mass fragmentation pattern for a representative 
compound of each series is depicted below. 
 
4.7.1.1 Mass fragmentation pattern for DDK-B-06 
+
+
m/z =407
+
+
+
+
+
+
+
m/z =106
m/z =144
NN
N
H
OO
m/z =521
NN
N
H
NN
N
H
m/z =371
NHN
N
H
OO
m/z =283NHN
N
H
OO
m/z =271
NH2N
N
H
OO
m/z =271 H2N
N
H
OO
m/z =246
N
H
OO
m/z =220
N
H
m/z =188 NN
m/z =219
+
NHN +
O
+
m/z =91
+
m/z =77
OCH3
NN
N
H
OO
m/z =491
+
NN
N
H
OO
m/z =507
+
OH
 
 
 
 
Chapter 4                                                                                                          Acridines  
     
   145
4.7.1.2 Mass fragmentation pattern for DDK-B-11 
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4.7.2 IR spectral study 
IR spectra were recorded on Shimadzu FT-IR-8400 model using KBr pellet method. 
Various functional groups present in molecule were identified by characteristic 
frequency obtained for them. For acridines (DDK-B-01 to DDK-B-20), a 
characteristic band of carbonyl group was observed in the range of 1629-1680 cm-1. 
Another characteristic C-H asymmetrical and symmetrical stretching bands of methyl 
groups were observed at 2955-2958 cm-1 and 2835-2877 cm-1 respectively. Also, N-H 
stretching band of secondary amine was observed at 3252-3282 cm-1 suggesting 
formation of desired products (DDK-B-01 to DDK-B-20).     
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4.7.3 1H NMR spectral study 
1H NMR spectra were recorded in DMSO-d6 solution on a Bruker Ac 400 MHz 
spectrometer using TMS as an internal standard. Number of protons and their 
chemical shifts were found to support the structure of the synthesized compounds. 
For acridines (DDK-B-01 to DDK-B-10), characteristic singlets were 
observed for methyl and methylene groups at 0.94-1.04 δ ppm and 2.01-2.38 δ ppm 
respectively. Confirmatory signal of methine proton was observed at 5.01-5.02 δ ppm. 
The aromatic ring protons were observed at 7.00-8.15 δ ppm and J value were found 
to be in accordance with substitution pattern on phenyl ring. The singlet for secondary 
amine (-NH) proton was observed at 9.07-9.11 δ ppm.  
While, for acridines (DDK-B-11 to DDK-B-20), characteristic singlets were 
observed for methyl and methylene groups at 0.87-1.08 δ ppm and 1.98-2.53 δ ppm 
respectively. Confirmatory signal of methine proton was observed at 4.49-4.62 δ ppm. 
The aromatic ring protons were observed at 7.09-8.13 δ ppm and J value were found 
to be in accordance with substitution pattern on phenyl ring. The singlet for secondary 
amine (-NH) proton was observed at 11.25-11.59 δ ppm. 
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IR spectrum of DDK-B-02 
 
 
Mass spectrum of DDK-B-02 
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1H NMR spectrum of DDK-B-02 
 
 
Expanded 1H NMR spectrum of DDK-B-02 
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Expanded 1H NMR spectrum of DDK-B-02 
 
 
IR spectrum of DDK-B-06 
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Mass spectrum of DDK-B-06 
 
 
1H NMR spectrum of DDK-B-06 
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Expanded 1H NMR spectrum of DDK-B-06 
 
 
Expanded 1H NMR spectrum of DDK-B-06 
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IR spectrum of DDK-B-09 
 
 
Mass spectrum of DDK-B-09 
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1H NMR spectrum of DDK-B-09 
  
 
Expanded 1H NMR spectrum of DDK-B-09 
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Expanded 1H NMR spectrum of DDK-B-09 
 
 
IR spectrum of DDK-B-11 
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Mass spectrum of DDK-B-11 
 
 
1H NMR spectrum of DDK-B-11 
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Expanded 1H NMR spectrum of DDK-B-11 
 
 
Expanded 1H NMR spectrum of DDK-B-11 
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IR spectrum of DDK-B-13 
 
 
Mass spectrum of DDK-B-13 
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1H NMR spectrum of DDK-B-13 
 
 
Expanded 1H NMR spectrum of DDK-B-13 
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Expanded 1H NMR spectrum of DDK-B-13 
 
 
IR spectrum of DDK-B-18 
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Mass spectrum of DDK-B-18 
 
 
1H NMR spectrum of DDK-B-18 
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Expanded 1H NMR spectrum of DDK-B-18 
 
 
Expanded 1H NMR spectrum of DDK-B-18 
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4.8 Biological evaluation 
4.8.1 Antimicrobial evaluation 
All of the synthesized compounds (DDK-B-01 to DDK-B-20) were tested for their 
antibacterial and antifungal activity (MIC) in vitro by broth dilution method [74] with 
two Gram-positive bacteria Staphylococcus aureus MTCC-96, Streptococcus 
pyogenes MTCC 443, two Gram-negative bacteria Escherichia coli MTCC 442, 
Pseudomonas aeruginosa MTCC 441 and three fungal strains Candida albicans 
MTCC 227, Aspergillus Niger MTCC 282, Aspergillus clavatus MTCC 1323 taking 
Ampicillin, Chloramphenicol, Ciprofloxacin, Norfloxacin, Nystatin, and Griseofulvin 
as standard drugs. The standard strains were procured from the Microbial Type 
Culture Collection (MTCC) and Gene Bank, Institute of Microbial Technology, 
Chandigarh, India.  
 The minimal inhibitory concentration (MIC) values for all the newly 
synthesized compounds, defined as the lowest concentration of the compound 
preventing the visible growth, were determined by using microdilution broth method 
according to NCCLS standards [74(a)].  Serial dilutions of the test compounds and 
reference drugs were prepared in Muellere-Hinton agar. Drugs (10 mg) were 
dissolved in dimethylsulfoxide (DMSO, 1 mL). Further progressive dilutions with 
melted Muellere-Hinton agar were performed to obtain the required concentrations. In 
primary screening 1000 μg mL-1, 500 μg mL-1 and 250 μg mL-1 concentrations of the 
synthesized drugs were taken. The active synthesized drugs found in this primary 
screening were further tested in a second set of dilution at 125 μg mL-1, 62.5 μg mL-1, 
50 μg mL-1, 25 μg mL-1, 12.5 μg mL-1, and 6.250 μg mL-1 concentration against all 
microorganisms. The tubes were inoculated with 108 cfu mL-1 (colony forming 
unit/mL) and incubated at 37 ºC for 24 h. The MIC was the lowest concentration of 
the tested compound that yields no visible growth (turbidity) on the plate. To ensure 
that the solvent had no effect on the bacterial growth, a control was performed with 
the test medium supplemented with DMSO at the same dilutions as used in the 
experiments and it was observed that DMSO had no effect on the microorganisms in 
the concentrations studied. The results obtained from antimicrobial susceptibility 
testing are depicted in Table 1. 
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Table 1. Antibacterial and antifungal activity of synthesized compounds DDK-B-
01 to DDK-B-20 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Code Minimum inhibition concentration (µg mL-1 ) 
Gram-positive Gram-negative Fungal species 
S.a. S. p. E.c. P.a. C. a. A. n. A.c. 
DDK-B-01 500 1000 500 100 1000 500 500 
DDK-B-02 1000 500 1000 1000 500 500 1000 
DDK-B-03 500 500 250 500 >1000 1000 500 
DDK-B-04 250 62.5 125 250 1000 500 250 
DDK-B-05 125 100 1000 500 100 1000 500 
DDK-B-06 500 1000 250 1000 500 500 >1000 
DDK-B-07 1000 250 500 500 500 100 250 
DDK-B-08 100 125 100 62.5 >1000 1000 1000 
DDK-B-09   10 25   50    25 100 100 100 
DDK-B-10 25 500 250 100 500 1000 >1000 
DDK-B-11 500 500 >1000 1000 500 1000 >1000 
DDK-B-12 62.5 250 500 125 1000 100 500 
DDK-B-13 100 500 1000 1000 500 500 100 
DDK-B-14 1000 1000 250 >1000 500 250 1000 
DDK-B-15 250 250 500 500 1000 100 1000 
DDK-B-16 250 1000 1000 250 >1000 1000 500 
DDK-B-17 125 500 >1000 1000 500 250 500 
DDK-B-18 100 500 500 500 125 250 250 
DDK-B-19 500 1000 250 1000 500 1000 500 
DDK-B-20 250 100 500 >1000 1000 500 1000 
Ampicillin 250 100 100 100 - - - 
Chloramphenicol 50 50 50 50 - - - 
Ciprofloxacin 50 50 25 25 - - - 
Norfloxacin 10 10 10 10 - - - 
Nystatin - - - - 100 100 100 
Griseofulvin - - - - 500 100 100 
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 Chapter 5 
 Studies on microwave assisted   
 synthesis of polyhydroquinolines 
 
 
 
5.0 Introduction 
Quinoline is a heterocyclic scaffold of paramount importance to human race. Several 
quinoline derivatives isolated from natural resources or prepared synthetically are 
significant with respect to medicinal chemistry and biomedical use. Compounds 
containing quinoline motif are most widely used as antimalarials [1], antibacterials [2] 
antifungals [3] and anticancer agents [4]. Additionally, quinoline derivatives find use 
in the synthesis of fungicides, virucides, biocides, alkaloids, rubber chemicals and 
flavoring agents. [5]. Because of their importance as substructures in a broad range of 
natural and designed products, significant efforts continue to be directed into the 
development of new quinoline-based structures. 
In view of these observations and with a view to further explore the 
pharmacological profile of this class of compounds, the present study includes 
synthesis of novel quinoline derivatives viz. 5,6,7,8-tetrahydroquinolines and 7,8-
dihydro-2,4-disubstituted-quinolin-5(1H,4H,6H)-ones. The study is divided in two 
sections: 
 
5.1 : Synthesis and biological evaluation of 2-amino-5,6,7,8-tetrahydro-4- 
        heteroaryl- quinoline-3-carbonitriles   
 
5.2 : Synthesis and biological evaluation of 7,8-dihydro-7,7-dimethyl-2,4- 
        disubstituted-quinolin-5(1H,4H,6H)-ones 
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5.1: Synthesis and biological evaluation  
       of 2-amino-5,6,7,8-tetrahydro-4-  
       heteroaryl-quinoline-3-carbonitriles      
 
 
5.1.1 Introduction 
Among quinoline derivatives, tetrahydroquinolines are an important structural subunit 
of natural products and many tetrahydroquinoline derivatives exhibit interesting 
biological and pharmaceutical activities [6], including anti-HIV [7], anti-cancer [8] 
anti-malarial [9], cholesteryl ester transfer protein inhibitors [10], anti-diabetic [11] 
etc. Among various tetrahydroquinolines, biological profile of 1,2,3,4-
tetrahydroquinolines and 5,6,7,8-tetrahydroquinolines is extensively studied. 
 
N
H N
5,6,7,8-tetrahydroquinoline1,2,3,4-tetrahydroquinoline  
 
Recently, the 5,6,7,8-tetrahydroquinolines have drawn considerable attention 
due to their interesting pharmacological applications as RET tyrosine kinase inhibitors 
[12], antimicrobial [13], anti-fungal [14], acetylcholinesterase inhibitory [15], anti-
cancer [16, 17],  anti-HIV [18, 19], C5a receptor antagonists agents [20, 21], anti-
ulcer [22-24], anti-depressant [25, 26], anti-inflammatory [27, 28], antimalarial [29], 
Na+/H+ exchange inhibitors [30], tachykinin receptor antagonist [31], modulators of 
chemokine receptors [32], alpha-2B-adrenergic receptor antagonist [33] etc. Some 
examples of published derivatives of 5,6,7,8-tetrahydroquinolines with their 
biological activities are  shown in the following figure. 
 
 
 
 
 
 
 
Chapter 5-Section-1                                                          5,6,7,8-Tetrahydroquinolines         
     
   171
N
N
NH2
N NH .HCl
N
CN
NH2
O
N
CN
N N
H
SO2NHR
N
OCH3
C2H5
C2H5
N
Activity: Anti-HIV[18]
Activity: Antifungal [14]
Activity: Anticancer [16]
Activity: C5a Receptor Antagonist [20]
N
H
O
NH
Activity: Acetylcholinesterase inhibitory [15]
N
OCH3
C2H5O
Activity: Anti-inflammatory [27]
NO2
 
 
 
5.1.2 Reported synthetic strategies 
Synthetic methodologies for preparing tetrahydroquinoline derivatives have attracted 
considerable interest and several methods offering good results have been reported. 
However, most of them describe the synthesis of 1,2,3,4-tetrahydroquinoline nucleus 
and concise methods to access usefully functionalized 5,6,7,8-tetrahydroquinolines 
are scarce in the literature [34].  
Few researchers have reported hydrogenation of quinolines to 5,6,7,8-
tetrahydroquinolines. Skupinska et al. have reported concise preparation of amino-
5,6,7,8-tetrahydroquinolines and amino-5,6,7,8-tetrahydroisoquinolines via catalytic 
hydrogenation of acetamidoquinolines and acetamidoisoquinolines [34] (Scheme 
5.1.2.1). Different researchers have reported hydrogenation under variety of  
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conditions, viz. using Ru/ZrO2·xH2O [35] or polymer-supported Rhodium(I)-1,3-
Bis(diphenylphosphino)propane moieties [36] as catalysts, and hydrogenation over 
raney-nickel and ruthenium/carbon [37]. Huck et al. have reported hydrogenation of 
cinchona alkaloids and cincholidine over 5 wt% Pt/Al2O3 in acetic acid [38].  
 
N
NHCOCH3 (i) H2 (1atm), 5% PtO2,
    TFA, 60oC
(ii) 6% HCl, reflux N
NH2
Scheme 5.1.2.1  
 
Literature survey revealed number of reports describing synthesis of 5,6,7,8-
tetrahydroquinoline-3-carbonitriles. Several reports describe the synthesis of 2-amino- 
5,6,7,8-tetrahydroquinoline-3-carbonitriles by the reaction of arylidene malononitrile 
with cyclohexanone and ammonium acetate [28, 39, 40] (Scheme 5.1.2.2).  
 
CN
CN
+
R
NH4OAc
N
R
NH2
CN
R = alkyl or aryl
Scheme  5.1.2.2
O
 
 
The same compounds were obtained by the reaction of 3-amino-2-cyclohexen-1-one 
(enaminone) with arylidene malononitriles in better yields [14] (Scheme 5.1.2.3).  
 
CN
CN
+R
NH4OAc
N
R
NH2
CN
R = aryl
Scheme  5.1.2.3
O
NH2
 
 
Reaction of arylidene cyanoacetate with cyclohexanone in excess of 
ammonium acetate yielded 2-oxo-5,6,7,8-tetrahydroquinoline-3-carbonitriles [41]. 
One pot synthesis from aldehyde, ethyl cyanacetate, cyclohexanone and ammonium  
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acetate is also reported yielding same compounds [42]. 
Synthesis of 4-alkyl/aryl-3-cyano-5,6,7,8-tetrahydroquinoline-2(1H)-thiones is 
also reported using different methods viz. cyclocondensation of arylmethylene cyclo- 
hexanones with cyanothioacetamide [13, 43], reaction of cyclohexanone [12, 44, 47] 
or its enamine [45] with arylmethylenecyanothioacetamides. Three component 
condensation of cyanothioacetamide with aliphatic aldehydes and enamine is reported 
to give 4-alkyl-3-cyano-5,6,7,8-tetrahydroquinoline-2(1H)-thiones [46] (Scheme 
5.1.2.4). 
 
+R
O
N
H
R
S
CN
R = alkyl
Scheme  5.1.2.4
(i) EtOH, r.tC
CN
S
H2N
O
N
O
+
(ii) HCl
 
 
Yao et al. have reported synthesis and structures of (S)- and (R)-2-[3-cyano-4-
(2-thienyl)-5,6,7,8-tetrahydroquinolin-2-ylsulfanyl]-3-methyl-N-phenylbutyramide by 
the reaction of 4-(2-thienyl)-3-cyano-5,6,7,8-tetrahydroquinoline-2(1H)-thione with 
(R) and (S) 2-Bromo-3-methyl-1-phenyl-butan-1-one respectively [47] (Scheme 
5.1.2.5). 
 
O
Br
N
H
S
CN
S
+ (i) K2CO3, THF
NH
O
N
H
S
CN
S
H
N
R
S
Scheme  5.1.2.5
 
Literature survey also revealed few reports on the synthesis of chiral 5,6,7,8-
tetrahydroquinolines. Recently, Hapke et al. have reported asymmetric synthesis of 
axially chiral 1-Aryl-5,6,7,8-tetrahydroquinolines by cobalt-catalyzed [2+2+2] 
cycloaddition reaction of 1-aryl-1,7-octadiynes and nitriles [48]. Synthesis of chiral 
ethyl-5-(acetoxyimino)-2,7,7-trimethyl-4-(1-naphthyl)-5,6,7,8-tetrahydroquinoline-3-
 
Chapter 5-Section-1                                                          5,6,7,8-Tetrahydroquinolines         
     
   174
carboxylate via lipase-catalyzed hydrolysis was reported by Zhou et al. [49]. Chelucci 
et al. have reported synthesis of chiral 2-methyl-5,6,7,8-tetrahydroquinolines from 
naturally occurring monoterpenes [50]. Regioselective syntheses of optically active 
(R)-5-methyl- and (R)-7-methyl-5,6,7,8-tetrahydroquinolines was reported by 
Chelucci et al. earlier [51].   
Cyclocondensation of 3-amino-2-cyclohexen-1-one with malonic acid 
bis(2,4,6-trichlorophenyl) ester  yielded  2,4-Dichloro-7,8-dihydro-6H-quinolin-5-one, 
which upon Suzuki cross-coupling with 2,6-diethylphenylboronic acid followed by 
reaction with sodium methoxide, sodium borohydride, thionyl chloride and secondary 
amines yielded [2-(2,6-Diethyl-phenyl)-4-methoxy-5,6,7,8-tetrahydro-quinolin-5-yl]-
dialkyl/aryl-amine [20] (Scheme 5.1.2.6). 
 
(i) PhBr, reflux
N
Cl
Cl
 R =
Scheme  5.1.2.6
O
NH2
O
OR
O
RO
Cl Cl
Cl
+
(ii) POCl3 reflux
O
(i) NaOMe, MeOH
(ii) NaBH4, MeOH
2,6-DiEtPhB(OH)2, 
       Pd(PPh3)4,
Na2CO3
N
ClO
C2H5
C2H5
N
OOH
C2H5
C2H5
(i) SOCl2, CH2Cl2
(ii) R1R2NH, K2CO3
N
ON
C2H5
C2H5
R1 R2
, R1 = H, aryl , R1 = H, Me, Et, aryl
 
 
Recently, few approaches involving Kronhke pyridine ssynthesis for the 
synthesis of 5,6,7,8-tetrahydroquinolines have been reported. Yan and co-workers 
have reported a one pot approach using modified two-step synthesis via Krohnke 
pyridine synthesis involving a three-component tandem reaction of N-
phenacylpyridinium bromide, aromatic aldehydes and substituted cyclic ketones in 
ammonium acetate-acetic acid under microwave irradiation [52] (Scheme 5.1.2.7).  
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N+
O
Ph
Br-
O
+
NH4OAc
HOAc
Ph
N
R
R O+
MWI
Scheme  5.1.2.7  
 
While Brahmbhatt et al. have reported synthesis of 6-(4-aryl-8-aryledine-5, 
6,7,8-tetrahydroquinolin-2-yl)coumarins from 3-phenyl-4-methyl-6-coumarinoyl 
methylpyridinium bromide and 2,6-dibenzylidene-cyclohexanone using Krohnke’s 
reaction condition under conventional heating [53] (Scheme 5.1.2.8).   
 
N+
OO
O
Br-
O
RR+
NH4OAc
HOAc
OO
N
R
R
R = aryl
Scheme  5.1.2.8
 
Taylor et al. have reported the synthesis of 5,6,7,8-tetrahydroquinolines by the 
intramolecular Diels-Alder Reactions of 1,2,4-Triazines [54] (Scheme 5.1.2.9).  
 
N
N
N
CNNC
Cl
N
NNCl
Dioxane
reflux
Scheme  5.1.2.9  
 
A highly selective transformation of 5,6,7,8-tetrahydro-2H-1-benzopyran-2,5-
diones  with hydrazides, arylhydrazines and heterocyclic hydrazines as nitrogen-contg. 
nucleophiles into the corresponding 1-amino-5,6,7,8-tetrahydroquinoline-2,5-diones 
was investigated by Trebse et al. [55]. Koyama et al. have reported synthesis of  
5,6,7,8-tetrahydroquinolines by thermolysis of oxime O-allyl ethers in presence of 
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boron trifluoride etherate [56] (Scheme 5.1.2.10). 
 
N
O
BF3.Et2O
N N
+
Scheme  5.1.2.10  
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5.1.3 Current Work 
The chemistry of quinoline and its derivatives has been studied for over a 
century due to their diverse biological activities. Among various quinoline derivatives, 
5,6,7,8-tetrahydroquinoline derivatives draw a special attention for their wide 
spectrum biological activities viz. anti-microbial, anti-cancer, anti-HIV, anti-
inflammatory, antimalarial and antidepressant etc.  
Keeping in mind various biomedical applications and with a view to further 
assess the pharmacological profile of this class of compounds, two novel series of 
5,6,7,8-tetrahydroquinolines (DDK-C-01 to DDK-C-20) have been synthesized. The 
synthesis of 5,6,7,8-tetrahydroquinolines (DDK-C-01 to DDK-C-10) and (DDK-C-
11 to DDK-C-20) was achieved by the one pot microwave-assisted reaction of  
cyclohexanone with 2-((3-(aryl)-1-phenyl-1H-pyrazol-4-yl)methylene)malononitrile 
& 2-((2-chloro-substitutedquinolin-3-yl)methylene)malononitrile respectively and 
excess of ammonium acetate. The products were characterized by FT-IR, mass, 1H 
NMR spectroscopy and elemental analyses. The newly synthesized compounds were 
subjected to antimicrobial activity. 
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5.1.4 Reaction scheme 
O
+
 Reagents and conditions: (a) NH4OAc, MeOH, MWI, 5-7 mins. ;
                                           (b) NH4OAc, MeOH, MWI, 7-8 mins.
NN
N
NN a
NH2
CN
O
+ b
DDK-C-01 to DDK-C-10
N NH2
CN
N
Cl
DDK-C-11 to DDK-C-20
N Cl
R1
R1
R1
R1
CN
CN
CN
CN
 
 
Code R1 M.F. M.W. M.P. ºC Yield % Rf1 Rf2 
DDK-C-01 H C25H21N5 391 237-239 73 0.48 0.62 
DDK-C-02 4-Cl C25H20ClN5 425 209-211 78 0.47 0.65 
DDK-C-03 3-NO2 C25H20N6O2 436 199-201 74 0.51 0.69 
DDK-C-04 4-NO2 C25H20N6O2 436 213-215 75 0.50 0.64 
DDK-C-05 2-OCH3 C26H23N5O 421 237-239 61 0.48 0.63 
DDK-C-06 4-OCH3 C26H23N5O 421 207-209 81 0.55 0.69 
DDK-C-07 2-OH C25H21N5O 407 223-225 62 0.52 0.68 
DDK-C-08 4-OH C25H21N5O 407 201-203 72 0.51 0.66 
DDK-C-09 4-F C25H20FN5 409 207-209 81 0.52 0.67 
DDK-C-10 4-Br C25H20Br N5 470 233-235 78 0.52 0.69 
DDK-C-11 4-F C19H14ClFN4 352 196-198 78 0.52 0.68 
DDK-C-12 3-Cl C19H14Cl2N4 369 219-221 77 0.53 0.63 
DDK-C-13 4-Cl C26H26Cl2N2O2 369 195-197 80 0.51 0.56 
DDK-C-14 2-OCH3 C20H17ClN4O 364 214-216 59 0.53 0.60 
DDK-C-15 3-OCH3 C20H17ClN4O 364 203-205 71 0.59 0.70 
DDK-C-16 4-OCH3 C20H17ClN4O 364 238-240 80 0.54 0.61 
DDK-C-17 3-CH3 C20H17ClN4 348 229-231 69 0.51 0.62 
DDK-C-18 4-CH3 C20H17ClN4 348 205-207 81 0.52 0.63 
DDK-C-19 4-NO2 C19H14ClN5O2 379 239-241 65 0.52 0.60 
DDK-C-20 4-Br C19H14BrClN2O2 413 242-244 79 0.55 0.64 
      
     TLC Solvent system Rf1: Hexane: Ethyl acetate – 6:4,  
     TLC Solvent system Rf2: Chloroform:Methanol – 9.5:0.5. 
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5.1.5 Mechanism 
O
R CN
CN
R
CN
N C
A
N
H
R
CN
NH
B
N
R
CN
NH2
2H
CH3COONH4
H2
N
N
H
R
CN
NH
C
N
H
R
CN
NH2
D
1 2
NN
R1R =
NCl
or R1
3
 
The probable mechanism involves the synthesis of 5,6,7,8-tetrahydroquinolines via 
formation of the intermediate Michael type products, followed by intramolecular 
cyclization and aromatization as suggested by Elkholy et al. [40]. 
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5.1.6 Experimental 
5.1.6.1 Materials and Methods 
 
Melting points were determined in open capillary tubes and are uncorrected. 
Formation of the compounds was routinely checked by TLC on silica gel-G plates of 
0.5 mm thickness and spots were located by iodine. Microwave assisted reactions 
were carried out in QPro-M microwave synthesizer. IR spectra were recorded 
Shimadzu FT-IR-8400 instrument using KBr pellet method. Mass spectra were 
recorded on Shimadzu GC-MS-QP-2010 model using Direct Injection Probe 
technique. 1H NMR was determined in DMSO-d6 solution on a Bruker Ac 400 MHz 
spectrometer. Elemental analysis of the all the synthesized compounds was carried out 
on Elemental Vario EL III Carlo Erba 1108 model and the results are in agreements 
with the structures assigned. 
 
5.1.6.2 Synthesis of 2-((3-(aryl)-1-phenyl-1H-pyrazol-4-yl)methylene)malononitriles 
 
A mixture of  3-(aryl)-1-phenyl-1H-pyrazole-4-carbaldehyde (0.01 mol) and 
malononitrile (0.01 mol) in ethanol (3 mL) in presence of catalytic amount of 
piperidine (4-5 drops) was subjected to microwave irradiation at 80 °C for 1-2 min. 
The microwave irradiation was operated in 30-second cycles. The progress of the 
reaction was monitored by TLC. Upon completion of the reaction, the separated solid 
was filtered, dried and crystallized from ethanol. 
 
5.1.6.3 General procedure for the synthesis of 2-Amino-4-[3-(aryl)-1-phenyl-1H-
pyrazol-4-yl]-5,6,7,8-tetrahydro-quinoline-3-carbonitriles  (DDK-C-01 to DDK-C-
10) 
 
A mixture of the cyclohexanone (0.01 mol), 2-((3-(aryl)-1-phenyl-1H-pyrazol-4-
yl)methylene)malononitrile (0.01 mol) and ammonium aceate (0.08 mol) in ethanol (5 
mL) was irradiated under microwave irradiation at 80 °C for 5-7 min. The microwave 
irradiation was operated in 30-second cycles. The progress of the reaction was 
monitored by TLC. Upon completion of the reaction, the separated solid was filtered, 
dried and crystallized from ethanol.  
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5.1.6.3.1 2-Amino-4-(1,3-diphenyl-1H-pyrazol-4-yl)-5,6,7,8-tetrahydro-quinoline-3- 
carbonitrile (DDK-C-01) 
Yield: 73%; m.p. 237-239 ºC; IR (cm-1): 3416 
and 3286 (N-H stretching of primary amine), 
3062 (C-H stretching of aromatic ring), (C-H 
stretching of CH2 group of cyclohexane ring) 
2214 (C≡N stretching of nitrile group), 1644 (N-H 
deformation of NH2 group), 1562, 1506 and 
1462 (C=C stretching of aromatic ring), 1246 (C-N stretching of primary amine), 
1074 (C-H in plane bending for aromatic ring); 1H NMR (DMSO-d6) δ ppm: 1.54-
1.81 (m, 4H, Ha, b), 2.74-2.86 (m, 2H, Hc), 2.35-2.42 (m, 2H, Hd), 6.55 (s, 1H, He), 
7.30-7.54 (m, 8H, Hf, g, g’, h, h’, i, i’, j, j’), 7.87-7.90 (m, 2H, Hk, k’), 8.38 (s, 1H, Hl); MS: m/z 
391; Anal. Calcd. for C25H21N5: C, 76.70; H, 5.41; N, 17.89. Found: C, 76.62; H, 5.34; 
N, 17.81% 
 
5.1.6.3.2 2-Amino-4-[3-(4-chloro-phenyl)-1-phenyl-1H-pyrazol-4-yl]-5,6,7,8-tetra 
hydro-quinoline-3-carbonitrile (DDK-C-02) 
Yield: 78%; m.p. 209-211 ºC; MS: m/z 425; 
Anal. Calcd. for C25H20ClN5: C, 70.50; H, 4.73; 
N, 16.44. Found: C, 70.43; H, 4.65; N, 16.36%. 
 
 
 
5.1.6.3.3 2-amino-5,6,7,8-tetrahydro-4-(3-(3-nitrophenyl)-1-phenyl-1H-pyrazol-4-
yl)quinoline-3-carbonitrile (DDK-C-03) 
Yield: 74%; m.p. 199-201 ºC; MS: m/z 436; 
Anal. Calcd. for C25H20N6O2: C, 68.80; H, 4.62; 
N, 19.25. Found: C, 68.72; H, 4.53; N, 19.18%. 
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5.1.6.3.4 2-amino-5,6,7,8-tetrahydro-4-(3-(4-nitrophenyl)-1-phenyl-1H-pyrazol-4-
yl)quinoline-3-carbonitrile (DDK-C-04) 
Yield: 75%; m.p. 213-215 ºC; MS: m/z 436; 
Anal. Calcd. for C25H20N6O2: C, 68.80; H, 4.62; 
N, 19.25. Found: C, 68.73; H, 4.54; N, 19.18%. 
 
 
 
5.1.6.3.5 2-amino-5,6,7,8-tetrahydro-4-(3-(2-methoxyphenyl)-1-phenyl-1H-pyrazol 
-4-yl)quinoline-3-carbonitrile (DDK-C-05) 
Yield: 61%; m.p. 237-239 ºC; MS: m/z 421; 
Anal. Calcd. for C26H23N5O: C, 74.09; H, 5.50; 
N, 16.62. Found: C, 74.02; H, 5.43; N, 16.55%. 
 
 
 
5.1.6.3.6 2-amino-5,6,7,8-tetrahydro-4-(3-(4-methoxyphenyl)-1-phenyl-1H-pyrazol-
4-yl)quinoline-3-carbonitrile (DDK-C-06) 
Yield: 81%; m.p. 207-209 ºC; IR (cm-1): 3396 
and 3381 (N-H stretching of primary amine), 
3014 (C-H stretching of aromatic ring), 2981 
(C-H stretching of CH2 group of cyclohexane 
ring), 2214 (C≡N stretching of nitrile group), 1649 
(N-H deformation of NH2 group), 1570, 1524 
and 1454 (C=C stretching of aromatic ring), 
1342 (C-N stretching of primary amine), 1230 (C-O-C asymmetrical stretching of 
OCH3 group), 1080 (C-O-C symmetrical stretching of OCH3 group), 966 (C-H in 
plane bending for aromatic ring); 1.54-2.72 (m, 8H, Ha, b, c, d), 6.28 (s, 1H, He), 7.27-
7.45 (m, 5H, Hf, g, g’, h, h’), 6.80-6.82 (d, 2H, Hi, i’, J = 7.4 Hz), 7.83-7.85 (d, 2H, Hj, j’, J = 
6.72 Hz), 8.34 (s, 1H, Hk), 3.75 (s, 3H, Hl); MS: m/z 421; Anal. Calcd. for C26H23N5O: 
C, 74.09; H, 5.50; N, 16.62. Found: C, 74.01; H, 5.44; N, 16.54%. 
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5.1.6.3.7 2-amino-5,6,7,8-tetrahydro-4-(3-(2-hydroxyphenyl)-1-phenyl-1H-pyrazol 
-4-yl)quinoline-3-carbonitrile (DDK-C-07) 
Yield: 62%; m.p. 223-225 ºC; MS: m/z 407; 
Anal. Calcd. for C25H21N5O: C, 73.69; H, 5.19; 
N, 17.19. Found: C, 73.61; H, 5.12; N, 17.11%. 
 
 
 
5.1.6.3.8 2-amino-5,6,7,8-tetrahydro-4-(3-(4-hydroxyphenyl)-1-phenyl-1H-pyrazol 
-4-yl)quinoline-3-carbonitrile (DDK-C-08) 
Yield: 72%; m.p. 201-203 ºC; MS: m/z 407; 
Anal. Calcd. for C25H21N5O: C, 73.69; H, 5.19; 
N, 17.19. Found: C, 73.62; H, 5.12; N, 17.12%. 
 
 
 
5.1.6.3.9 2-amino-4-(3-(4-fluorophenyl)-1-phenyl-1H-pyrazol-4-yl)-5,6,7,8-tetra 
hydroquinoline-3-carbonitrile (DDK-C-09) 
Yield: 81%; m.p. 207-209 ºC; IR (cm-1): 3487 
and 3392 (N-H stretching of primary amine), 
3045 (C-H stretching of aromatic ring), 2974 
(C-H stretching of CH2 group of cyclohexane 
ring), 2837 (C-H symmetrical stretching of CH2 
group), 2214 (C≡N stretching of nitrile group), 
1651 (N-H deformation of NH2 group), 1560, 
1504 and 1456 (C=C stretching of aromatic ring), 1232 (C-N stretching of primary 
amine), 1080 (C-F stretching), 964 (C-H out of plane bending for aromatic ring). 1H 
NMR (DMSO-d6) δ ppm: : 1.57-1.62 (m, 2H, Ha), 1.69-1.79 (m, 2H, Hb), 2.75-2.80 
(m, 2H, Hc), 2.06-2.13 (m, 1H, Hd), 2.36-2.41 (m, 1H, Hd), 6.34 (s, 1H, He), 7.32-7.36 
(m, 1H, Hf), 7.48-7.53 (m, 4H, H g, g’, h, h’), 7.04-7.09 (t, 2H, Hi, i’), 7.87-7.90 (m, 2H, Hj, 
j’), 8.40 (s, 1H, Hk); MS: m/z 409; Anal. Calcd. for C25H20FN5: C, 73.33; H, 4.92; N, 
17.10. Found: C, 73.27; H, 4.85; N, 17.02%. 
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5.1.6.3.10 2-amino-4-(3-(4-bromophenyl)-1-phenyl-1H-pyrazol-4-yl)-5,6,7,8-tetra 
hydroquinoline-3-carbonitrile (DDK-C-10) 
Yield: 78%; m.p. 233-235 ºC; MS: m/z 470; 
Anal. Calcd. for C25H20BrN5: C, 63.84; H, 4.29; N, 
14.89. Found: C, 63.76; H, 4.23; N, 14.81%. 
 
 
 
 
5.1.6.4 General procedure for the synthesis of 2-((2-chloro-substitutedquinolin-3-
yl)methylene)malononitriles  
 
A mixture of the substituted 2-chloroquinoline-3-carbaldehyde (0.01 mol) and 
malononitrile (0.01 mol) in ethanol (3 mL) in presence of catalytic amount of 
piperidine (4-5 drops) was subjected to microwave irradiation at 80 °C for 1-2 min. 
The microwave irradiation was operated in 30-second cycles. The progress of the 
reaction was monitored by TLC. Upon completion of the reaction, the separated solid 
was filtered, dried and crystallized from ethanol. 
 
5.1.6.5 General procedure for the synthesis of 2-Amino-5,6,7,8-tetrahydro-4-
quinoline-3-carbonitriles (DDK-C-11 to DDK-C-20) 
 
A mixture of the cyclohexanone (0.01 mol), 2-((2-chloro-substitutedquinolin-3-
yl)methylene)malononitrile (0.01 mol) and ammonium aceate (0.08 mol) in ethanol (5 
mL) was irradiated under microwave irradiation at 80 °C for 5-7 min. The microwave 
irradiation was operated in 30-second cycles. The progress of the reaction was 
monitored by TLC. Upon completion of the reaction, the separated solid was filtered, 
dried and crystallized from ethanol.  
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5.2.6.5.1 2-amino-4-(2-chloro-6-fluoroquinolin-3-yl)-5,6,7,8-tetrahydroquinoline-3- 
carbonitrile (DDK-C-11) 
Yield: 78%; m.p. 196-198 ºC; IR (cm-1): 3391 
and 3296 (N-H stretching of primary amine), 
3043 (C-H stretching of aromatic ring), 2922 
(C-H stretching of CH2 group of cyclohexanone 
ring), 2214 (C≡N stretching of nitrile group), 1645 
(N-H deformation of NH2 group), 1587, 1558 
and 1446 (C=C stretching of aromatic ring), 
1222 (C-N stretching of primary amine), 1062 (C-H out of plane bending for aromatic 
ring), 756 (C-Cl stretching); 1H NMR (DMSO-d6) δ ppm: 1.56-1.62 (m, 2H, Ha), 
1.69-1.79 (m, 2H, Hb), 2.76-2.81 (m, 2H, Hc), 2.06-2.14 (m, 1H, Hd), 2.36-2.41 (m, 
1H, Hd), 6.34 (s, 1H, He), 7.75-7.77 (m, 1H, Hf,), 7.32-7.39 (m, 1H, Hg), 7.47-7.49 (d, 
1H, Hh), 7.90 (s, 1H, Hi); MS: m/z 352; Anal. Calcd. for C19H14ClFN4: C, 64.68; H, 
4.00; N, 15.88. Found: C, 64.62; H, 3.93; N, 15.81% 
 
5.2.6.5.2 2-amino-4-(2,7-dichloroquinolin-3-yl)-5,6,7,8-tetrahydroquinoline-3-
carbonitrile (DDK-C-12) 
Yield: 78%; m.p. 219-221 ºC; IR (cm-1): 3393 
and 3360 (N-H stretching of primary amine), 
3059 (C-H stretching of aromatic ring), 2952 
(C-H stretching of CH2 group of cyclohexanone 
ring), 2212 (C≡N stretching of nitrile group), 
1646 (N-H deformation of NH2 group), 1554, 
1502 and 1444 (C=C stretching of aromatic 
ring), 1226 (C-N stretching of primary amine), 1010 (C-H out of plane bending for 
aromatic ring), 734 (C-Cl stretching); 1H NMR (DMSO-d6) δ ppm: 1.54-1.82 (m, 4H, 
Ha, b), 2.06-2.14 (m, 1H, Hd), 2.35-2.42 (m, 1H, Hd), 2.74-2.86 (m, 2H, Hc), 6.33 (s, 
1H, He), 8.04-8.07 (d, 1H, Hf,), 7.51-7.54 (m, 1H, Hg), 7.77-7.78 (d, 1H, Hh), 8.17 (s, 
1H, Hi); MS: m/z 368; Anal. Calcd. for C19H14Cl2N4: C, 61.80; H, 3.82; N, 15.17. 
Found: C, 61.73; H, 3.74; N, 15.08%. 
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5.2.6.5.3 2-amino-4-(2,6-dichloroquinolin-3-yl)-5,6,7,8-tetrahydroquinoline-3-
carbonitrile (DDK-C-13) 
Yield: 80%; m.p. 195-197 ºC; ): 3489 and 3392 
(N-H stretching of primary amine), 3055 (C-H 
stretching of aromatic ring), 2943 (C-H 
stretching of CH2 group of cyclohexane ring), 
2208 (C≡N stretching of nitrile group), 1647 
(N-H deformation of NH2 group), 1543, 1506 
and 1467 (C=C stretching of aromatic ring), 1236 (C-N stretching of primary amine), 
1064 (C-H out of plane bending for aromatic ring), 721 (C-Cl stretching); 1H NMR 
(DMSO-d6) δ ppm: 1.61-1.79 (m, 4H, Ha, b), 2.75-2.80 (m, 2H, Hc), 2.06-2.14 (m, 1H, 
Hd), 2.36-2.41 (m, 1H, Hd), 6.33 (s, 1H, He), 7.83-7.85 (m, 2H, Hf, h), 7.68-7.71 (m, 1H, 
Hg), 8.10 (s, 1H, Hi); MS: m/z 368; Anal. Calcd. for C19H14Cl2N4: C, 61.80; H, 3.82; N, 
15.17. Found: C, 61.73; H, 3.73; N, 15.09%. 
 
5.1.6.5.4   2-amino-4-(2-chloro-8-methoxyquinolin-3-yl)-5,6,7,8-tetrahydro 
quinoline-3-carbonitrile (DDK-C-14) 
Yield: 59%; m.p. 214-216 ºC; MS: m/z 364; 
Anal. Calcd. for C20H17ClN4O: C, 65.84; H, 4.70; 
N, 15.36. Found: C, 65.77; H, 4.62; N, 15.27% 
 
 
 
5.2.6.5.5 2-amino-4-(2-chloro-7-methoxyquinolin-3-yl)-5,6,7,8-tetrahydroquinoline-
3-carbonitrile (DDK-C-15) 
Yield: 71%; m.p. 203-205 ºC; MS: m/z 364; 
Anal. Calcd. for C20H17ClN4O: C, 65.84; H, 
4.70; N, 15.36. Found: C, 65.76; H, 4.61; N, 
15.29% 
 
 
i
N NH2
CN
N
Cl
a
b
c
d
e
h
g
f Cl
N NH2
CN
N
Cl
H3CO
 
N NH2
CN
N
Cl
OCH3
 
 
Chapter 5-Section-1                                                          5,6,7,8-Tetrahydroquinolines         
     
   187
5.2.6.5.6 2-amino-4-(2-chloro-6-methoxyquinolin-3-yl)-5,6,7,8-tetrahydro 
quinoline-3-carbonitrile (DDK-C-16) 
Yield: 80%; m.p. 238-240 ºC; MS: m/z 364; Anal. 
Calcd. for C20H17ClN4O: C, 65.84; H, 4.70; N, 
15.36. Found: C, 65.76; H, 4.62; N, 15.28% 
 
 
 
5.2.6.5.7 2-amino-4-(2-chloro-7-methylquinolin-3-yl)-5,6,7,8-tetrahydroquinoline-
3-carbonitrile (DDK-C-17) 
Yield: 81%; m.p. 205-207 ºC; MS: m/z 348; 
Anal. Calcd. for C20H17ClN4: C, 68.86; H, 4.91; 
N, 16.06. Found: C, 68.78; H, 4.85; N, 15.00%. 
 
 
 
 
5.2.6.5.8 2-amino-4-(2-chloro-6-methylquinolin-3-yl)-5,6,7,8-tetrahydroquinoline-
3-carbonitrile (DDK-C-18) 
Yield: 69%; m.p. 229-231 ºC; MS: m/z 348; 
Anal. Calcd. for C20H17ClN4: C, 68.86; H, 4.91; 
N, 16.06. Found: C, 68.77; H, 4.82; N, 15.99%. 
 
 
 
5.2.6.5.9 2-amino-4-(2-chloro-6-nitroquinolin-3-yl)-5,6,7,8-tetrahydroquinoline-3-
carbonitrile (DDK-C-19) 
Yield: 65%; m.p. 239-241 ºC; MS: m/z 379; 
Anal. Calcd. for C19H14ClN5O2: C, 60.09; H, 
3.72; N, 18.44. Found: C, 60.01; H, 3.64; N, 
18.35%. 
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5.2.6.5.10  2-amino-4-(6-bromo-2-chloroquinolin-3-yl)-5,6,7,8-tetrahydroquinoline-
3-carbonitrile (DDK-C-20) 
Yield: 79%; m.p. 242-244 ºC; MS: m/z 413; 
Anal. Calcd. for C19H14BrClN4: C, 55.16; H, 
3.41; N, 13.54. Found: C, 55.09; H, 3.33; N, 
13.45%. 
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5.1.7 Spectral discussion 
5.1.7.1 Mass spectral study 
Mass spectra were recorded on Shimadzu GC-MS-QP-2010 model using Direct 
Injection Probe technique. Systematic fragmentation pattern was observed in mass 
spectral analysis. Molecular ion peak was observed in agreement with molecular 
weight of respective compound. Mass fragmentation pattern for a representative 
compound of each series is depicted below. 
 
5.1.7.1.1 Mass fragmentation pattern for DDK-C-09 
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5.1.7.1.2 Mass fragmentation pattern for DDK-C-12 
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5.1.7.2 IR spectral study 
IR spectra were recorded on Shimadzu FT-IR-8400 model using KBr pellet method. 
Various functional groups present in molecule were identified by characteristic 
frequency obtained for them. For 5,6,7,8-tetrahydroquinolines (DDK-C-01 to DDK-
C-20), two characteristic bands of primary amine were observed in the range of 3286-
3489 cm-1 respectively.  Another characteristic band of nitrile group was observed at 
2208-2214 cm-1 suggesting formation of desired products (DDK-C-01 to DDK-C-
20).     
 
Chapter 5-Section-1                                                          5,6,7,8-Tetrahydroquinolines         
     
   191
5.1.7.3 1H NMR spectral study 
1H NMR spectra were recorded in DMSO-d6 solution on a Bruker Ac 400 MHz 
spectrometer using TMS as an internal standard. Number of protons and their 
chemical shifts were found to support the structure of the synthesized compounds. 
For 5,6,7,8-tetrahydroquinolines (DDK-C-01 to DDK-C-10), characteristic 
multiplets were observed for methylene groups of cyclohexane ring at 1.54-2.86 δ 
ppm. The aromatic ring protons were observed at 6.80-8.40 δ ppm and J value were 
found to be in accordance with substitution pattern on phenyl ring. The singlet for 
primary amine (-NH2) proton was observed at 6.28-6.55 δ ppm.  
While, for 5,6,7,8-tetrahydroquinolines (DDK-C-11 to DDK-C-20), 
characteristic multiplets were observed for methylene groups of cyclohexane ring at 
1.56-2.81 δ ppm. The aromatic ring protons were observed at 7.32-8.17 δ ppm and J 
value were found to be in accordance with substitution pattern on phenyl ring. The 
singlet for primary amine (-NH2) proton was observed at 6.33-6.34 δ ppm.  
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IR spectrum of DDK-C-01 
 
 
Mass spectrum of DDK-C-01 
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1H NMR spectrum of DDK-C-01 
 
 
Expanded 1H NMR spectrum of DDK-C-01 
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Expanded 1H NMR spectrum of DDK-C-01 
 
 
IR spectrum of DDK-C-06 
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Mass spectrum of DDK-C-06 
 
 
1H NMR spectrum of DDK-C-06 
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Expanded 1H NMR spectrum of DDK-C-06 
 
 
IR spectrum of DDK-C-09 
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Mass spectrum of DDK-C-09 
 
 
1H NMR spectrum of DDK-C-09 
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Expanded 1H NMR spectrum of DDK-C-09 
 
 
Expanded 1H NMR spectrum of DDK-C-09 
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IR spectrum of DDK-C-11 
 
 
Mass spectrum of DDK-C-11 
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1H NMR spectrum of DDK-C-11 
 
 
Expanded 1H NMR spectrum of DDK-C-11 
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Expanded 1H NMR spectrum of DDK-C-11 
 
 
IR spectrum of DDK-C-12 
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Mass spectrum of DDK-C-12 
 
 
1H NMR spectrum of DDK-C-12 
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Expanded 1H NMR spectrum of DDK-C-12 
 
 
Expanded 1H NMR spectrum of DDK-C-12 
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IR spectrum of DDK-C-13 
 
 
Mass spectrum of DDK-C-13 
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1H NMR spectrum of DDK-C-13 
 
 
Expanded 1H NMR spectrum of DDK-C-13 
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5.1.8 Biological evaluation 
5.1.8.1 Antimicrobial evaluation 
All of the synthesized compounds (DDK-C-01 to DDK-C-20) were tested for their 
antibacterial and antifungal activity (MIC) in vitro by broth dilution method [57, 58] 
with two Gram-positive bacteria Staphylococcus aureus MTCC-96, Streptococcus 
pyogenes MTCC 443, two Gram-negative bacteria Escherichia coli MTCC 442, 
Pseudomonas aeruginosa MTCC 441 and three fungal strains Candida albicans 
MTCC 227, Aspergillus Niger MTCC 282, Aspergillus clavatus MTCC 1323 taking 
Ampicillin, Chloramphenicol, Ciprofloxacin, Norfloxacin, Nystatin, and Griseofulvin 
as standard drugs. The standard strains were procured from the Microbial Type 
Culture Collection (MTCC) and Gene Bank, Institute of Microbial Technology, 
Chandigarh, India.  
 The minimal inhibitory concentration (MIC) values for all the newly 
synthesized compounds, defined as the lowest concentration of the compound 
preventing the visible growth, were determined by using microdilution broth method 
according to NCCLS standards [57].  Serial dilutions of the test compounds and 
reference drugs were prepared in Muellere-Hinton agar. Drugs (10 mg) were 
dissolved in dimethylsulfoxide (DMSO, 1 mL). The active synthesized drugs found in 
this primary screening were further tested in a second set of dilution at 125 μg mL-1, 
62.5 μg mL-1, 50 μg mL-1, 25 μg mL-1, 12.5 μg mL-1, and 6.250 μg mL-1 concentration 
against all microorganisms. The tubes were inoculated with 108 cfu mL-1 (colony 
forming unit/mL) and incubated at 37 ºC for 24 h. The MIC was the lowest 
concentration of the tested compound that yields no visible growth (turbidity) on the 
plate. To ensure that the solvent had no effect on the bacterial growth, a control was 
performed with the test medium supplemented with DMSO at the same dilutions as 
used in the experiments and it was observed that DMSO had no effect on the 
microorganisms in the concentrations studied. The results obtained from antimicrobial 
susceptibility testing are depicted in Table 1. 
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Table 1. Antibacterial and antifungal activity of synthesized compounds DDK-C-
01to DDK-C-20 
 
Code Minimum inhibition concentration (µg mL-1 ) 
Gram-positive Gram-negative Fungal species 
S.a. S. p. E.c. P.a. C. a. A. n. A.c. 
DDK-C-01 50 25 125 500 1000 1000 500 
DDK-C-02 250 250 100 500 100 500 500 
DDK-C-03 100 500 125 1000 500 1000 1000 
DDK-C-04 250 1000 250 500 500 250 250 
DDK-C-05 50 125 250 62.5 1000 1000 500 
DDK-C-06 500 500 500 >1000 100 500 250 
DDK-C-07 1000 500 1000 1000 500 500 100 
DDK-C-08 500 1000 1000 500 500 100 500 
DDK-C-09 62.5 100 250 125 1000 >1000 1000 
DDK-C-10 1000 500 500 1000 500 100 500 
DDK-C-11 1000 100 100 500 250 100 250 
DDK-C-12 125 100 100 500 500 250 1000 
DDK-C-13 500 500 1000 >1000 1000 500 125 
DDK-C-14 125 100 50 250 500 1000 500 
DDK-C-15 100 1000 250 1000 1000 500 1000 
DDK-C-16 500 1000 500 100 1000 500 500 
DDK-C-17 1000 500 1000 1000 500 500 1000 
DDK-C-18 500 500 250 500 >1000 1000 500 
DDK-C-19 25 62.5 10 25 100 500 250 
DDK-C-20 125 100 1000 500 100 1000 500 
Ampicillin 250 100 100 100 - - - 
Chloramphenicol 50 50 50 50 - - - 
Ciprofloxacin 50 50 25 25 - - - 
Norfloxacin 10 10 10 10 - - - 
Nystatin - - - - 100 100 100 
Griseofulvin - - - - 500 100 100 
 
5.1.8.2 Antimycobacterial, anticancer and antiviral evaluation 
Antimycobacterial, anticancer and antiviral screening of all the newly synthesized 
compounds (DDK-C-01 to DDK-C-20) is currently under investigation and results 
are awaited.  
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5.2: Synthesis and biological evaluation  
       of 7,8-dihydro-7,7-dimethyl-2,4-di 
  substituted-quinolin-5(1H,4H,6H)-  
       ones 
   
5.2.1 Introduction 
Among quinoline derivatives, dihydroquinolines are an important structural subunit of 
bioactive molecules and many dihydroquinolines derivatives exhibit interesting 
biological and pharmaceutical activities including anti-tubercular [59, 60], anti-HIV 
[61], anti-cancer [62], apical sodium-dependent bile acid transporter (ASBT) 
inhibitors [63], anti-secretory [64], anti-inflammatory [65, 66] etc. Among various 
dihydroquinolines, chemistry and biological profile of 1,2-dihydroquinolines and 1,4-
dihydroquinolines is extensively studied. Some examples of published derivatives of 
diydroquinolines with their biological activities are shown in the following figure. 
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The chemistry and biology of 7,8-dihydroquinoline is not widely studied in 
literature. However, the present 7,8-dihydroquinoline derivatives of type (1) are  
polyfunctionalized 1,4-dihydropyridine type derivatives. 1,4-Dihydropyridines (1,4-
DHPs) are well-known compounds because of their biological activities [69-71]. The 
chemical modifications on the DHP ring, such as different substituents [69] or 
heteroatoms [71], have allowed the study of the extended structure and activity 
relationship and also provided some insight into the molecular interactions at the 
receptor level. In this context, It was thought worthwhile to study the biological 
activity profile of 7,8-dihydroquinolines of type (1), which may prove useful 
modification as 1,4-DHP type derivatives.  
 
N
H
R1
R2
O
(1) 7,8-dihydro-7,7-dimethyl-2,4-disubstituted-
     quinolin-5(1H,4H,6H)-ones
R1 = aryl, R2 =  2-thienyl, 4-fluorophenyl
 
 
 
4.2 Reported synthetic strategies 
Literature survey revealed a very few strategies describing the synthesis of 7,8-
dihydroquinolines. Rosen et al. have reported the synthesis of 7,8-dihydroquinolines 
based on joining onto a pyridine ring a specific partially reduced aromatic ring. The 
critical ring closure reaction onto the pyridine nucleus was an electrocyclic reaction 
[72] (Scheme 5.2.2.1). 
 
N
CH3
Pyrolysis
N
CH3
Scheme 5.2.2.1  
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Jacobs et al. have prepared 6,7-dihydroquinolines starting from and tested 
them as dual inhibitors of Thromboxane A2 Synthase and aromatase [73] (Scheme 
5.2.2.1). 
 
N
O
(EtO)2POCH2COOEt,
NaOEt
N
COOEt
LiAlH4
N
OH
(i) SOCl2
(ii) Imidazole, NaI, Na2CO3
N
N
N
Scheme 5.2.2.2  
 
Huang et al. have reported the synthesis of 7,8-dihydro-quinoline-5(6H)-one 
from1,3-diketones, ammonium acetate and 1,1,3,3-tetraethoxylpropane [74]. 
An efficient method for the synthesis of novel 3-(1,3-thiazolyl)-7,8-
dihydroquinoline-2,5-(1H, 6H)-diones from various 2-dimethylaminomethylidene 
cyclohexanone-1,3-diones, (1,3-thiazol-2-yl)acetonitriles and dimethylfromamide 
dimethyl acetal was reported by Dzhavakhishvili et al. [75] (Scheme 5.2.2.3). 
 
O
O
N + NC S
N
R1
R2
piperidine
O
O
S
N
R1
R2
Scheme 5.2.2.3
R1 = aryl, R2 = H
 
 
 Recently, number of approaches have been reported for the synthesis of 7,8-
dihydro-7,7-dimethyl-2,4-disubstituted-quinolin-5(1H,4H,6H)-ones by the reaction of 
1,3-diaryl-prop-2-en-1-ones with 5,5-dimethylcyclohexane-1,3-dione and ammonium 
acetate. The reaction is genrally carried out using DMF as solvent [76] and under 
solvent-free conditions using conventional heating [77]. 
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 Sakai et al. have reported Yb(OTf)3-catalyzed cyclization of an N-
silylenamine with 2-methylene-1,3-cyclohexanedione to afford a 7,8-dihydroquinolin- 
5(6H)-one derivative and its application to the one-pot conversion to a 2,3,5-
trisubstituted quinoline derivative [78] (Scheme 5.2.2.4). 
 
R
Ph NH SiMe3
OO
NH+Me2Cl-
Yb (OTf)3
N
R
Ph
R = 2-pyridyl
Scheme 5.2.2.4  
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5.2.3 Current work 
1,4-Dihydropyridines (1,4-DHPs) are well-known compounds because of their 
biological activities [69-71]. The chemical modifications on the DHP ring, such as 
different substituents [69] or heteroatoms [71], have allowed the study of the extended 
structure and activity relationship and also provided some insight into the molecular 
interactions at the receptor level. In this context, It was thought worthwhile to study 
the biological activity profile of the present 7,8-dihydroquinolines, which may prove 
useful modification as 1,4-DHP type derivatives.  
7,8-dihydro-7,7-dimethyl-2,4-disubstituted-quinolin-5(1H,4H,6H)-ones 
(DDK-C-21 to DDK-C-35) and (DDK-C-21 to DDK-C-35) were synthesized by the 
one pot solvent-free microwave-assisted reaction of 5,5-dimethylcyclohexane-1,3-
dione and ammonium acetate with 3-(aryl)-1-(thiophen-2-yl)prop-2-en-1-ones and 3-
(aryl)-1-(4-fluorophenyl)prop-2-en-1-ones respectively. The products were 
characterized by FT-IR, mass, 1H NMR spectroscopy and elemental analyses. The 
newly synthesized compounds were subjected to antimicrobial activity. 
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5.2.4 Reaction scheme 
OO
O
+ a
S
N
H
O
DDK-C-21 to DDK-C-35
R1
R1
S
OO
O
+ b
N
H
O
DDK-C-36 to DDK-C-50
R1
R1
F
F
 Reagents and conditions: (a) NH4OAc, MWI, 6-7 mins. ; (b) NH4OAc, MWI,5-6 mins.  
Code R1 M.F. M.W. M.P. ºC Yield % Rf1 Rf2 
DDK-C-21 H C21H21NOS 335 206-208 80 0.47 0.61 
DDK-C-22 2-Cl C21H20ClNOS 369 197-199 72 0.48 0.68 
DDK-C-23 3-Cl C21H20ClNOS 369 217-219 78 0.51 0.69
DDK-C-24 4-Cl C21H20ClNOS 369 209-211 84 0.50 0.65 
DDK-C-25 2-NO2 C21H20N2O3S 380 225-227 66 0.48 0.65 
DDK-C-26 3-NO2 C21H20N2O3S 380 233-235 76 0.53 0.68
DDK-C-27 4-NO2 C21H20N2O3S 380 241-243 78 0.53 0.72 
DDK-C-28 4-OCH3 C22H23NO2S 365 199-201 83 0.51 0.67 
DDK-C-29 4- CH3 C22H23NOS 349 213-215 81 0.54 0.67
DDK-C-30 4- F C32H32BrN3O2 353 244-246 79 0.52 0.69 
DDK-C-31 2-OH C26H26ClFN2O2 351 198-200 62 0.51 0.63 
DDK-C-32 3- OH C26H26Cl2N2O2 351 203-205 63 0.54 0.65
DDK-C-33 4- OH C26H26Cl2N2O2 351 212-214 67 0.51 0.60 
DDK-C-34 2-C5H4N C27H29ClN2O3 452 237-239 70 0.53 0.60 
DDK-C-35 2,3,4-(OMe)3 C27H29ClN2O3 425 249-251 76 0.59 0.65
DDK-C-36 H C23H23FNO 347 238-240 73 0.53 0.59 
DDK-C-37 2-Cl C23H22ClFNO 381 198-200 69 0.50 0.62 
DDK-C-38 3-Cl C23H22ClFNO 381 197-199 72 0.53 0.62
DDK-C-39 4-Cl C23H22ClFNO 381 218-220 79 0.51 0.58 
DDK-C-40 2-NO2 C23H21FN2O3 392 229-231 60 0.58 0.65 
DDK-C-41 3-NO2 C23H21FN2O3 392 217-219 69 0.55 0.60
DDK-C-42 4-NO2 C23H21FN2O3 392 206-208 74 0.52 0.61 
DDK-C-43 4-OCH3 C24H24FNO2 377 237-239 83 0.53 0.65 
DDK-C-44 4- CH3 C24H24FNO 361 213-215 81 0.53 0.59 
DDK-C-45 4- F C23H21F2NO 365 194-196 82 0.51 0.62 
DDK-C-46 2-OH C23H22FNO2 448 201-203 60 0.53 0.65 
DDK-C-47 3- OH C23H22FNO2 464 215-217 62 0.53 0.59 
DDK-C-48 4- OH C23H22FNO2 363 194-196 65 0.51 0.62 
DDK-C-49 2-C5H4N C22H21F2NO 348 239-241 72 0.53 0.63 
DDK-C-50 2,3,4-(OMe)3 C26H28 FNO4 437 222-224 75 0.52 0.58 
     TLC Solvent system Rf1: Hexane: Ethyl acetate – 6:4,  
     TLC Solvent system Rf2: Chloroform:Methanol – 9.5:0.5. 
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5.2.5 Mechanism 
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The proposed mechanism involves the Michael addition reaction of of 5,5-dimethyl-
1,3-cyclo-hexanedione 1 reacted with 1,3-diaryl-2- propen-1-one 2 to give addition 
product 3. Then the intermediate 3 upon condensation with ammonium acetate, loses 
the acetic acid and water to afford the intermediate 4. Cyclization takes place by the 
nucleophilic attack of amine (NH2) group on the carbonyl (C=O) group to give the 
intermediate 5, which loses a water to give the 7,8-dihydroquinolines 6 [77]. 
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5.1.6 Experimental 
5.1.6.1 Materials and Methods 
 
Melting points were determined in open capillary tubes and are uncorrected. 
Formation of the compounds was routinely checked by TLC on silica gel-G plates of 
0.5 mm thickness and spots were located by iodine. Microwave assisted reactions 
were carried out in QPro-M microwave synthesizer. IR spectra were recorded 
Shimadzu FT-IR-8400 instrument using KBr pellet method. Mass spectra were 
recorded on Shimadzu GC-MS-QP-2010 model using Direct Injection Probe 
technique. 1H NMR was determined in DMSO-d6 solution on a Bruker Ac 400 MHz 
spectrometer. Elemental analysis of the all the synthesized compounds was carried out 
on Elemental Vario EL III Carlo Erba 1108 model and the results are in agreements 
with the structures assigned. 
 
5.1.6.2 Synthesis of 3-(aryl)-1-(thiophen-2-yl)prop-2-en-1-ones  
 
Synthesis of 3-(aryl)-1-(thiophen-2-yl)prop-2-en-1-ones was achieved using 
previously published method [79]. 
 
5.1.6.3 General procedure for the synthesis of 2-Amino-4-[3-(4-chloro-phenyl)-1-
phenyl-1H-pyrazol-4-yl]-5,6,7,8-tetrahydro-quinoline-3-carbonitrile  (DDK-C-21 
to DDK-C-35) 
 
A mixture of the 5,5-dimethyl-1,3-cyclohexanone (0.01 mol), 3-(aryl)-1-(thiophen-2-
yl)prop-2-en-1-one (0.01 mol) and ammonium aceate (0.08 mol) was irradiated with 
microwave irradiation at 120 °C for 5-7 min. The microwave irradiation was operated 
in 30-second cycles. The progress of the reaction was monitored by TLC. Upon 
completion of the reaction, the reaction mass was poured into ice-cold water, the 
product was filtered, washed with water, dried and crystallized from ethanol-DMF 
(9:1) mixture. 
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5.2.6.3.1   7,8-dihydro-7,7-dimethyl-4-phenyl-2-(thiophen-2-yl)quinolin-5(1H,4H,  
6H)-one (DDK-C-21) Yield: 80%; m.p. 206-
208 ºC; MS: m/z 335; Anal. Calcd. for 
C21H21NOS: C, 75.19; H, 6.31; N, 4.18. Found: 
C, 75.12; H, 6.23; N, 4.11% 
 
 
5.2.6.3.2   4-(2-chlorophenyl)-7,8-dihydro-7,7-dimethyl-2-(thiophen-2-yl)quinolin- 
5(1H,4H,6H)-one (DDK-C-22) Yield: 72%; 
m.p. 197-199 ºC; MS: m/z 369; Anal. Calcd. for 
C21H20ClNOS: C, 68.19; H, 5.45; N, 3.79. Found: 
C, 68.10; H, 5.37; N, 3.72%. 
 
 
5.2.6.3.3   4-(3-chlorophenyl)-7,8-dihydro-7,7-dimethyl-2-(thiophen-2-yl)quinolin- 
5(1H,4H,6H)-one (DDK-C-23) Yield: 78%; 
m.p. 217-219 ºC; MS: m/z 369; Anal. Calcd. for 
C21H20ClNOS: C, 68.19; H, 5.45; N, 3.79. 
Found: C, 68.11; H, 5.38; N, 3.73%. 
 
 
5.2.6.3.4   4-(4-chlorophenyl)-7,8-dihydro-7,7-dimethyl-2-(thiophen-2-yl)quinolin- 
5(1H,4H,6H)-one (DDK-C-24) Yield: 84%; 
m.p. 209-211 ºC; IR (cm-1): 3277 (N-H 
stretching of secondary amine), 3028 (C-H 
stretching of aromatic ring), 2924 (C-H 
asymmetrical stretching of CH2 group), 2874 
(C-H symmetrical stretching of CH3 group), 
1681 (C=O stretching of carbonyl group), 1647 (N-H deformation of secondary 
amine), 1581, 1487 and 1444 (C=C stretching of aromatic ring), 1406 (C-H 
asymmetrical deformation of CH3 group), 1300 (C-H symmetrical deformation of 
CH3 group), 1006 (C-H in plane bending for aromatic ring), 823 (C-H out of plane 
bending for 1,4-disubstituted aromatic ring), 700 (C-Cl stretching), 628 (C-S-C 
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stretching); 1H NMR (DMSO-d6) δ ppm: 1.08 (s, 3H, Ha,), 1.10 (s, 3H, H a’), 2.05-2.21 
(m, 2H, Hb), 2.39 (s, 2H, Hc), 4.59-4.61 (d, 1H, Hd), 5.21-5.23 (d, 1H, He), 6.92-6.94 (d, 
2H, Hj, j’ , J = 8.6 Hz), 7.23-7.25 (d, 2H, H i, i’, J = 8. 08 Hz), 7.00-7.02 (m, 1H, Hf), 
7.13-7.17 (m, 1H, Hg), 7.33-7.34 (m, 1H, Hh), 8.40 (s , 1H, Hk); MS: m/z 369; Anal. 
Calcd. for C21H20ClNOS: C, 68.19; H, 5.45; N, 3.79. Found: C, 68.10; H, 5.37; N, 
3.71.%. 
 
5.2.6.3.5   7,8-dihydro-7,7-dimethyl-4-(2-nitrophenyl)-2-(thiophen-2-yl)quinolin- 
5(1H,4H,6H)-one (DDK-C-25) Yield: 66%; 
m.p. 225-227 ºC; MS: m/z 380; Anal. Calcd. for 
C21H20N2O3S: C, 66.29; H, 5.30; N, 7.36. Found: 
C, 66.23; H, 5.22; N, 7.29%. 
 
 
5.2.6.3.6   7,8-dihydro-7,7-dimethyl-4-(3-nitrophenyl)-2-(thiophen-2-yl)quinolin- 
5(1H,4H,6H)-one (DDK-C-26) Yield: 76%; 
m.p. 233-235 ºC; MS: m/z 380; Anal. Calcd. for 
C21H20N2O3S: C, 66.29; H, 5.30; N, 7.36. Found: 
C, 66.22; H, 5.22; N, 7.28%. 
 
 
5.2.6.3.7  7,8-dihydro-7,7-dimethyl-4-(3-nitrophenyl)-2-(thiophen-2-yl)quinolin- 
5(1H,4H,6H)-one (DDK-C-27) Yield: 78%; 
m.p. 241-243 ºC; MS: m/z 380; Anal. Calcd. for 
C21H20N2O3S: C, 66.29; H, 5.30; N, 7.36. 
Found: C, 66.22; H, 5.21; N, 7.28%. 
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5.2.6.3.8   7,8-dihydro-4-(4-methoxyphenyl)-7,7-dimethyl-2-(thiophen-2-yl) 
quinolin-5(1H,4H,6H)-one (DDK-C-28) Yield: 
83%; m.p. 199-201 ºC; IR (cm-1): 3255 (N-H 
stretching of secondary amine), 3061 (C-H 
stretching of aromatic ring), 2955 (C-H 
asymmetrical stretching of CH2 group), 2866 
(C-H symmetrical stretching of CH3 group),  
1653 (C=O stretching of carbonyl group), 1577 and 1498 (C=C stretching of aromatic 
ring), 1477 (C-H asymmetrical deformation of CH3 group), 1388 (C-H symmetrical 
deformation of CH3 group), 1251 (C-O-C asymmetrical stretching of OCH3 group), 
1165 (C-O-C symmetrical stretching OCH3 group), 1035 (C-H in plane bending for 
aromatic ring), 825 (C-H out of plane bending for 1,4-disubstituted aromatic ring), 
692 (C-S-C stretching); 1H NMR (DMSO-d6) δ ppm: 1.00 (s, 3H, Ha,), 1.08 (s, 3H, H 
a’), 2.04-2.21 (m, 2H, Hb), 2.47 (s, 2H, Hc), 4.52-4.53 (d, 1H, Hd), 5.21-5.23 (d, 1H, He), 
6.76-6.78 (d, 2H, Hj, j’ , J = 7.92 Hz), 7.23-7.25 (d, 2H, H i, i’, J = 8.56 Hz), 7.00-7.02 (m, 
1H, Hf), 7.15-7.17 (m, 1H, Hg), 7.33-7.34 (t, 1H, Hh), 8.42 (s , 1H, Hk), 3.75 (s, 1H, Hl); 
MS: m/z 365; Anal. Calcd. for C22H23NO2S: C, 72.30; H, 6.34; N, 3.83. Found: C, 
72.23; H, 6.26; N, 3.76%. 
 
5.2.6.3.9   7,8-dihydro-4-(4-methoxyphenyl)-7,7-dimethyl-2-(thiophen-2- yl) 
quinolin-5(1H,4H,6H)-one (DDK-C-29) Yield: 
81%; m.p. 213-215 ºC; MS: m/z 349; Anal. 
Calcd. for C23H22NOS: C, 75.61; H, 6.63; N, 
4.01. Found: C, 75.55; H, 6.55; N, 3.92% 
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5.2.6.3.10 4-(4-fluorophenyl)-7,8-dihydro-7,7-dimethyl-2-(thiophen-2-yl)quinolin- 
5(1H,4H,6H)-one (DDK-C-30) Yield: 79%; 
m.p. 244-246 ºC; IR (cm-1): 3287 (N-H 
stretching of secondary amine), 3032 (C-H 
stretching of aromatic ring), 2929 (C-H 
asymmetrical stretching of CH2 group), 2837 
(C-H symmetrical stretching of CH3 group), 
1701 (C=O stretching of carbonyl group), 1581, 1552 and 1496 (C=C stretching of 
aromatic ring), 1440 (C-H asymmetrical deformation of CH3 group), 1350 (C-H 
symmetrical deformation of CH3 group), 1093 (C-H in plane bending for aromatic 
ring), 1006 (C-F stretching), 823 (C-H out of plane bending for 1,4-disubstituted 
aromatic ring), 709 (C-S-C stretching); 1H NMR (DMSO-d6) δ ppm: 1.03 (s, 3H, Ha,), 
1.08 (s, 3H, H a’), 2.02-2.19 (m, 2H, Hb), 2.50 (s, 2H, Hc), 4.57-4.58 (d, 1H, Hd), 5.19-
5.21 (d, 1H, He), 6.92-6.97 (t, 2H, Hj, j’), 7.22-7.29 (m, 2H, H i, i’), 7.01-7.03 (m, 1H, Hf), 
7.12-7.16 (m, 1H, Hg), 7.35-7.36 (m, 1H, Hh), 8.49 (s , 1H, Hk); MS: m/z 353; Anal. 
Calcd. for C21H21FNOS: C, 71.36; H, 5.70; N, 3.96. Found: C, 71.27; H, 5.62; N, 
3.90%. 
 
5.2.6.3.11  7,8-dihydro-4-(2-hydroxyphenyl)-7,7-dimethyl-2-(thiophen-2-yl)  
quinolin-5(1H,4H,6H)-one (DDK-C-31) Yield: 
62%; m.p. 198-200 ºC; MS: m/z 351; Anal. 
Calcd. for C21H21NO2S: C, 71.76; H, 6.02; N, 
3.99. Found: C, 71.68; H, 5.95; N, 3.93%. 
 
 
5.2.6.3.12   7,8-dihydro-4-(3-hydroxyphenyl)-7,7-dimethyl-2-(thiophen-2-yl)  
quinolin-5(1H,4H,6H)-one (DDK-C-32) Yield: 
63%; m.p. 203-205 ºC; MS: m/z 351; Anal. 
Calcd. for C21H21NO2S: C, 71.76; H, 6.02; N, 
3.99. Found: C, 71.69; H, 5.94; N, 3.92%. 
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5.2.6.3.13 7,8-dihydro-4-(4-hydroxyphenyl)-7,7-dimethyl-2-(thiophen-2-yl)  
quinolin-5(1H,4H,6H)-one (DDK-C-33) Yield: 
67%; m.p. 212-214 ºC; MS: m/z 351; Anal. 
Calcd. for C21H21NO2S: C, 71.76; H, 6.02; N, 
3.99. Found: C, 71.69; H, 5.95; N, 3.91%. 
 
 
 
5.2.6.3.14 7,8-dihydro-7,7-dimethyl-4-(pyridin-3-yl)-2-(thiophen-2-yl)quinolin- 
5(1H,4H,6H)-one (DDK-C-34) Yield: 70%; 
m.p. 237-239 ºC; MS: m/z 352; Anal. Calcd. for 
C21H24N2OS: C, 71.55; H, 6.86; N, 7.95. Found: 
C, 71.47; H, 6.79; N, 7.87%. 
 
 
5.2.6.3.15 7,8-dihydro-4-(2,3,4-trimethoxyphenyl)-7,7-dimethyl-2-(thiophen-2-yl)  
quinolin-5(1H,4H,6H)-one (DDK-C-35) Yield: 
76%; m.p. 249-251 ºC; MS: m/z 425; Anal. 
Calcd. for C24H27NO4S: C, 67.74; H, 6.40; N, 
3.29. Found: C, 67.65; H, 6.33; N, 3.23% 
 
 
 
5.1.6.4 Synthesis of 3-(aryl)-1-(4-fluorophenyl)prop-2-en-1-ones 
 
Synthesis of 3-(aryl)-1-(4-fluorophenyl)prop-2-en-1-ones was achieved using 
previously published method [80].  
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5.2.6.5 General procedure for the synthesis of 2-Amino-5,6,7,8-tetrahydro-4-
quinoline-3-carbonitriles (DDK-C-36 to DDK-C-50) 
 
A mixture of the 5,5-dimethyl-1,3-cyclohexanone (0.01 mol), 3-(aryl)-1-(4-
fluorophenyl)prop-2-en-1-ones (0.01 mol) and ammonium aceate (0.08 mol) was 
irradiated with microwave irradiation at 120 °C for 5-7 min. The microwave 
irradiation was operated in 30-second cycles. The progress of the reaction was 
monitored by TLC. Upon completion of the reaction, the reaction mass was poured 
into ice-cold water, the product was filtered, washed with water, dried and crystallized 
from ethanol-DMF (9:1) mixture. 
 
5.2.6.5.1   2-(4-fluorophenyl)-7,8-dihydro-7,7-dimethyl-4-phenylquinolin- 
5(1H,4H,6H)-one (DDK-C-36) Yield: 73%; 
m.p. 198-200 ºC; IR (cm-1): 3377 (N-H 
stretching of secondary amine), 3084 (C-H 
stretching of aromatic ring), 2956 (C-H 
asymmetrical stretching of CH2 group), 2860 
(C-H symmetrical stretching of CH3 group), 
1683 (C=O stretching of carbonyl group), 1651 (N-H deformation of secondary 
amine), 1581 and 1494 (C=C stretching of aromatic ring), 1423 (C-H asymmetrical 
deformation of CH3 group), 1332 (C-H symmetrical deformation of CH3 group), 1035 
(C-F stretching), 956 (C-H in plane bending for aromatic ring), 833 (C-H out of plane 
bending for 1,4-disubstituted aromatic ring), 719 (C-S-C stretching); 1H NMR 
(DMSO-d6) δ ppm: 1.01 (s, 3H, Ha,), 1.08 (s, 3H, H a’), 1.99-2.20 (m, 2H, Hb), 2.46 (s, 
2H, Hc), 4.60-4.61 (d, 1H, Hd), 5.17-5.18 (d, 1H, He), 7.21=7.26 (m, 1H, Hh), 7.27-7.35 
(m, 4H, Hi, i, j, j’), 7.07-7.11 (m, 1H, Hf,f’), 7.43-7.47 (t, 2H, Hg, g’), 8.52 (s , 1H, Hk); MS: 
m/z 347; Anal. Calcd. for C23H22FNO: C, 79.51; H, 6.38; N, 4.03. Found: C, 79.43; H, 
6.31; N, 3.97%. 
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5.2.6.5.2   4-(2-chlorophenyl)-2-(4-fluorophenyl)-7,8-dihydro-7,7-dimethyl 
quinolin-5(1H,4H,6H)-one (DDK-C-37) Yield: 
69%; m.p. 197-199 ºC; MS: m/z 381; Anal. Calcd. 
for C23H22Cl FNO: C, 72.34; H, 5.54; N, 3.67. 
Found: C, 72.27; H, 5.46; N, 3.59%. 
 
 
5.2.6.5.3   4-(3-chlorophenyl)-2-(4-fluorophenyl)-7,8-dihydro-7,7-dimethyl  
quinolin-5(1H,4H,6H)-one (DDK-C-38) Yield: 
72%; m.p. 203-205 ºC; MS: m/z 381; Anal. Calcd. 
for C23H22ClFNO: C, 72.34; H, 5.54; N, 3.67. 
Found: C, 72.26; H, 5.47; N, 3.60%. 
 
 
 
5.2.6.5.4   4-(3-chlorophenyl)-2-(4-fluorophenyl)-7,8-dihydro-7,7-dimethyl  
quinolin-5(1H,4H,6H)-one (DDK-C-39) Yield: 
79%; m.p. 218-220 ºC; IR (cm-1): 3257 (N-H 
stretching of secondary amine), 3032 (C-H 
stretching of aromatic ring), 2947 (C-H 
asymmetrical stretching of CH2 group), 2850 
(C-H symmetrical stretching of CH3 group), 
1680 (C=O stretching of carbonyl group), 1584 
1558 and 1485 (C=C stretching of aromatic ring), 1452 (C-H asymmetrical 
deformation of CH3 group), 1334 (C-H symmetrical deformation of CH3 group), 1085 
(C-F stretching), 1001 (C-H in plane bending for aromatic ring), 813 (C-H out of 
plane bending for 1,4-disubstituted aromatic ring), 723 (C-Cl stretching), 692 (C-S-C 
stretching); 1H NMR (DMSO-d6) δ ppm: 0.98 (s, 3H, Ha,), 1.03 (s, 3H, H a’), 2.03-2.07 
(d, 1H, Hb), 2.17-2.20 (d, 1H, Hb), 2.45 (s, 2H, Hc), 4.59-4.61 (d, 1H, Hd), 5.21-5.23 (d, 
1H, He), 7.00-7.02 (d, 2H, Hh, h’, J = 8.76 Hz), 7.23-7.25 (d, 2H, Hi, i, J = 8.2 Hz), 6.90-
6.95 (t, 2H, H f, f’), 7.13-7.17 (t, 2H, Hg, g’), 8.52 (s, 1H, Hj); MS: m/z 381; Anal. Calcd. 
for C23H22ClFNO: C, 72.34; H, 5.54; N, 3.67. Found: C, 72.27; H, 5.46; N, 3.58%. 
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5.2.6.5.5   2-(4-fluorophenyl)-7,8-dihydro-7,7-dimethyl-4-(2-nitrophenyl)quinolin- 
5(1H,4H,6H)-one (DDK-C-40) Yield: 60%; m.p. 
229-231 ºC; MS: m/z 392; Anal. Calcd. for 
C23H21FN2O3: C, 70.40; H, 5.39; N, 7.14. Found: 
C, 70.34; H, 5.32; N, 7.07%. 
 
 
5.2.6.5.6   2-(4-fluorophenyl)-7,8-dihydro-7,7-dimethyl-4-(3-nitrophenyl)quinolin- 
5(1H,4H,6H)-one (DDK-C-40) Yield: 69%; 
m.p. 217-219 ºC; MS: m/z 392; Anal. Calcd. for 
C23H21FN2O3: C, 70.40; H, 5.39; N, 7.14. Found: 
C, 70.34; H, 5.32; N, 7.07%. 
 
 
5.2.6.4.7   2-(4-fluorophenyl)-7,8-dihydro-7,7-dimethyl-4-(4-nitrophenyl)quinolin- 
5(1H,4H,6H)-one (DDK-C-42) Yield: 74%; 
m.p. 206-208 ºC; MS: m/z 392; Anal. Calcd. for 
C23H21FN2O3: C, 70.40; H, 5.39; N, 7.14. Found: 
C, 70.34; H, 5.32; N, 7.07%. 
 
 
 
5.2.6.4.8   2-(4-fluorophenyl)-7,8-dihydro-4-(4-methoxyphenyl)-7,7-dimethyl  
quinolin-5(1H,4H,6H)-one (DDK-C-43) Yield: 
83%; m.p. 237-239 ºC; IR (cm-1): 3296 (N-H 
stretching of secondary amine), 3043 (C-H 
stretching of aromatic ring), 2945 (C-H 
asymmetrical stretching of CH2 group), 2847 
(C-H symmetrical stretching of CH3 group), 
1645 (C=O stretching of carbonyl group), 1587 
1558 and 1502 (C=C stretching of aromatic ring), 1446 (C-H asymmetrical 
deformation of CH3 group), 1350 (C-H symmetrical deformation of CH3 group), 1222 
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(C-O-C asymmetrical stretching of OCH3 group), 1174 (C-O-C symmetrical 
stretching OCH3 group), 1022 (C-F stretching), 960 (C-H in plane bending for 
aromatic ring), 825 (C-H out of plane bending for 1,4-disubstituted aromatic ring), 
709 (C-S-C stretching); 1H NMR (DMSO-d6) δ ppm: 0.99 (s, 3H, Ha,), 1.07 (s, 3H, H 
a’), 2.02-2.06 (d, 1H, Hb), 2.16-2.20 (d, 1H, Hb), 2.45 (s, 2H, Hc), 4.54-4.55 (d, 1H, Hd), 
5.10-5.12 (d, 1H, He), 6.75-6.77 (d, 2H, Hh, h’, J = 8.32 Hz), 7.16-7.18 (d, 2H, Hi, i, J = 
7.84 Hz), 7.06-7.10 (t, 2H, H f, f’), 7.46-7.50 (t, 2H, Hg, g’), 8.51 (s, 1H, Hj), 3.72 (s, 1H, 
Hk); MS: m/z 377; Anal. Calcd. for C24H24FNO2: C, 76.37; H, 6.41; N, 3.71. Found: C, 
76.30; H, 6.33; N, 3.65%. 
 
5.2.6.4.9   2-(4-fluorophenyl)-7,8-dihydro-4-(4-methoxyphenyl)-7,7-dimethyl  
quinolin-5(1H,4H,6H)-one (DDK-C-44) 
Yield: 81%; m.p. 213-215 ºC; MS: m/z 361; 
Anal. Calcd. for C24H24FNO: C, 79.75; H, 
6.69; N, 3.88. Found: 79.68; H, 6.61; N, 
3.82% 
 
 
5.2.6.4.10   2,4-bis(4-fluorophenyl)-7,8-dihydro-7,7-dimethylquinolin- 
5(1H,4H,6H)-one (DDK-C-45) Yield: 82%; 
m.p. 194-196 ºC; MS: m/z 365; Anal. Calcd. for 
C23H21F2NO: C, 75.60; H, 5.79; N, 3.83. Found: 
C, 75.54; H, 5.72; N, 3.76%. 
 
 
 
5.2.6.4.11   2-(4-fluorophenyl)-7,8-dihydro-4-(2-hydroxyphenyl)-7,7-dimethyl  
quinolin-5(1H,4H,6H)-one (DDK-C-46) Yield: 
60%; m.p. 201-203 ºC; MS: m/z 363; Anal. 
Calcd. for C23H22FNO2: C, 76.01; H, 6.10; N, 
3.85. Found: C, 75.94; H, 6.04; N, 3.78%. 
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5.2.6.4.12 2-(4-fluorophenyl)-7,8-dihydro-4-(3-hydroxyphenyl)-7,7-dimethyl  
quinolin-5(1H,4H,6H)-one (DDK-C-47) Yield: 
62%; m.p. 215-217 ºC; MS: m/z 363; Anal. 
Calcd. for C23H22FNO2: C, 76.01; H, 6.10; N, 
3.85. Found: C, 75.93; H, 6.02; N, 3.78%. 
 
 
 
5.2.6.4.13 2-(4-fluorophenyl)-7,8-dihydro-4-(4-hydroxyphenyl)-7,7-dimethyl  
quinolin-5(1H,4H,6H)-one (DDK-C-48) Yield: 
65%; m.p. 194-196 ºC; MS: m/z 363; Anal. 
Calcd. for C23H22FNO2: C, 76.01; H, 6.10; N, 
3.85. Found: C, 75.94; H, 6.03; N, 3.77%. 
 
 
 
5.2.6.4.14   2-(4-fluorophenyl)-7,8-dihydro-7,7-dimethyl-4-(pyridin-3-yl)quinolin- 
5(1H,4H,6H)-one (DDK-C-49) Yield: 72%; 
m.p. 239-241 ºC; MS: m/z 348; Anal. Calcd. for 
C22H21F2NO: C, 75.84; H, 6.08; N, 8.04. Found: 
C, 75.78; H, 6.00; N, 7.97%. 
 
 
5.2.6.4.15 2-(4-fluorophenyl)-7,8-dihydro-4-(2,3,4-trimethoxyphenyl)-7,7-dimethyl  
quinolin-5(1H,4H,6H)-one (DDK-C-50) Yield: 
75%; m.p. 222-224 ºC; MS: m/z 437; Anal. 
Calcd. for C26H28 FNO4: C, 71.38; H, 6.45; N, 
3.20. Found: C, 71.32; H, 6.38; N, 3.14%. 
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5.2.7 Spectral discussion 
5.2.7.1 Mass spectral study 
Mass spectra were recorded on Shimadzu GC-MS-QP-2010 model using Direct 
Injection Probe technique. Systematic fragmentation pattern was observed in mass 
spectral analysis. Molecular ion peak was observed in agreement with molecular 
weight of respective compound. Mass fragmentation pattern for a representative 
compound of each series is depicted below. 
 
5.2.7.1.1 Mass fragmentation pattern for DDK-C-30 
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5.2.7.1.2 Mass fragmentation pattern for DDK-C-36 
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5.2.7.2 IR spectral study 
IR spectra were recorded on Shimadzu FT-IR-8400 model using KBr pellet method. 
Various functional groups present in molecule were identified by characteristic 
frequency obtained for them. For 7,8-dihydroquinolines (DDK-C-21 to DDK-C-50), 
a characteristic band of carbonyl group was observed in the range of 1645-1701 cm-1. 
Another characteristic C-H asymmetrical and symmetrical stretching bands of methyl 
groups were observed at 2924-2956 cm-1 and 2847-2874 cm-1 respectively. Also, N-H 
stretching band of secondary amine was observed at 3255-3377 cm-1 suggesting 
formation of desired products (DDK-C-21 to DDK-C-50).     
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5.2.7.3 1H NMR spectral study 
1H NMR spectra were recorded in DMSO-d6 solution on a Bruker Ac 400 MHz 
spectrometer using TMS as an internal standard. Number of protons and their 
chemical shifts were found to support the structure of the synthesized compounds. 
For 7,8-dihydroquinolines (DDK-C-21 to DDK-C-35), characteristic singlets 
were observed for methyl and methylene groups at 1.00-1.10 δ ppm and 2.02-2.50 δ 
ppm respectively. Confirmatory signal of two adjacent methine protons were 
observed at 4.52-4.61 δ ppm and 5.19-5.23 δ ppm. The aromatic ring protons were 
observed at 6.76-7.36 δ ppm and J value were found to be in accordance with 
substitution pattern on phenyl ring. The singlet for secondary amine (-NH) proton was 
observed at 8.40-8.49 δ ppm.  
While, for 7,8-dihydroquinolines (DDK-C-36 to DDK-C-50), characteristic 
singlets were observed for methyl and methylene groups at 0.98-1.08 δ ppm and 1.99-
2.46 δ ppm respectively. Confirmatory signal of two adjacent methine protons were 
observed at 4.54-4.61 δ ppm and 5.10-5.23 δ ppm. The aromatic ring protons were 
observed at 6.75-7.50 δ ppm and J value were found to be in accordance with 
substitution pattern on phenyl ring. The singlet for secondary amine (-NH) proton was 
observed at 8.51-8.52 δ ppm. 
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IR spectrum of DDK-C-24 
 
 
Mass spectrum of DDK-C-24 
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1H NMR spectrum of DDK-C-24 
 
 
Expanded 1H NMR spectrum of DDK-C-24 
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Expanded 1H NMR spectrum of DDK-C-24 
 
 
IR spectrum of DDK-C-28 
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Mass spectrum of DDK-C-28 
 
 
1H NMR spectrum of DDK-C-28 
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Expanded 1H NMR spectrum of DDK-C-28 
 
 
IR spectrum of DDK-C-30 
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Mass spectrum of DDK-C-30 
 
 
1H NMR spectrum of DDK-C-30 
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Expanded 1H NMR spectrum of DDK-C-30 
 
 
Expanded 1H NMR spectrum of DDK-C-30 
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IR spectrum of DDK-C-36 
 
 
Mass spectrum of DDK-C-36 
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1H NMR spectrum of DDK-C-36 
 
 
Expanded 1H NMR spectrum of DDK-C-36 
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Expanded 1H NMR spectrum of DDK-C-36 
 
 
IR spectrum of DDK-C-39 
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Mass spectrum of DDK-C-39 
 
 
1H NMR spectrum of DDK-C-39 
 
 
Chapter 5-Section-2                                                                     7,8-Dihydroquinolines         
     
   240
Expanded 1H NMR spectrum of DDK-C-39 
 
 
Expanded 1H NMR spectrum of DDK--C-39 
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IR spectrum of DDK-C-43 
 
 
Mass spectrum of DDK-C-43 
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1H NMR spectrum of DDK-C-43 
 
 
Expanded 1H NMR spectrum of DDK-C-43 
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Expanded 1H NMR spectrum of DDK-C-43 
 
 
 
5.2.8 Biological evaluation 
5.2.8.1 Antimicrobial evaluation 
All of the synthesized compounds (DDK-C-21 to DDK-C-50) were tested for their 
antibacterial and antifungal activity (MIC) in vitro by broth dilution method [57, 58] 
with two Gram-positive bacteria Staphylococcus aureus MTCC-96, Streptococcus 
pyogenes MTCC 443, two Gram-negative bacteria Escherichia coli MTCC 442, 
Pseudomonas aeruginosa MTCC 441 and three fungal strains Candida albicans 
MTCC 227, Aspergillus Niger MTCC 282, Aspergillus clavatus MTCC 1323 taking 
Ampicillin, Chloramphenicol, Ciprofloxacin, Norfloxacin, Nystatin, and Griseofulvin 
as standard drugs. The standard strains were procured from the Microbial Type 
Culture Collection (MTCC) and Gene Bank, Institute of Microbial Technology, 
Chandigarh, India.  
 The minimal inhibitory concentration (MIC) values for all the newly 
synthesized compounds, defined as the lowest concentration of the compound 
preventing the visible growth, were determined by using microdilution broth method 
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according to NCCLS standards [57].  Serial dilutions of the test compounds and 
reference drugs were prepared in Muellere-Hinton agar. Drugs (10 mg) were 
dissolved in dimethylsulfoxide (DMSO, 1 mL). Further progressive dilutions with 
melted Muellere-Hinton agar were performed to obtain the required concentrations. In 
primary screening 1000 μg mL-1, 500 μg mL-1 and 250 μg mL-1 concentrations of the 
synthesized drugs were taken. The active synthesized drugs found in this primary 
screening were further tested in a second set of dilution at 125 μg mL-1, 62.5 μg mL-1, 
50 μg mL-1, 25 μg mL-1, 12.5 μg mL-1, and 6.250 μg mL-1 concentration against all 
microorganisms. The tubes were inoculated with 108 cfu mL-1 (colony forming 
unit/mL) and incubated at 37 ºC for 24 h. The MIC was the lowest concentration of 
the tested compound that yields no visible growth (turbidity) on the plate. To ensure 
that the solvent had no effect on the bacterial growth, a control was performed with 
the test medium supplemented with DMSO at the same dilutions as used in the 
experiments and it was observed that DMSO had no effect on the microorganisms in 
the concentrations studied. The results obtained from antimicrobial susceptibility 
testing are depicted in Table 1. 
  
Table 1. Antibacterial and antifungal activity of synthesized compounds DDK-C-
21 to DDK-C-50 
 
Code Minimum inhibition concentration (µg mL-1 ) 
Gram-positive Gram-negative Fungal species 
S.a. S. p. E.c. P.a. C. a. A. n. A.c. 
DDK-C-21 250 1000 1000 250 >1000 1000 500 
DDK-C-22 125 500 >1000 1000 500 250 500 
DDK-C-23 100 500 500 500 125 250 250 
DDK-C-24 500 1000 250 1000 500 1000 500 
DDK-C-25 250 100 500 >1000 1000 500 1000 
DDK-C-26 500 1000 250 1000 500 500 >1000 
DDK-C-27 1000 250 500 500 500 100 250 
DDK-C-28 100 125 100 62.5 >1000 1000 1000 
DDK-C-29   50 25   50    25   10    25    10 
DDK-C-30 500 1000 500 100 1000 500 500 
DDK-C-31 1000 500 1000 1000 500 500 1000 
DDK-C-32 500 500 250 500 >1000 1000 500 
DDK-C-33 250 62.5 125 250 1000 500 250 
DDK-C-34 500 1000 500 100 1000 500 500 
DDK-C-35 250 250 500 500 1000 100 1000 
DDK-C-36 500 500 500 500 500 500 >1000 
DDK-C-37 1000 1000 1000 1000 1000 500 500 
DDK-C-38 >1000 500 250 500 1000 250 250 
DDK-C-39 100 62.5 125 100 500 500 500 
DDK-C-40 1000 1000 1000 1000 1000 >1000 500 
DDK-C-41 25 100 200 100 1000 500 500 
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DDK-C-42 125 200 500 250 500 500 250 
DDK-C-43 100 125 100 100 1000 500 500 
DDK-C-44 50 100 25 100 >1000 500 1000 
DDK-C-45 25 50 100 50 500 500 1000 
DDK-C-46 500 500 500 500 500 500 >1000 
DDK-C-47 50 125 100 200 >1000 500 >1000 
DDK-C-48 125 100 250 125 500 500 >1000 
DDK-C-49 125 250 125 50 500 1000 500 
DDK-C-50 100 125 100 250 500 1000 >1000 
Ampicillin 250 100 100 100 - - - 
Chloramphenicol 50 50 50 50 - - - 
Ciprofloxacin 50 50 25 25 - - - 
Norfloxacin 10 10 10 10 - - - 
Nystatin - - - - 100 100 100 
Griseofulvin - - - - 500 100 100 
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Summary 
 
The work presented in the Thesis entitled “Studies on Heterocyclic Compounds of 
Medicinal Interest” can be summarized as below. 
 
Chapter 1 briefly introduces importance of bicyclic and tricyclic aromatic 
heterocycles in drug discovery as well as concept of “privileged structures”. Chapter 1 
further describes aims and objectives of the proposed research work. 
Chapter 2 covers the synthesis of two types of cyanopyridines in two sections. 
The Section-1 of Chapter 2 includes the synthesis of twenty novel 2-alkoxy-pyridine-
3-carbonitriles (2-alkoxy-3-cyanopyridines), which occupy a special position among 
various pyridine derivatives due to their wide spectrum biological activities along 
with their importance and utility as intermediates in preparing variety of heterocyclic 
compounds. The synthesis of these derivatives was achieved by Michael addition of 
α,β-unsaturated ketones (chalcones) to malononitrile in sodium methoxide/methanol 
and sodium ethoxide/ethanol systems resepectively. While Section-2 of Chapter 2 
covers the synthesis of twenty novel fused cyanopyridines viz. pyrazolo[3,4-
b]pyridine-5-carbonitriles. The pyrazolo[3,4-b]pyridines occupy a special position 
among fused pyridine systems containing an annelated five membered heteroaromatic 
ring due to their wide spectrum biological activities. The synthesis of 6-alkoxy-
pyrazolo[3,4-b]pyridine-5-carbonitriles was achieved by the reaction of arylidene 
malononitrile and 3-methyl-1H-pyrazol-5H-one in sodium methoxide/methanol and 
sodium ethoxide/ethanol systems resepectively.    
Chapter-3 briefly discusses the history of microwave assisted organic 
synthesis and their application in the synthesis of different heterocycles. Further it 
describes our aims and objectives to explore the microwave-assisted chemistry for the 
synthesis of two of our aimed heterocyclic scaffolds viz. acridines and 
polyhydroquinolines. 
In Chapter 4, synthesis of twenty novel polyhydroacridine-1,8-diones is 
reported. Acridines posses a wide variety of pharmacological activities and many 
acridine derivatives are in clinical use as antimalarials and anticancer agents. 
Polyhydroacridine-1,8-diones are polyfunctionalized 1,4-dihydropyridine type 
derivatives. Synthesis of these derivatives may prove useful modification of 1,4-
dihydropyridine nucleus in terms of biological activity. The synthesis of 
polyhydroacridine-1,8-dione derivatives was achieved by microwave-assisted one pot 
reaction of 5,5-dimethylcyclohexane-1,3-dione (dimedone) with 3-(aryl)-1-phenyl-
1H-pyrazole-4-carbaldehyde and substituted 2-chloro-quinoline-3-carbaldehyde 
respectively in presence of excess of ammonium acetate.  
Chapter 5 covers the synthesis of two types of polyhydroquinolines viz. 
5,6,7,8-tetrahydroquinolines and 7,8-dihydro-2,4-disubstituted-quinolin-5(1H,4H,6H) 
-ones in two sections. The Section-1 of Chapter 5 includes the synthesis of twenty 
novel 2-amino-5,6,7,8-tetrahydro-4-heteroaryl-quinoline-3-carbonitriles. The 
synthesis was accomplished by the one pot microwave-assisted reaction of  
cyclohexanone with 2-((3-(aryl)-1-phenyl-1H-pyrazol-4-yl)methylene)malononitrile 
& 2-((2-chloro-substitutedquinolin-3-yl)methylene)malononitrile respectively in 
presence of excess of ammonium acetate.  While Section-2 of Chapter-5 includes the 
synthesis of 7,8-dihydro-2,4-disubstituted-quinolin-5(1H,4H,6H) –ones by the one pot 
solvent-free microwave-assisted reaction of 5,5-dimethylcyclohexane-1,3-dione with 
3-(aryl)-1-(thiophen-2-yl)prop-2-en-1-ones and 3-(aryl)-1-(4-fluorophenyl)prop-2-en-
1-ones respectively in presence of excess of ammonium acetate. 
Thus, new green chemistry approaches were developed for the synthesis of 
novel acridines and polyhydroquinolines leading to the improvement in the reaction 
time, yield and simplicity of work up procedure. 
All the synthesized compounds were characterized by IR, Mass, 1H NMR 
spectroscopy and elemental analyses. 
Thus, 110 compounds are synthesized and characterized in entire thesis work. 
The synthesized compounds are screened for antimicrobial activity, results of which 
are incorporated in the thesis. Looking at the antimicrobial activity results (i.e. 
antibacterial and antifungal), remarkable number of compounds have demonstrated 
excellent antimicrobial activity as compared to the standard drugs.  
All the newly synthesized compounds are also under antimycobacterial, 
anticancer and antiviral evaluation and their results are awaited.  
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